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Abstract 
Background: Current legislations such as paediatric investigation plan (PIP) require 
pharmaceutical companies seeking marketing authorisation for a new medicine to provide 
evidence of studies in paediatrics to justify the use of such medicine in this population. In spite 
of these legislations, there are still challenges with conduct of clinical trials in paediatrics; thus, 
there is lack of commercially available dosage forms appropriate for use in this population. 
Consequently, a good proportion of medicines used in treating paediatric patients are used in 
the unlicensed (UL) or off-label (OL) manner. Use of UL or OL medicines has been associated 
with higher safety incidents such as, adverse drug reactions (ADRs) than licensed medicines. 
ADRs are only a subset of medicine related problems (MRPs) associated with the use of 
medicines. Currently, no studies have explored all aspects of problems associated with the use 
of OL and UL medicines in paediatrics.  
Aim: To investigate the prevalence of the use of OL and UL medicines and problems 
associated with their use in paediatrics patients admitted to intensive care units of a Children’s 
Hospital. 
Method: A systematic literature review was carried out to identify problems that are associated 
with the use of OL and UL medicines. A retrospective review of case notes (n=194) of patients 
who were admitted to Paediatric Intensive Care Unit (PICU) was carried out at medical records 
units of the hospital. This was followed by a prospective review of case notes (n=147) of 
patients admitted to PICU. The last study involved a prospective review of case notes (n=87) 
admitted to Neonatal Intensive Care Unit (NICU); NICU had migrated to electronic prescribing 
at the time the study was carried out. 
Licensing status of medicines was determined using Summary of Product Characteristics of 
medicines. Definition and categories of MRPs were based on the Pharmaceutical Care Network 
Europe classification system version 6.2. Naranjo causality scale was used to identify the 
medicines that was associated with MRPs. Severity and preventability of identified MRPs were 
assessed using the National Patient Safety Agency categorisation for level of harm and 
Schumock and Thornton scale respectively. Data was analysed using computer programmes 
including Excel, Statistical Package for the Social Sciences and STATA. 
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Results: In the retrospective study, 53% of the total number of patients developed at least one 
MRP and 8% (n=165/2000) of the total number of medicines were associated with MRPs.  
From the total number of MRPs, 43% were associated with licensed medicines, while 57% 
were associated with OL and/or UL medicines. Identified MRPs were mostly ADRs and 
treatment effectiveness problems (84% vs.16%).  
In the prospective PICU study, 66% of the total number of patients developed at least one MRP 
and 11% (n=178/1578) of prescribed medicines were associated with MRPs. From the total 
number of MRPs, 40.4% were associated with licensed medicines, while 59.6% were 
associated with OL and/or UL medicines. Among the identified MRPs, 83% were ADRs and 
17% were treatment effectiveness problems. In the NICU study, 90% of the patients developed 
MRPs and 9% (n= 186/1978) of the total number of medicines were associated with MRPs. 
From the total number of MRPs, 55% were associated with licensed medicines, while 45% 
were associated with OL and/or UL medicines.  All the identified MRPs were ADRs. 
Conclusion: This research is the first to investigate MRPs associated with the use of OL and 
UL medicines in paediatric in-patients. MRPs associated with the use of OL and UL medicines 
were higher than with the use of licensed medicines. Inclusion of paediatrics in clinical trials 
of new medicines is fundamental to reducing the use of OL and UL medicines and the problems 
associated with their use.  
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Thesis summary 
Chapter 1 of this thesis provided a background on patient safety, medicines optimisation, and 
research and development in paediatric population. It also introduced MRPs and the different 
systems that have been used in classifying MRPs. 
In Chapter 2, results from a systematic literature review regarding the use of OL and/or UL 
medicines in paediatric patients are presented. Research justification, aim, and objectives are 
also discussed. 
Chapter 3 describes research philosophies; the link between these philosophies and the 
different research methodologies are described. The tools employed in this research are also 
presented as well as the different study phases.  
In chapter 4, findings of a retrospective review conducted in medical records department are 
presented. MRPs were higher with OL and/or UL medicines than licensed medicines (57% vs 
43%) and were ADRs and treatment effective problems. 
In Chapter 5, findings of a prospective review of case notes of patients admitted to PICU are 
described. Findings were consistent with those of the retrospective study. 
Chapter 6 of this thesis describes the prospective study conducted in NICU where electronic 
prescribing had been implemented. Findings were consistent with those of Chapters 4 and 5 in 
terms of prevalence of use of OL and UL medicines and MRPs occurrence. However, MRPs 
identified were only ADRs; there were no treatment effectiveness problems. 
In Chapter 7, overall discussion of this thesis, research contribution to knowledge, 
implication for practice, and recommendations are presented.  
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Chapter 1: Introduction 
 
Medicines have always contributed to improving quality of life and an increase in life 
expectancy in humans. The fundamental aims of using medicines are to prevent illnesses, 
manage chronic conditions and/or cure diseases (Royal Pharmaceutical Society, 2013). 
Although medicines have contributed to an increase in life span, especially in developed 
countries, use of medicines has been associated with a number of problems and safety 
incidents. For example, a report commissioned by the Department of Health to explore the 
costs of unsafe care in the NHS from documented reports of adverse events and harm, found 
that 5 to 8% of unplanned hospital admissions are due to medicines-related incidents (Frontier 
Economics, 2014).  Medication-related safety incidents in paediatrics have been reported as 
the most common medical errors; these included dispensing errors, prescribing errors and 
administration errors (Rees et al., 2017). Reporting, analysis, reduction and prevention of these 
safety incidents are crucial elements of patients’ safety (Aspden, Corrigan, Wolcott et al., 
2004). The following section will explore patient safety in the context of medicines use. 
1.1 Patient safety and key organisational reports 
 
Patient safety is defined as the prevention of errors and adverse effects to patients associated 
with healthcare (Aspden, Corrigan, Wolcott et al., 2004; World Health Organisation, WHO 
2017). According to the WHO, medical errors and health-care related adverse events occur in 
8% to 12% of hospitalisations (WHO, 2017). Patient safety awareness has increased following 
the Institute of Medicine (IOM) launch of the report “To Err Is Human” in 1999. In the United 
Kingdom (UK), a Department of Health report titled: “An organisation with a Memory” 
estimated that about 850 000 adverse events occurs a year, and highlighted the importance of 
incidents reporting to improve the healthcare quality (Department of Health, 2000). Patient 
safety is therefore a healthcare discipline that emphasises minimisation of harm in healthcare 
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through the prevention, reduction, reporting, and analysis of medical error that often leads to 
adverse effects (Emmanuel et al., 2008). To integrate patient safety into health care, national 
and international agencies have been established. In England for example, following the 
publication of “An organisation with a memory” report, “Building A Safer NHS For Patients” 
was published which set out the Government’s plans to promote patient safety. One of the plans 
included establishment of a system (the National Reporting and Learning System, NRLS) to 
report and learn from adverse events resulting from medical and other errors occurring in the 
delivery of care and treatment to NHS patients. It also included introduction of the National 
Patient Safety Agency (NPSA), whose main function was to unite the functions, skills and 
experience needed to implement and operate the system (Department of Health, 2001). The 
NPSA defines a patient safety incident as ‘any unintended or unexpected incident which could 
have or did lead to harm for one or more patients’ (NPSA, 2007). When the harm results from 
use of medicines, this is referred to as medication incidents. The NPSA classify harm resulting 
from medications as non-preventable, preventable and near-miss depending on whether an 
error occurred or not. Where harm occurs and no error took place in the medication process, 
this is judged non-preventable; harm that occurs due to an error is judged preventable. 
Medication incidents that do not cause harm but have the potential to cause harm are called 
‘near misses’. In a review of 526, 186 medication incidents reported to the National Reporting 
and Learning System (NRLS) in England in Wales between 2005 and 2010, 16% reported 
actual harm to patients, of which 0.9% resulted in death or severe harm.  Serious incidents 
(death or severe harm) are often caused by errors in medicine administration and prescribing 
(NPSA, 2007). In the NRLS report, the most common incidents were those related to medicine 
administration 50%, prescribing 18%, omitted and delayed medicine 16%, and wrong dose 
15%.  (Cousins, Gerrette & Warner, 2012). In a more recent report of medication incidents 
between October 2014 and March 2015, 71.2% of the total number of incidents were reported 
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as causing no harm, 23.9% were low harm, 4.3% were moderate harm, less than 1% of all 
incidents reported severe harm or death (NHS, 2015).   
In the NRLS, age is not a mandatory field. Consequently, a significant proportion of the data 
(39 percent) do not contain information on the patient’s age. Although the NRLS reports do 
not contain information on the patient’s age as data presented are combined, incidents reported 
between October 2007 and September 2008 showed that 2.1% (n= 19,307/910,089) occurred 
in children treated in acute settings (NPSA, 2009). The NRLS reports do not provide 
information on the category of incidents involving children whether they were serious 
incidents, critical incidents or near miss; however, the majority of incidents involving children 
are reported to have resulted in no harm or low harm (NPSA, 2009). The safety of patients in 
relation to medicines has led to the concept of medicine optimisation (Royal Pharmaceutical 
Society, 2013).  Medicines optimisation and patient safety, therefore, aim to achieve the same 
goals in healthcare settings. Medicines optimisation will be discussed in the following section. 
1.2 Medicines’ optimisation principles 
 
Medicines optimisation refers to the practice of making sure patients get the best out of their 
medicines (NHS England, 2016). To implement medicines optimisation initiatives in 
healthcare settings, the National Institute for Health and Care Excellence (NICE) recommends 
a multidisciplinary team (comprising physicians, pharmacists, nurses) who must work together 
to individualise care, monitor outcomes, review medicines frequently and support patients. The 
key priorities for implementing medicines optimisation include (NICE, 2015):   
i. having systems for identifying, reporting and learning from medicines-related patient 
safety incidents. Organisations are required to use multiple methods to identify 
medicines-related patient safety incidents, including health record review, patient 
surveys and direct observation of medicines administration. 
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ii. having medicines-related communication systems when patients move from one care 
setting to another. The guideline recommends health and social care practitioners 
should share relevant information about patients and their medicines when they move 
from one care setting to another.  
iii. ensuring medicines reconciliation is carried out by a trained and competent health 
professional (a pharmacist, pharmacy technician, nurse or doctor) with the necessary 
knowledge, skills, and expertise. 
Other guidelines that have been suggested for effective implementation of medicines 
optimisation are medication review, self-management plans, patient decision aids, and clinical 
decision support software (NHS England, 2016). 
The components of optimal practice in medicines optimisation have been described by the 
Royal Pharmaceutical Society. These are summarised in the figure below: 
 
Figure 1:1: Summary of the four principles of medicines optimisation (Source: Royal 
Pharmaceutical Society, 2013) 
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Each of the guiding principles seeks to achieve specific outcomes (Royal Pharmaceutical 
Society, 2013).  The outcome of implementing principle 1 (aim to understand the patient’s 
experience) includes: 
 Patients are more engaged, understand more about their medicines and are able to make 
choices, including choices about prevention and healthy living.  
 Patients’ beliefs and preferences about medicines are understood to enable a shared 
decision about treatment.   
 Patients are able to take/use their medicines as agreed.   
 Patients feel confident enough to share openly their experiences of taking or not taking 
medicines, their views about what medicines mean to them, and how medicines impact 
on their daily life. 
The expected outcome of implementing principle 2 (evidence based choice of medicines) 
includes: 
 Optimal patient outcomes are obtained from choosing a medicine using best evidence 
(for example, following NICE guidance, local formularies etc) and these outcomes are 
measured.  
 Treatments of limited clinical value are not used and medicines no longer required are 
stopped.  
 Decisions about access to medicines are transparent and in accordance with the NHS 
Constitution. 
The outcome of implementing principle 3 (ensuring medicines use is as safe as possible) 
includes:  
 reduction of incidents of avoidable harm from medicines 
 making sure patients have more confidence in taking their medicines 
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 ensuring patients feel able to ask healthcare professionals when they have a query or a 
difficulty with their medicines 
 ensuring patients remain well and there is a reduction in admissions and readmissions 
to hospitals related to medicines usage. 
Implementing principle 4 in the healthcare setting will achieve the following outcomes: 
 Patients feel able to discuss and review their medicines with anyone involved in their 
care.  
 Patients receive consistent messages about medicines because the healthcare team liaise 
effectively.   
 It becomes routine practice to signpost patients to further help with their medicines and 
to local patient support groups.  
 Inter-professional and inter-agency communication about patients’ medicines is 
improved.  
 Medicines wastage is reduced.  
 The NHS achieves greater value for money invested in medicines.   
 The impact of medicines optimisation is routinely measured 
Although the four guiding principles are interrelated, this thesis is more closely related to the 
third guiding principle. This implies that safety and efficacy of medicines must be considered 
when prescribed as off-label (OL) and/or unlicensed (UL). 
Harm from medicines occur both in adult and paediatric patient populations, the goal of 
medicines optimisation is therefore to improve patient outcomes and minimise harm from 
medicines in all patient groups. However, medicine-related incidents are more prevalent in 
paediatric patients than in adults (Wong, Wong & Cranswick, 2009). Children are thus more 
vulnerable to healthcare harm than adults for a number of reasons, including weight-based 
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dosing; use of medicines in an OL and UL manner, and dependency on caregivers to advocate 
for them (Rees et al., 2017; WHO, 2007).  The following sections provide an overview of 
classification of paediatric population and medicines use in this population. 
1.3 Classification of paediatric population 
 
Children and young adults constitute one of the vulnerable groups in any population 
(Shivayogi, 2013). Monitoring the use of medicine in this population is of paramount 
importance as they represent a spectrum of different physiologies and must not be treated as 
miniature adults (WHO, 2007). The paediatric population range from the very small preterm 
newborn infant to the adolescent. The paediatric age range is defined in terms of completed 
days, months, or years as follows (European Medicines Agency, 2001; WHO, 2007). 
• preterm newborn infants 
• term newborn infants (0 to 27 days) 
•  infants and toddlers (28 days to 23 months) 
• children (2 to 11 years) 
• adolescents (12 to 16-18 years (dependent on region)  
A number of pharmacokinetic changes occur as children develop into adulthood. Some of these 
changes include a decrease in the proportion of body water, immaturity of gastro-intestinal and 
hepatic medicine-metabolising enzymes and transporters, and immature renal functions 
(WHO, 2007). Neonates, for example, eliminate medicines slowly due to underdeveloped 
enzymes and renal functions. The following section describes the pharmacokinetics in children. 
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1.4 Pharmacokinetics in paediatrics 
 
The pharmacokinetics of many medicines varies with age (Kearns, 1998). Some medicines that 
are completely safe for adults may produce toxic effects in children and adverse events to 
medicines that have been tolerated by adults have been observed in children when the 
medicines have not been adequately studied before their use in the paediatric population. For 
instance, because of the rapid changes in size, body composition, and organ function that occur 
during the first year of life, clinicians as well as pharmacokineticists and toxicologists are 
presented with challenges in prescribing safe and effective doses of therapeutic agents (Milsap 
and Jusko, 1994). Anatomical, physiological and biochemical changes that occur from birth 
affect pharmacokinetics and pharmacodynamics of medicines. (Fernandez et al., 2011). 
Pharmacokinetic parameters are age-related and that affects medicine’s dose and frequency 
needed to maintain optimal therapeutic concentration (Fernandez et al., 2011). These 
parameters include absorption, distribution, metabolism and elimination. 
1.4.1 Absorption 
 
Changes in the gastrointestinal tract that occur during growth and development of children 
affect the absorption rate and bioavailability of medicines after oral administration (Strolin & 
Baltes., 2003). In percutaneous administration of medicines, absorption is determined by the 
thickness of the epidermal stratum corneum and the state of skin hydration, this in turn affects 
the dose required to reach therapeutic concentration (Koren, 1997). In intramuscular 
administration of medicines, the absorption rate is affected by the perfusion in the injection 
area and the penetration of the medicine through the endothelium capillary, this affects the 
choice of the correct dose (Strolin et al., 2005). When patients are unable to tolerate the oral 
and intravenous routes of administration, the rectal route serves as a useful alternative. This 
route is less modified by changes during growth and development, for example, the local pH 
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of the rectum is close to neutral in adults, but alkaline in most children.  When the rectal route 
is used is used, the dose, frequency and duration of medicine must be optimised to reach the 
required plasma level. Although intrapulmonary administration is increasingly used in 
children, developmental changes in the lungs affect the absorption of medicines (Fernandez et 
al., 2011). 
1.4.2 Distribution 
 
Many distribution processes of medicines are different in children when compared to adults. 
For example, the plasma protein binding is continuously fluctuating throughout the first years 
of life, which affects the distribution of medicines (Strolin et al., 2005). Also, the blood-brain 
barrier (BBB) is not fully mature and medicines with low penetration capacity might enter  the 
central nervous system with higher concentrations which might cause toxicity (Cohen-
Wolkowiez et al., 2009). The total body water is high in young infants (80-90% of the body 
weight. This decreases to 55-60% by adulthood. Consequently, there is higher volume of 
distribution of water-soluble medicines is paediatric patients than in adult patients (McLeod et 
al., 1992).  
1.4.3 Metabolism 
 
Metabolism of medicines depends on many factors including, blood flow, hepatic enzyme 
activities, transport systems and plasma protein binding (Anderson & Lynn., 2009). Blood flow 
and drug-metabolising enzymes are reduced in children when compared to adults and some 
medicines produce metabolites in children that are not normally present in adults such as 
caffeine production in neonates receiving theophylline (Benedetti & Whomsley., 2007). 
1.4.4 Excretion  
 
Changes that occur during growth and maturation of the renal function have implications for 
medicines that are primarily excreted by the kidney. Factors that affect medicines excretion via 
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the renal system include glomerular filtration (GFR), tubular secretion and reabsorption. They 
are dependent on renal blood and plasma flow and increase with age as a result of increase in 
cardiac output and a reduction in peripheral vascular resistance (Alcorn et al., 2002). Excretion 
of many medicines in urine in unchanged form is restricted by the immaturity of glomerular 
filtration and renal tubular secretion observed in neonates, the unchanged form of the medicine 
therefore remains longer in the blood and may reach toxic levels (Fernandez et al., 2011). 
The changing pharmacokinetic profiles in children affect medicines efficacy, toxicity and 
dosing regimens and therefore optimisation of medicines for this population is crucial. Dosing 
of medicines in paediatric patients is based on the modification of adult doses and formulations 
(Batchelor & Marriott, 2015; Standing & Tuleu, 2005; Richey et al., 2013) which might not 
give good estimates of suitable dosages in some cases (Kimland & Odlind, 2012). To ensure 
optimal use of medicines and availability of age-appropriate medicines in this population, a 
number of legislations have been introduced. The following section summarises key 
legislations in paediatric medicines use. 
1.5 Legislation of medicinal products for paediatric use 
 
Following the thalidomide disaster (that is, phocomelia or malformation of the limbs in infants 
whose mothers were treatment with thalidomide for nausea during pregnancy) (Kelsey, 1967; 
Kelsey, 1988; Lenz, 1988; Smithells & Newman, 1992; Vargesson, 2013), pharmaceutical 
companies are required to provide information on the safety, efficacy and quality of medicines 
to national medicines regulatory agencies. When the medicine is approved, a marketing 
authorisation or license is issued with a Summary of Product Characteristics (SPC) (Silva, 
Ansotegui & Morais-Almeida, 2014). The medicine marketing authorisation or license usually 
states which indication the medicine can be used for, what doses can be used, how the medicine 
should be given (e.g. by mouth, by injection), and which group of patients it can be used for 
(Royal College of Paediatrics and Child Health (RCPCH), Neonatal and Paediatric Pharmacists 
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Group (NPPG) & WellChild, 2013). The aim of licensing is to control the manufacture, 
promotion and supply of medicines. To this aim, different regulatory agencies have been set 
up to ensure safety, efficacy and quality of medicines. These agencies include the Medicines 
and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK), European 
Medicines Agency (EMA), responsible for licensing of medicines in the European Commission 
(EC); and the Food and Drug Administration (FDA) in United States of America (USA).  
A mutual recognition agreement between the European Union (EU) and the United States (US) 
to recognise inspections of manufacturing sites for human medicines came into force in 
November 2017 and allows for recognition of each other’s inspection outcomes. This 
agreement helps to strengthen use of each other’s medicine inspection expertise and resources, 
avoids duplication of inspection, and directs resources towards inspection of manufacturing 
facilities of medicines that have a global public health risks. The FDA now confirms the 
capability of eight EU Member States including United Kingdom, which is a giant step to 
benefit from the available resources to safeguard quality and safety of medicines.  
1.6 History of medicines legislations 
 
In the UK, the first primary licensing legislation came into existence through the Medicines 
Act of 1968 (UK Act of Parliament, 1968). The act prohibited all companies to manufacture, 
promote, sell, or supply any kind of medicine without a prior license from the UK licensing 
authority (comprising UK Ministers of Health) which is advised by MHRA. The Act was 
gradually introduced into European Union (EU) legislation, and it is now known as Marketing 
Authorisation (MA). In order for any product to obtain a MA in the UK, the company is 
required to offer sufficient evidence to the MHRA to show that the medicine meet all 
satisfactory standards of efficacy, safety, and quality, when used for its specified indications. 
The MHRA requires companies seeking a MA to provide information on the medicine for the 
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prescribers (SPC) as well as for the patients via patients information leaflets (PIL).  The 
information provided become part of the MA and states the indication(s), the dosage, and other 
important information, including the formulation of the product, the constituents, side effects, 
and interactions with other substances, warnings, and contraindications (Collier, 1999). 
The EMEA was established in 1995 with the mandate to implement a new European medicine 
registration system. The aim of this new system was to give patients quick access to innovatory 
new medicines, to facilitate the free movement of medicines within the European Union, and 
to provide rigorous scientific evaluation of new products (Herxheimer, 1996).  
The system used two licensing procedures, namely the centralised procedure through the 
EMEA (applies to companies that seek license for biotechnology products), and a decentralised 
procedure which applies to conventional products (Herxheimer, 1996; Impicciatore & 
Choonara, 1999). Products approved under these procedures are issued the European Public 
Assessment Reports (EPARs), which provide reasons for approval, summary of product 
characteristics, and information to be included in patient information leaflet (PIL). A review to 
evaluate the activity of EMEA regarding paediatric medicines four years after its establishment 
showed that of 45 substances licensed as of January 1995, 29 (64%) were of possible use in 
children but only 10 were licensed for paediatric use (Impicciatore & Choonara, 1999). This 
means that the majority of medicines are licensed for adults but sometimes are used in paediatic 
patients in an unlicensed/off-label manner. 
Similarly, in 1997, the European Commission (EC) organised a round table discussion 
involving experts to discuss paediatric medicines. In 1998, the Commission supported the need 
for international discussion on the performance of clinical trials in children in the context of 
the International Conference on Harmonisation (ICH). ICH is an organisation for the 
harmonisation of pharmaceutical regulatory requirements between the EU, Japan and the USA. 
The goal of ICH is to encourage and facilitate timely paediatric medicinal product 
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development, provide an outline of critical issues in paediatric drug development, and promote 
safe, efficient and ethical studies of medicinal products (European Medicines Agency, 2007). 
As a result, the guidelines provided by the ICH became the standard guidelines of Europe on 
clinical investigation of medicinal products in the paediatric population and has been in force 
since July 2002 (European Medicines Agency, 2007). The adoption of ICH guidelines by the 
EU was shortly followed by the introduction of Good Clinical Practice (GCP) for Clinical 
Trials in 2001, which came into force in 2004. The GCP directive, in particular lay down 
criteria for the conduct of clinical trials in children and protection of children in these clinical 
trials (European Medicines Agency, 2007). 
In 2006, a European parliament and the council of the EU regulation required companies 
intending to apply for a marketing authorisation to draw up a paediatric investigation plan (PIP) 
(European Parliament & EU Council, 2006).  PIP is a development plan aimed at ensuring that 
the necessary data are obtained through studies in children, to support the authorisation of a 
medicine for children. All applications for marketing authorisation for new medicines have to 
include the results of studies as described in an agreed PIP, unless the medicine is exempt 
because of a deferral or waiver (European Medicines Agency, 2007). The PIP includes the 
following (European Parliament & EU Council, 2006; European Medicines Agency, 2007): 
• a description of the measures to be carried out in children with the medicine; 
• description of the measures to adapt the medicine's formulation to make its use more 
acceptable in children, such as use of a liquid formulation rather than large tablets; 
• coverage for all age groups of children, from birth to adolescence; 
• definition of the timing of measures in children compared to adults. 
Figure 1.2 below shows the timeline of legislations of medicinal products: 
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Figure 1:2: Timeline of legislations of medicinal products 
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In spite of these legislations, there are still challenges with conduct of clinical trials in children. 
The following section describes the challenges associated with carrying out trials in the paediatric 
population. 
1.7 Research and development of medicines for paediatrics 
 
The limited number of clinical trials involving children has presented practical obstacles and 
difficulties for healthcare providers (Fontan, 2004). In their review, Rieder and Hawcutt, 2016 
outlined a number of factors that make conduct of early clinical studies difficult in children. These 
include ethics, acceptability, rarity, standardisation, end points and safety, dosing and feasibility.  
1.7.1 Ethics and informed consent 
 
There has been an ongoing discussion on the inclusion of children in clinical trials following the 
establishment of the value of ethics and informed consent in research (Rieder & Hawcutt, 2016). 
For a research study to be ethical, consent of participants must be sought and obtained prior to 
commencement of such research, and respect for research participants must be maintained 
throughout the research. Respect for persons includes respect for autonomous decision-making 
which requires attention to all the elements of informed consent, namely adequate information, 
voluntariness and capacity to understand the information (Canadian Paediatric Society, 2008). 
While adults have capacity to understand information, and provide informed consent based on 
their understanding of information provided, the same is not the case with children who are unable 
to provide full consent themselves. Responsibility for consent to participate in medicine research 
by children therefore rests on parents or guardians who may be unwilling to consent to enrolment 
of their children for fear of risk that may be associated with unproven treatment. While there are 
currently ethical situation that permit or encourage involvement of children in drug research, 
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especially if such treatment will be beneficial to children with the disorder, current discourse 
requires that such involvement must pose minimal risk to children. Even in this scenario, children 
are not ethically eligible to be enrolled in phase 1 trials (testing of new medicines in healthy 
volunteers to determine the highest dose that can be given safely without serious side effects). 
However, children are ethically eligible for Phase II (first stages of drug testing for efficacy and 
safety in patients) and Phase III (comparison of the effectiveness of the drug with a ‘gold standard’) 
studies. There is also an increasing call that ethical approval should require not only consent from 
parents but also assent from the children, particularly for adolescents. Thus securing consent for 
drug research in adolescents remains a problem (Rieder & Hawcutt, 2016). 
Recently, the EU General Data Protection Regulation (GDPR) has published a guideline that will 
ensure the protection of personal data, including paediatric data. This guideline, which came into 
effect May 2018, highlighted the age at which data subjects can lawfully give consent and 
introduced changes for the language used in consent requests for children. The age at which a 
person is no longer considered a child is 16 according to the EU GDPR, however member states 
are allowed to adjust that limit to anywhere between 13 and 16. Thus the age of consent in 
particular member states must be taken into account by data controllers and should be obtained 
from a person holding a “parental responsibility”. As well as consent, data controllers must make 
sure that privacy notices are written in clear and plain language that a child will understand when 
services are offered directly to a child. The reason for these rules is to protect safety of children 
because they may be less aware of the risks, consequences and safeguards of handing of their 
personal details.  
This new regulations have potential benefits and drawbacks. The main drawback of the new 
regulations is that it might affect the number of paediatric patients that can participate in clinical 
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trials and research of new medicinal products, because of the complexity of obtaining consent. 
Also, limited number of trial participants might lead to failure because of the drop-off of 
participants and the difficulty in obtaining post marketing data. This will in turn lead to decrease 
the number of paediatric clinical trials and new medicines. On the other hand, the benefits might 
be that pharmaceutical companies are unable to share or obtain information from third parties; 
therefore, the recruitment procedure of participants will be with less bias. In addition, children who 
are able to provide an assent form will be able to understand the form because of the intended 
simplicity of the form’s language.  
1.7.2  Acceptability 
 
Acceptability concerns the extent to which families and physicians are willing to enroll children 
in drug research. Not only are parents reluctant to enroll their children in clinical trial; findings of 
a study have also shown that paediatricians with limited training in ethics are very reluctant to 
enroll children in clinical trials (Sammons et al., 2007). Thus, the degree of comfort of study 
personnel in working with paediatricians and families is a key factor in the success or failure of 
drug studies in children (Rieder & Hawcutt, 2016). 
1.7.3 Rarity 
 
Rarity concerns absence of some paediatric disorders in some institutions, but relatively common 
in other institutions. As a result, clinical trials of new drugs in a single centre are difficult as sample 
size is usually small. To ensure multi-centre trials, national and regional networks have been 
formed, especially in the fields of paediatric haematology and oncology to assess drug therapy and 
develop evidence-based treatment protocols that have resulted in survival of pre-term babies and 
high rate of cure of many childhood cancers (Rieder & Hawcutt, 2016). 
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1.7.4 Standardisation, end points and safety 
 
A key decision in clinical trials is selection of suitable end points. This is particularly an issue that 
complicates clinical trials in children as many of the end points used in adults have not been 
validated in children. There is also the problem of design of clinical trials in children.  Clinical 
trials conducted in children are reported to be associated with high risk of bias, especially with 
allocation and concealment (Hartling et al., 2012). In relation to safety concerns, the medicine 
approval process is designed to detect serious and common risks associated with medicinal 
therapy. Initial clinical trials are conducted to detect these risks; however, serious adverse effects 
do occur at early phase trials. This makes conducting clinical trials in children difficult.  
1.7.5 Dosing and feasibility 
 
One of the problems with involving children in clinical trials is dose selection of the trial product. 
This is because children’s doses are usually extrapolated from adult doses. A review of failed 
paediatric medicines’ development trials reported that, in up to a quarter of trials that fail to 
establish efficacy or safety, the selection of the correct dose was a factor in the failure (Momper, 
Mulugeta & Burckart, 2015). 
As a result of the difficulties in conducting clinical trials in children, and lack of commercially 
available dosage forms appropriate, experts involved in treatment of this population have been left 
with no other choice than use of medicines in the OL or UL manner (Kimland et al., 2012; 
Magalhães et al., 2015; RCPCH, 2013; Turner, Nunn, Fielding & Choonara, 1999). The following 
sections describe OL and UL medicines’ use in peadiatrics. 
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1.8 Off-label and unlicensed medicine use in paediatic patients 
 
The definition of off-label (OL) and unlicensed (UL) use of medicines varies between authors, and 
are sometimes used interchangeably. Turner, Longworth, Nunn, & Choonaran (1998) have 
described different categories of OL and UL use of medicines. According to these authors, 
unlicensed use of medicines includes the following: 
 modifications to licensed medicines (such as, dispensing a medicine in a different form, 
for example, crushing tablets to prepare a suspension) 
 Extemporaneous medicines that are licensed but the particular formulation is manufactured 
under a special license (such as, when an adult preparation is not suitable for use in children 
and a smaller dose must be formulated) 
 new medicines available under a special manufacturing license (such as, caffeine injections 
for apnea of prematurity) 
  use of raw chemicals materials as medicines and medicines used before a license has been 
granted. 
  imported medicines which are licensed in other countries but do not have a license in the 
UK. 
Off-label use of medicines includes use in situations not covered by the product license such as:  
 administration of a greater dose or more often  
 administration for indications not described in the license 
 administration to children outside the age range for which the product is licensed 
 the use of alternative routes of administration  
  use when the product is contraindicated 
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In an effort to define OL and UL use of medicines in children, Neubert et al. (2008) in a Delphi 
survey defined “off-label use” as ‘all uses of a marketed medicine not detailed in the SPC including 
therapeutic indication, use in age-subsets, appropriate strength (dosage), pharmaceutical form and 
route of administration’. “Unlicensed use” was defined as ‘all uses of a medicine which has never 
received a European Marketing Authorisation as medicinal for human use in either adults or 
children’.  
The Neonatal and Paediatric Pharmacists Group (NPPG), Royal College of Paediatrics and Child 
Health (RCPCH) & WellChild, have used a number of terms to describe unlicensed medicines. 
According to these bodies, off-label use of medicines is using a medicine in a different way to its 
license. While UL use of medicines includes: 
 ‘specials’- medicines made under a special license by a manufacturer  
 imports- products with a license, usually in another country, which are imported into the 
UK  
 extemporaneous products (‘extemps’)- formulations for an individual patient and an 
individual purpose made by a pharmacist combining ingredients 
 manipulated products—medicines in which the formulation has been altered (e.g. by 
crushing tablets or opening capsules) 
 
When there are no suitable medicines for paediatric practice, Medicines Act and Regulations 
(RCPCH, 2013) provide exemptions which enable prescribers to: 
• prescribe UL medicines; 
• use clinical trials medicines which are not yet authorised to be marketed. 
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• use or advise on the use of licensed medicines for indications, or in doses, or by routes of 
administration, outside the recommendations of the license; 
• override the warnings and the precautions given in the license. 
The figure below provides a summary of UL or OL use of medicines in paediatric patients: 
 
Figure 1:3: Unlicensed and off-label medicine paediatric use, DF- dosage form; iv- 
intravenous 
 
The term ‘special’ refers to an extemporaneous non-sterile liquid preparation produced under good 
manufacturing practice (GMP) conditions by a specials manufacturer, which includes suitably 
licensed hospitals units. Companies are allowed to supply unlicensed medicinal products 
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formulated in accordance with the requirement of a doctor (‘named patient supply’) if they hold a 
manufacturer’s (specials) license issued by the Medicine and Healthcare Products Regulatory 
Agency (MHRA).  Extemporaneous preparations, on the other hand are non-sterile liquid oral 
preparations are prepared mainly from manipulated solid dosage forms; either by the carers or 
hospital or community pharmacies. They are also prepared by dilution of an existing liquid dosage 
form (e.g. injection) or cytotoxic reconstitutions (Standing & Tuleu, 2005). For the purpose of this 
thesis, Turner et al (1998) definition of OL and UL use of medicines was adopted.  
The use of OL and UL medicines is common in paediatric healthcare settings. However, a 
systematic review assessing OL/UL prescription in paediatrics found higher rates in neonatal 
versus pediatric wards, and in hospital versus community and primary care settings (Pandolfini & 
Bonati, 2005). In hospital settings, 90% of patients who were admitted to neonatal intensive care 
unit (NICU) and 67% of patients who were admitted to paediatric intensive care unit (PICU) were 
prescribed OL and/or UL medicine (Conroy, McIntyre & Choonara, 1999; Conroy et al., 2000). 
While UL and OL use of medicines is prevalent in paediatric population (Batchelor & Marriott, 
2015; Kimland et al., 2012; Magalhães et al., 2015; RCPCH, 2013; Richey et al., 2013; Turner, 
Nunn, Fielding & Choonara, 1999), it has been associated with higher incidence of medicine-
related problems (Rees et al., 2017; Turner et al., 1999; WHO, 2007).  The following section 
describes medicine related problems. 
1.9 Medicines related problems (MRPs) 
 
Problems associated with the use of medicines occur at various stages of the medication use 
process (prescribing, dispensing, administration and monitoring) (Al Hamid et al, 2016). 
Medicine-related problems (MRPs) are therefore an important patient safety issue.  MRPs have 
been associated with hospital admissions, emergency department admissions and primary care 
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visits with increased risk of morbidity and mortality (Johnson & Bootman, 1995). MRP represents 
a wide array of concepts, consisting of adverse drug reactions (ADRs), adverse drug events 
(ADEs), and medication errors (MEs).  
1.9.1 ADRs  
The WHO defines an ADR as “a response to a drug which is noxious and unintended and which 
occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiologic function” (WHO, 1975). ADRs are classified into different subtypes, 
namely: type A reactions: are dose-dependent, predictable and are augmentations of known 
pharmacologic effects of the drug. Type B reactions are independent of administered dose; are 
uncommon and unpredictable, and often occur in a small population of patients. Host/patient 
factors therefore play role in their occurrence. Type C reactions: are chronic reaction, are 
uncommon and relate to the cumulative dose of medicine over time. Type D reactions are delayed 
reactions that appear sometime after the medicines have been administered; they are uncommon 
and dose-related. Type E reactions are withdrawal effects following discontinuation or end of use 
of medicines. Type F reactions are unexpected treatment failure due to interactions with other 
medicines, food or diseases and are dose-related (Edwards & Aronson, 2000). Most ADRs in 
hospital settings or causing admissions are type A reactions and are avoidable and predictable 
(Pirmohamed 1998).  
The paediatric population is especially prone to ADRs due to changes in the pharmacodynamics 
and pharmacokinetics as they develop into adulthood. The high prevalence of off-label and 
unlicensed prescribing, due to the limited availability of paediatric medicinal products also 
increases the risk of ADRs (Neubert 2004; Turner 1999). Up to 4.4 to 16.8% of hospitalised 
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children develop at least one ADR, especially paediatric patients admitted to intensive care units 
(Du et al., 2013).  
1.9.2 ADEs  
ADRs are sometimes mistaken for adverse drug events. According to the WHO, an ADE is “any 
untoward medical occurrence that may present during treatment with a pharmaceutical product but 
which does not necessarily have a causal relationship with this treatment” (WHO 2005). ADE is 
defined as “an injury or harm resulting from medical intervention related to a drug” (Bates et al., 
1995).  ADR differs from ADE in that it is directly attributable to pharmacology and would occur 
whether prescribing and dosing are appropriate or not. ADE on the other hand may result from 
inappropriate use of medicine or medication error, but not necessarily due to the pharmacology of 
the medicine; ADR is therefore a type of ADE (Schatz & Weber, 2015). The relationship between 
ADR, ADE and ME is shown in Figure 1.4 below: 
 
 
Figure 1:4: Relationship between adverse drug reaction; ADE, adverse drug event and 
medication error 
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1.9.3 MEs 
 
There is no consensus on the definition of medication errors (MEs) between different authors in 
the literature. The European Medicines Agency however defines MEs as “unintentional errors in 
the prescribing, dispensing, administration or monitoring of a medicine while under the control of 
a healthcare professional, patient or consumer” (European Medicines Agency, 2012). The United 
States National Coordinating Council for Medication Error Reporting and Prevention defines a 
medication error as “any preventable event that may cause or lead to inappropriate medication use 
or patient harm while the medication is in the control of the healthcare professional, patient, or 
consumer. Such events may be related to professional practice, health care products, procedures, 
and systems, including prescribing, order communication, product labelling, packaging, and 
nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and 
use” (US National Coordinating Council for Medication Error Reporting and Prevention, 2015). 
MEs are reported to cause as many as 7000 deaths per year in the US. In the UK, prescribing errors 
have been reported in 1.5% of prescriptions (Dean et al, 2002), and administration errors occurred 
in 3-8% of non-intravenous medicines’ doses (Dean, 1999). Majority of ME studies are reportedly 
conducted among adults patient population (Ghaleb et al., 2006); however a comparative study 
which assessed the rate of MEs between adult and paediatric patients found that MEs are three 
times higher in paediatric inpatients than adult inpatients (Kaushal et al., 2001). The actual rate of 
MEs in paediatric patient population is still unknown due to the fact that ME reporting is voluntary 
and inconsistent. However, dosing errors have been found to be the most common type of 
paediatric MEs accounting for approximately one-fifth of all errors because of the high level of 
off-label and unlicensed prescribing in paediatric practice (Sutcliffe et al., 2014).  
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1.9.4  Medicines related problems classification systems 
 
MRPs are sometimes referred to as drug-related problems (DRPs), and are used interchangeably. 
For the purpose of this thesis, the term MRP was used. This is because in the UK the term 
'medicine' is preferred to the term 'drug' (Fernandez -Llimos et al., 2005). Moreover, the term 'drug' 
may refer to recreational drugs. MRPs have been defined and/or classified variously by different 
authors. Strand et al. (1990) first defined MRP as “an event or circumstance involving drug therapy 
that actually or potentially interferes with the desired health outcomes”.  The Strand classification 
of MRPs was developed as means refocusing the role of the pharmacist on patient need and 
outcome rather than medicines. The authors classified MRPs into eight different types, which 
included untreated indication, improper drug selection, sub-therapeutic dosage, over-dosage, 
adverse drug reaction (ADR), drug interactions, failure to receive medication, medication used 
without indication. The definition developed by Strand et al. (1990) has been a reference point for 
other authors, including: American Society of Hospital Pharmacists (ASHP), Cipolle et al, 
Granada Consensus II, Mackie, Westerlund, Hanlon, and Pharmaceutical Care Network Europe 
(PCNE).  
1.9.4.1 American Society of Hospital Pharmacists’ classification of medicines related 
problems 
 
The ASHP classification of DRP was first proposed in 1993 and later standardised in 1996 and 
referred to as “medication-therapy problems”. ASHP defined MRP as “an event or circumstance 
involving medication therapy that actually or potentially interferes with an optimum outcome for 
a specific patient” (ASHP, 1996).  The ASHP classification was developed as part of the 
standards of pharmaceutical care to enable pharmacists determine the presence of medication-
therapy problems and include the following categories: 
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 medications with no medical indication 
 medical conditions for which there is no medication prescribed 
 medications prescribed inappropriately for a particular  medical condition 
 inappropriate medication dose, dosage form, schedule, route of administration, or method 
of administration Therapeutic duplication 
 prescribing of medications to which the patient is allergic 
  actual and potential adverse drug events 
 actual and potential clinically significant drug–drug, drug–disease, drug–nutrient, and 
drug–laboratory test interactions 
 interference with medical therapy by social or recreational drug use 
 failure to receive the full benefit of prescribed medication therapy 
 problems arising from the financial impact of medication therapy on the patient 
 lack of understanding of the medication therapy by the patient 
 failure of the patient to adhere to the medication regimen 
1.9.4.2 Cipolle et al. classification 
 
Cipolle and colleagues used the term drug therapy problem and defined it as “any undesirable 
event experienced by the patient that involves or is suspected to involve drug therapy and that 
actually or potentially interferes with a desired patient outcome”.  This classification was 
developed to enhance pharmaceutical care in order to improve patients’ outcomes. The 
classification is used by US community pharmacists to assess pharmaceutical care services.  In 
this classification system, drug therapy problems include: the need for additional therapy, 
unnecessary therapy, wrong drug, dosage is too low, dose too high, ADRs and adherence problems 
(Cipolle et al., 1998). 
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1.9.4.3 Granada consensus II 
 
The Granada consensus was first produced in 1998 by Spanish experts.  According to these experts, 
a drug therapy related problem is “a health problem, related to pharmacotherapy that interferes or 
may interfere with the expected patient health outcomes” and they grouped drug therapy related 
problems into:  
 indication (the patient does not use the medicines that he needs or the patient uses 
medicines that he does not need). 
 effectiveness (the patient uses an erroneously chosen medicine or the patient uses a dose, 
interval or duration inferior to the one needed). 
 safety (the patient uses a dose, interval or duration superior to the one needed or the patient 
uses a medicine that causes an adverse drug reaction). 
 In 2002, a second version of Granada consensus provided further clarification to the definition 
and classification, in which potential problem was excluded. DRP was therefore defined as “health 
problems that are considered as negative clinical outcomes, resulting from pharmacotherapy that 
for different reasons, either do not achieve therapeutic objectives, or produce undesirable effect”. 
This updated version focused on negative clinical outcomes rather than on health problems of the 
patient (Granada Consensus, 2002). The last version was produced in 2007 which defined DRP as 
“situations in which the process of use of medicines cause or may cause the appearance of a 
negative outcome associated with medication” (Granada Consensus, 2007).  In this version, DRPs 
are classified as: 
 Wrongly administered drug 
 Personal characteristics 
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 Unsuitable storage 
 Contraindication 
 Inappropriate dose, dosage schedule and/or duration 
 Duplicity 
 Dispensing errors 
 Prescription errors 
 Non-compliance 
 Interactions 
 Other health problems that affect the treatment 
 Probability of adverse effects 
 Health problem insufficiently treated 
 Others 
1.9.4.4 Mackie classification 
 
Mackie’s classification was adapted from Cipolle et al. (1998) classification following review of 
50 patients for presence of drug therapy problem as part of doctoral research. According to Mackie 
“a clinical drug-related problem is considered to exist when a patient experiences or is likely to 
experience either a disease or symptom having an actual or suspected relationship with drug 
therapy”. This classification system includes the following categories (Mackie, 2002): 
 unnecessary therapy 
 no indication apparent 
 untreated indication  
 safety  
 adverse reaction  
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 clinically significant drug interaction  
 contraindication  
 effectiveness 
 ineffective therapy  
 inappropriate choice of therapy  
 inappropriate formulation/delivery  
 inappropriate dose/dosing schedule  
 admitted non-adherence 
1.9.4.5 Westerlund classification 
 
This classification system was developed by the author as part of PhD research, and was initially 
used in 1996 before its incorporation into the Swedish community pharmacy software in 2001. 
The definition proposed was “A drug-related problem is a circumstance related to the patient’s use 
of a drug that actually or potentially prevents the patient from gaining the intended benefit of the 
drug”. This classification system was adapted partly from Strand et al. (1990) classification system 
of drug related problems and the author’s professional experience. It has been used in community 
pharmacies in Sweden to estimate the frequency of different types of drug-related problems, to 
determine relationships between the types and number of the identified problems and gender, age 
and number of prescribed medicines, and to document interventions made by pharmacists. The 
system includes the following categories (Westerlund, 2002): 
 Uncertainty about aim of the drug 
 Drug duplication 
 Drug–drug interaction 
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 Contraindication 
 Therapy failure 
 Adverse effect  
 Underuse of drug 
 Overuse of the drug  
 Other dosage problem  
 Difficulty swallowing tablet/capsule  
 Difficulty opening drug container  
 Other problem 
1.9.4.6 Hanlon classification 
 
The problem of inappropriate prescribing, especially among the elderly who are often prescribed 
many medicines due to different comorbid conditions led to the development of Medication 
Appropriateness Index (MAI), a quality measure for assessing appropriateness of prescribing. The 
aim of MAI was to improve prescribing quality based on clinical pharmacists’ intervention. It 
consists of 10 questions with three rating choices: “A” being appropriate, “B” being marginally 
appropriate and “C” being inappropriate. The MAI contains instructions for use, and specific 
definitions of each criterion, instructions on how to answer each question. The MAI questions are 
shown in Table 1.1 (Hanlon & Schmader, 2013). 
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Table 1:1: Medication appropriateness index 
1 Is there an indication for the drug? 
2 Is the medication effective for the condition? 
3 Is the dosage correct? 
4 Are the directions correct? 
5 Are the directions practical? 
6 Are there clinically significant drug-drug interactions? 
7 Are there clinically significant drug-disease/condition interactions? 
8 Is there unnecessary duplication with other drug(s)? 
9 Is the duration of therapy acceptable? 
10 Is this drug the least expensive alternative compared to others of equal utility? 
 
Although the MAI is a tool for identifying inappropriate prescribing which results in MRPs, a 
classification of MRPs have been drawn from the 10 questions, which include (Adusumilli & 
Adepu, 2014):  
 Indication  
 Effectiveness  
 Dosage 
 Correct direction   
 Practical directions  
 Drug–drug interaction  
 Drug–disease interaction  
 Duplication 
 Duration 
 Expense 
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1.9.4.7 Pharmaceutical Care Network Europe classification 
 
The first version of the Pharmaceutical Care Network Europe (PCNE) classification system was 
developed in 1999 to provide a standardised classification system that is globally comparable. The 
PCNE classification system used the term drug related problems (DRPs), however; in this thesis 
the term medicines related problems (MRPs) was used.  It categorised MRP into problems, causes, 
and interventions and is hierarchically structured. For the purpose of this thesis, the PCNE 
definition and classification system for MRPs version 6.2 (appendix 1), was adopted which defines 
MRP as: “an event or circumstance involving drug therapy that actually or potentially interferes 
with desired health outcomes” (PCNE, 2010). The PCNE classifies MRP into 4 primary domains 
for problems, 8 primary domains for causes and 5 primary domains for interventions. The primary 
domains for problems include: 
 treatment effectiveness: which means there is a (potential) problem with the (lack of) effect 
of the pharmacotherapy and includes i) no effect of drug treatment/ therapy failure, ii) 
effect of drug treatment not optimal, iii) wrong effect of drug treatment, and iv) untreated 
indication 
 adverse reactions: means patient suffers, or will possibly suffer from an adverse drug event. 
This includes i) adverse drug event (non-allergic), ii) adverse drug event (allergic), and iii) 
toxic adverse drug-event 
 treatment costs: means the drug treatment is more expensive than necessary and includes 
i) drug treatment more costly than necessary, ii) unnecessary drug-treatment 
 others include i) patient dissatisfied with therapy despite optimal clinical and economic 
treatment outcomes, and ii) unclear problem/complaint.  
34 
 
According to PCNE classification systems, MRPs result from errors, such as prescribing errors, 
medicine-use or administration errors. Therefore, MRPs is a broad term that include all types of 
medication errors that can lead to treatment effectiveness’ problems as well as toxic, allergic and 
non-allergic adverse drug reactions (PCNE, 2010; van den Bemt, Egberts, de Jong-van den Berg, 
Brouwers, 2000).  
Although there are many classification systems of MRPs in the literature, they have similarities 
between each other in their definitions and categories, with the PCNE classification of MRPs being 
the only system that has separated the causes from the problems. This has an advantage over the 
other classification systems because it facilitates the analysis of the root causes of MRPs. 
MRPs in paediatrics have been investigated in a very limited number of studies (Rashed et al., 
2012; Ibrahim et al., 2013; Easton et al., 2003; Easton et al., 2004). A comparative study to 
determine the frequency of MRPs in paediatric patients in the UK and Kingdom of Saudi Arabia 
reported an overall incidence of 45.2% (Rashed et al, 2012). The study found that the incidents of 
MRPs were higher in PICU than in general paediatric medical ward (Rashed et al., 2012). A related 
study found that 4.3% of paediatric admissions and 3.3% of Accidents & Emergency (A&E) visits 
were related to MRPs (Easton et al., 2004).  
With respect to research on the use of OL and UL medicines in paediatric patients, the focus has 
been on ADRs only. In one study, the authors reported that ADRs were more frequent in paediatric 
in-patients with the use of OL and UL medicines, than with the use of licensed medicines 
representing 6% and 3.9% respectively (Turner et al., 1999). A related study concluded that OL 
and UL use of medicines are most likely to be implicated in ADRs than authorised medicines 
(Bellis et al., 2013). Incidences of ADRs associated with the use of OL and UL medicines in 
paediatric patients have been reported by other authors (dos Santos, 2012; Theisen, 2013). These 
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studies have only focused on ADRs, which is only one aspect of MRPs; therefore, there is a need 
for a holistic evaluation of MRPs associated with the use of OL and UL medicines in paediatric 
in-patient.  
1.10 Chapter summary 
 
This chapter provided an overview of medicines’ use in paediatrics population and the challenges 
encountered in treatment of paediatric illnesses. 
 Patient safety is concerned with reducing adverse events associated with medicines use 
 The paediatric population is particularly prone to medicine-related adverse events as a 
result of changes in pharmacokinetic profile as they into adulthood as well as high use of 
medicines in off-label or unlicensed manner due to underrepresentation of this group in 
clinical trials 
 Dosing in the paediatric population are often extrapolated from adults data with further 
exposes children to medication incidents 
 To promote inclusion of the children in clinical trials,  a number of legislation have been 
published, the latest among them being the paediatric investigation plan 
 In spite of these legislations, there is still lack of age-appropriate medicines. Consequently, 
off-label and unlicensed medicines use is still prevalent among the paediatric population, 
especially neonates. 
 This research sought to investigate the problems that are associated with the use of off-
label and unlicensed medicines in paediatric patients. 
In the next chapter, the extent of OL and UL medicines use in the paediatric population and 
the safety concerns are explored. 
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Chapter 2: Systematic literature review of the prevalence of off-label and unlicensed 
medicines use and associated problems in paediatric in-patients 
 
2.1  Introduction 
 
In Chapter 1, an overview of medicines’ use in paediatrics was provided. It was found that, as a 
result of difficulties encountered in conducting clinical trials in paediatric population, many of the 
medicines prescribed in this population are used in the off-label (OL) and/or unlicensed (UL) 
manner (Chapter 1, section 1.8). Previous reviews have assessed the extent of OL and UL 
medicines’ use in paediatric patients (Kimland & Odlind, 2012; Magalhães et al., 2015; Pandolfini 
& Bonati, 2005; Silva, Ansotegui & Morais-Almeida, 2014). A systematic review assessing OL 
prescription in children found it to be common in all settings, but higher rates were seen for 
neonatal versus paediatric wards and for hospital versus community settings. OL medicines use is 
also reported to be higher in hospital settings when compared to primary care settings (Pandolfini 
& Bonati, 2005).  In their review, Kimland & Odlind, (2012) reported that the proportion of OL 
use varied between 10 and 65% in hospital settings, and between 11 and 31% in primary care.  
Another systematic review of 34 studies on the use of OL and UL medicines in hospitalised 
paediatric patients reported that OL medicines’ use ranged between 12.2%- 70.6 %; and UL 
medicines’ use ranged between 0.2%- 47.9 % with newborns being the most exposed to these 
medicines (42.0 to 100 %) (Magalhães et al., 2015).  
Use of medicines is associated with problems such as ADRs, ADEs and MEs. The rate of ADRs 
and MEs in paediatric patient population has previously been investigated. A systematic review 
and meta-analysis of the incidence of ADRs among in- and out-patients reported an overall 
incidence of 9.53% and 1.46% among in- and out-patients respectively (Impicciatore et al., 2001). 
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ADRs associated with the use OL and UL use of medicines was found to be higher when compared 
with licensed medicines (Turner et al, 1999).  
With regard to MEs, different subsets of MEs including prescribing, administration and dispensing 
errors have been studied.  Miller et al. (2007) reported that 5–27% of all medication orders for 
paediatric patients includes an error within the spectrum of the entire delivery process. Particularly, 
dosing errors have been reported as the most common types of medication errors among paediatric 
patients (Ghaleb et al., 2006). In a systematic review to determine extent and nature of the MEs in 
the UK, Sutcliffe et al. (2014) reported the high prevalence of OL prescribing in primary care 
resulted in dosing errors in this setting.  In paediatric and neonatal acute care settings, the authors 
also reported that dosing errors were the most common type of ME, accounting for approximately 
one-fifth of all errors (Sutcliffe et al., 2014).  At the time of literature review of this thesis, no 
published study on MEs associated with the use of OL and UL medicines in paediatric patients in 
hospital settings was identified.  
Building on the reviews described in the preceding paragraphs, the literature review of this thesis 
sought to provide an update on studies that investigated the prevalence of OL and/or UL medicines 
in paediatric patients as well as identify studies that investigated problems that are associated with 
their use. The objectives of this review were therefore: 
i. To determine the prevalence of use of OL and UL medicines in paediatric population. 
ii. To determine problems associated with the use of OL and UL medicines in paediatric 
population. 
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2.2 Method 
 
A literature search for articles published between January 1997 and February 2016 was 
undertaken. The search was carried out in 9 databases namely Scopus, PubMed, British Nursing 
Index, Pharm-line, Web of Science, British Library Catalogue, CINHAL, Cochrane Library and 
Google Scholar.  A combination of search terms was used including: (“medicine related problems” 
OR “medicine-related problems” OR “medication errors” OR “medication problems” OR “drug 
problems” OR “drug-induced death” OR “Adverse drug reactions” OR “adverse reactions” OR 
“adverse events” OR “adverse drug events” OR “medicine mishap” OR “medication mistake” OR 
“inappropriate medicines”  OR “ADRs” OR “ADEs” OR “drug-death”); (“off-label medicines” 
OR “off-label prescribing” OR “off-label drugs” OR “off-label medication” OR “unlicensed 
medicines” OR “unlicensed drugs” OR “unlicensed medications” OR “unlicensed prescribing”); 
and (paediatrics OR paediatric OR pediatrics OR pediatric OR paed OR ped OR children OR child 
OR infants OR infant OR newborn OR newborns OR neonate OR neonates).  The search terms 
were derived from previous literature reviews and studies in paediatric population. All synonyms 
were agreed on by the researcher and supervision team.  
2.2.1 Inclusion and exclusion criteria 
 
The following were the inclusion criteria: 
 Primary studies investigating prevalence, incidence and problems associated with use of 
OL and UL medicines in paediatrics (0-18years) 
 Studies carried out in in-patient care settings 
 Studies published in English 
The exclusion criteria were: 
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 Studies of OL and UL use of medicines in adults. 
 Studies in out-patient and community care settings. 
 Studies where the full text article was not available in English. 
 Editorials, correspondences and opinions. 
Data was extracted and screened for inclusion by the researcher; however the included studies 
were further reviewed by the supervisory team to ensure validity. The quality of the studies was 
assessed using Critical Appraisal Skills Programme (CASP) checklist. References of the included 
studies were also searched for other articles. The review was updated in October 2017. 
2.3 Results  
 
In the literature search between January 1997 and February 2016, 1,362 articles were obtained.  
Duplicates and articles with irrelevant titles were removed, and inclusion and exclusion criteria 
were applied. Thirty-four papers were included in the initial review. Four more papers were 
included following an updated literature search covering the period up to October 2017. A 
summary following the Preferred Reporting Items for Systematic Review and Meta-Analyses 
(PRISMA) (Moher et al., 2009) is provided in Figure 2.1. 
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Figure 2:1: Flow diagram of literature search outcome 
 
 
 
 
Total number of titles/abstract 
retrieved: 1356 articles 
Number of articles excluded 
because of irrelevant titles: 718 
articles 
Screened for abstracts: 240 articles 
Number of articles excluded 
after screening abstract: 195 
articles 
Number of articles retrieved from 
secondary sources: 6 articles 
Assessed for inclusion: 45 
For inclusion:  34 articles 
Number of articles added after 
review update: 4 
Number of duplicates removed: 
404  
After removal of duplicates: 958 
articles 
Number of articles not included 
in the review:  11 articles 
(included adults’ patients) 
Final articles included in the review:  
38 articles 
Total number of articles from the search: 1362 
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2.3.1 Settings of included studies  
 
2.3.1.1 Studies conducted in neonatal units 
 
Of the 38 studies included in this review, ten were conducted in neonatal units including intensive 
care units (Carvalho et al., 2012; Conroy et al., 1999; Cuzzolin & Agostino, 2016; Kieran et al., 
2014; Laforgia et al., 2014; O’Donnell et al., 2002; Oguz et al., 2012) ) (Table 2.1): 
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Table 2:1: Studies conducted in neonatal units 
Author, Year/ Country Design Duratio
n 
No. of prescriptions 
reviewed 
No. of 
patients 
Main findings 
Cuzzolin & Agostino, 
2016, Italy 
Prospective 
cross-sectional 
survey 
 
1 day 
survey 
720 prescriptions 
corresponding to 79 
drugs 
220 
neonates 
191 (26.5 %) were license, 529 (73.5 %) were OL or 
UL. 193/220 newborns (87.7 %) received at least one 
OL/UL prescription. Most common categories of OL 
use were age (34.4 %) and dosing frequency (20.6 %).  
Schweigertova et al., 
2016, Slovak Republic  
Cross-sectional 
study 
6 months 962 prescriptions 
corresponding to 97 
different medications  
 202 
hospitalised 
newborns 
43% were OL and 4.8% as UL. At least one OL or UL 
drug was given to 88.6% of patients.  
Laforgia et al., 
2014 
Italy 
Prospective 
observational 
study 
1 month 483 prescriptions for 
87 different drugs 
126 
neonates 
88.6% were licensed and 11.4% were UL. Among 
licensed medicines, 37.4% were used as OL (range 
27.3- 53.4%). Each patient was exposed to three 
different medicines 
Kieran et al 
2014 
Ireland 
Prospective 
study 
2 months 900 prescriptions of 69 
different drugs 
110 
neonates 
29 (42%) were licensed, 13 (19%) were UL, and 27 
(39%) were OL. 45 infants (44%) received both an OL 
and UL medicines. 
Oguz et al 
2012, Turkey 
 Prospective 
observational 
cohort study 
24 hours  1315 prescriptions of 
93 different drugs 
464 
neonates 
62.3% were OL and UL 
Carvalho et al., 2012, 
Brazil 
Observational 
cohort study 
6 weeks 318prescriptions 61 neonates  UL medicines made up 7.5% of prescriptions; OL 
medicines made up 27.7%.  Only 13 patients with 
appropriate use of medications (21%).  
Lass et al.,  2011 
Estonia 
Prospective 
cohort study 
6 months 1981 prescriptions of 
115 products 
490 
neonates 
1729 (87%) of 1981 prescriptions were OL or UL 
medicines. All preterm, and 97% of treated term 
neonates received at least one OL or UL medicine. 
Dell’Aera et al.,  2007 
Italy 
Cross- sectional 
pilot and 
prospective 
study 
2months 176 prescriptions for 
61 different drugs 
34 new-
borns 
Medicines were licensed in 88%, and UL in 12% of 
cases. 
In licensed medicines, 37.5% were used following the 
terms of marketing authorization 
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High percentage of OL and UL medicines’ use in 
neonatology 
O’Donnell et al., 2002 
Australia 
Prospective 
cohort study 
10 weeks 1442 prescriptions 97 infants 
with 101 
admissions 
42% of the total prescriptions were licensed, 11% 
were UL, and 47% were OL 
80% of infants received UL or OL medicine, and rose 
to 93% of extremely low birth weight infants. 
Conroy et al., 1999 
UK 
Prospective 
chart review 
13weeks 455 prescriptions 70 neonates 90% (63) received at least one OL or UL medicine.  
54.7% (249) were OL, 9.9% (45) were UL, and 35.4% 
(161) were licensed. 
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Four studies were undertaken in NICU and other wards  (Table 2.2) (Lindell-Osuagwu et al., 
2009; Lindell-Osuagwu et al., 2014; Mukattash et al., 2016; Porta et al., 2010;). A summary is 
provided in Table 2.2.
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Table 2:2: Studies conducted in neonatal intensive care units and other neonatal wards 
 
 
Author, 
Year/Country 
Design Duration No. of 
prescriptions 
reviewed 
No. of 
patients 
Main findings 
Lindell-Osuagwu  
et al., 2014 
Finland 
Prospective 
study 
2 weeks 1054 prescriptions 
for 119 patients 
123 patients 
0-18 years 
Patients with prescription for OL/UL medicine were 
significantly higher in 2011 compared to 2001 (p< 0.001). 
Prescriptions for UL medicines was significantly higher in 
children < 2years than in older children in both years (21% 
vs. 5% in 2011 and 24% vs. 3% in 2001, P < 0.001). 
Lee et al 
2013 
Malaysia 
Prospective 
observational 
explanatory 
study 
2 months 1295 prescriptions 
for 168 patients 
194 patients 
aged 1 month 
to 18tears 
353 (27.3%) were UL, 442 (34.1%) were OL. 44% of 
patients received at least one medicine for UL use, and 
82.1% of patients received at least one medicine for OL use 
Porta et al., 2010 
Three European 
countries- Greece, 
Italy, UK,  
Prospective 
study 
2 weeks 1244 antibiotic 
prescriptions 
616 children 
aged 0 to 17 
years 
OL antibiotic use is very common among European 
paediatric patients 
Lindell-Osuagwu  
et al 2009 
Finland 
Prospective 
study 
2 weeks 629 prescriptions 
for 108 patients 
141 patients 
aged  0- 18 
years 
321 (51%) were for licensed medicines, 226 (36%) were 
OL and 82 (13%) were UL medicines. 24% of 108 children 
received licensed medicines; 66% received OL; 33% 
received UL medicines.  
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2.3.1.2 Studies carried out in paediatric intensive care units & other paediatric wards 
 
Four studies in were carried out in Paediatric Intensive Care Unit (PICU) and other wards (Berdkan 
et al., 2016; Garcia-Lopez et al., 2017; Jobanputra, Save & Bavdekar, 2015; Lee et al., 2013). The 
four studies are included in Table 2.3. 
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Table 2:3: Studies carried out in paediatric intensive care units & other paediatric wards 
 
 
Study 
Year/Countr
y 
Design Duratio
n 
No. of 
prescriptions 
reviewed 
No. of patients Main findings 
Garcia-
Lopez et al., 
2017 Spain 
Prospective 
observation
al  
 
6 weeks 696 prescriptions 
involving 102 
medicines 
42 patients aged 
0- 18years old 
8.6% of total prescription were UL and 53.9% were OL use. 
Main reasons for OL use were indication, age and dose. 
Berdkan et 
al., 2016, 
Lebanon 
Retrospecti
ve analysis 
 
10 
months 
2054 prescribed 
medicines 
500 patients 
Aged 0- 16years 
old 
11.1% and 15.8% of medicines prescribed were UL according 
the French Medical Regularity Authority and the Food and Drug 
Administration (FDA) respectively. 30.2% were OL and 33.5% 
were OL according to the French Medical Regularity Authority 
and FDA respectively.  
Jobanputra, 
Save & 
Bavdekar, 
2015, India 
Prospective 
observation
al 
12 
months 
1789 prescriptions 482 aged 28 days 
to 12years 
738(41.25%) were OL and 376(21.01%) were UL. OL medicines 
use was highest in infants (56.52%) with indication outside the 
license (32.37%) being the commonest category of OL 
medicines’ use across all age groups. 
Lee et al 
2013 
Malaysia 
Prospective 
observation
al 
explanatory 
study 
2 months 1295 prescriptions 
for 168 patients 
194 patients aged 
1 month to 18tears 
353 (27.3%) were UL and 442 (34.1%) were OL. 44% of patients 
received at least one medicine for UL use, and 82.1% of patients 
received at least one medicine for OL use 
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2.3.1.3 Studies carried out in emergency units 
 
Three studies were carried out in paediatric emergency units (Czarniak et al., 2015; Taylor et al., 
2015; Morales-Carpi et al., 2010); these are summarised in Table 2.4. 
Table 2:4: Studies carried out in emergency units 
 
 
 
 
 
 
 
Study 
Year/Cou
ntry 
Design Duration No. of 
prescription
s reviewed 
No. of patients Main 
finding
s 
Czarniak 
et al., 
2015, 
Australia 
Retrospective 
chart review 
12 months 2,654 
prescriptions 
for 330 drugs 
699 patients aged 0-
18years 
1905 (71.8) were licensed, 
681 (25.7%) were OL and 68 
were UL. Infants and 
children had the most OL 
prescription (31.7% and 
35.9% respectively) and 
highest UL prescribing 
(7.2%) occurred in infants (p 
< 0.0001).  
Taylor et 
al., 2015, 
Australia 
Retrospective 
observational 
12 months 6786 
medicines 
administered 
3343 aged 0-17years 2072 (30.5%) were OL/UL. 
1213 (36.3%)of the patients 
were prescribed OL/UL. 
Morales-
Carpi et al 
2010 
Spain 
Prospective 
observational 
and descriptive 
study 
14 months 667 
prescriptions 
for 336 
children 
462 children 
Aged 0- 14 years old. 
Of the 152 formulations 
prescribed, 107 were used in 
OL manner. 
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2.3.1.4 Studies carried out in general and surgical paediatric wards 
 
Majority (17) of the studies were conducted in general paediatric wards, surgical, and nephrology 
wards (Ballard et al., 2013; Bellis et al., 2013; Berg & Tak, 2011; Conroy et al., 2000; Craig, 
Henderson & Magee, 2001;; Di Paolo et al., 2006; Dos Santos & Heineck, 2012; Gavrilov et al., 
2000; Gomes et al., 2015; Hsien et al., 2008; Joret-Descout et al., 2015; Neubert et al., 2004; 
Palcevski et al., 2012;  Saiyed, Lalwani & Rana, 2015; Shah et al., 2010; Turner et al, 1999; 
Yasinta et al., 2015). A summary is provided in Table 2.5.
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Table 2:5: Studies carried out in general and surgical paediatric wards 
Study 
Year/Countr
y 
Design Duratio
n 
No. of 
prescriptions 
reviewed 
No. of 
patients 
Main findings 
Gomes et al., 
2015, Brazil 
Prospective cross-
sectional 
6 months 1,158 
corresponding 
to 65 drugs 
320 aged 28 
months to 
14 years 
57.2% were in-label, 36.4% were OL, and 6.3% were UL. Prevalence of 
UL and OL medicines’ use was 20.9% and 77.8% respectively. 
Joret-
Descout et 
al., 2015, 
France 
Retrospective  
cross-sectional 
1 day 315 
prescription 
medicines 
120 aged 1-
16 years 
190/60.3 % were licensed, 115/36.5 % were OL and 10/3.2 % were UL. 
54 % of patients received an OL/UL medicine.  
Saiyed, 
Lalwani & 
Rana, 2015, 
India 
Prospective non-
interventional 
6months 1,645 
medications 
administered 
320 aged 0 
to 12 years 
70% of 1645 medications were OL. ADRs occurred in 47 (10.85%) out of 
320 patients.  No. of OL medicines significantly increased the hazard of an 
ADR hazard ratio (P = 0.002). Most common ADRs were macupapular 
rash, chills, ataxia and pyrexia.  
Yasinta et 
al., 2015, 
China 
 Retrospective 
review 
1 year 1424 
corresponding 
to 35 drugs 
385 aged 
1months- 
18 years old 
16.64% of 1424 prescriptions were OL, and 31.43% of 35 medicines were 
prescribed in OL manner. 40.78% of 385 patients received OL nephrology 
medicines.   
 Ballard et 
al., 2013 
Australia 
Retrospective 
review  
7 weeks 887 medicines 300 patients 
aged 0- 12 
years old 
32% of medicines were OL 
57.3% of patients received an off-label medicine of the 106 different 
medicines,  
Bellis et al.,  
2013, UK 
Nested case-
control study 
within a 
prospective 
cohort study 
12month
s 
10,699 
different drugs 
1388 
patients 
aged 
between 0 
to 16 years 
and 11 
months. 
6980 (68.8%) of the total medicines were licensed, 2407 (23.7%) were OL, 
and 758 (7.5%) were UL. 435 (6.2%) of all medicines were implicated in at 
least one definite or probable ADR. 298 (12.4%) of OL medicines and 113 
(14.9%) of UL medicines were associated with ADRs. 
Dos Santos 
& Heineck 
2012 
Cross-sectional 
descriptive 
prospective study 
3 months 342 
prescriptions 
of 2026 items 
342 patients 
aged 0 to 14 
years 
12% of prescriptions were UL, and 39% were OL 
95.3% of patients received OL or UL medicine 
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Brazil  
Palcevski et 
al., 2012 
Croatia 
Prospective cross-
sectional study 
1 day 
each 
month 
for 12 
months 
1643prescripti
ons 
Of 198 
different drugs 
691 patients 
aged 1 day 
to 20 years 
old 
46% of the different drugs were OL or UL. 48% of patients received at 
least one OL or UL medicine. 25% of all the prescriptions were either OL 
or UL. 
Berg & Tak 
2011 
Netherland 
Retrospective 
Analysis of 
electronic  
prescriptions 
ordering system  
2 weeks 268 drug 
prescriptions 
39patients 
aged 0.25- 
17 years old 
87% of patients received OL or UL medicine 
59% of children received at least two UL medicines 
 
Shah et al., 
2010 
Northern 
Ireland & 
Singapore 
Prospective cross-
sectional study 
4 weeks 2073 
medicines NI 
674 medicines 
Singapore 
389 
children in 
NI; 
252 
children in 
Singapore 
(authors did 
not specify 
age of 
children) 
More medicines were prescribed in an OL and UL manner in NI (10.4% 
and 32.6% respectively) compared to Singapore (1.3% and 20.6% 
respectively). 
 
 
 
Hsien et al., 
2008 
Germany 
Prospective 
observational 
study 
6 months 1,812 
prescriptions 
representing 
211 
different drugs 
417 patients 
aged 0- 18 
years 
31% of all were OL.  61% of 417 patients received at least one OL 
prescription.  The percentage of OL prescriptions among the five most 
frequently prescribed medicines groups were: cardiovascular medicines, 
60%; anti-infectives, 42%; respiratory medicines, 30%; medicines for GIT, 
25%; analgesics and antipyretics, 3%.  
Di Paolo et 
al., 2006 
Switzerland 
Prospective study 6 months 
pilot 
study 
483 
prescriptions 
60 patients 
aged 0 to 18 
years 
51% (247) prescriptions were licensed, 24% (114), were UL and 25% (122) 
were OL. All patients received at least one UL or OL medicine. 
 
Neubert et 
al., 2004, 
Germany 
Prospective 
pharmacoepidemi
ological 
8months 740 drug 
prescriptions 
178 patients 
aged 0- 18 
years old 
198 (27.7%) medicines were used in either OL or UL manner. 46 ADRs 
were observed in 31 patients (17.4%); ADRs were associated with 5.6% of 
the 517 licensed medicines prescriptions, and with 6.1% of the 198 OL or 
UL medicine prescriptions. 
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Cohort-based 
survey  
Craig, 
Henderson 
& Magee, 
2001, 
Northern 
Ireland 
Prospective study 2 months 237 
prescriptions 
74 patients 
aged from 
one week 
old to 13 
years 
77.2% medicines were licensed; 22.8% prescriptions were non-licensed 
(3.4% were UL and 19.4% were OL). 
Gavrilov et 
al., 2000 
Israel 
Retrospective 
analysis of 
medical records 
2 months 222 medicine 
prescriptions 
132 patients 
aged 
1month to 
18 years 
8% of the 222 medicines were UL and 26% were OL. 42% of children 
received either OL or UL medicine. 
Conroy et 
al., 2000, 5 
European 
countries 
Prospective study 4weeks 2262 drug 
prescriptions 
624patients 
aged 4days 
to 16 years 
1036 (46%) of all prescribed medicines were either UL or OL. 67% (421) 
of patients received an UL or OL medicine.   
Turner et 
al., 1999, UK 
Prospective 
surveillance study 
13 weeks 4,455 drug 
courses  
936patients 
aged from 
1day to 18 
years 
48% (507) out of 1046 admitted patients received one or more OL or UL 
medicine. ADRs occurred in 11% (116) of the 1046 admissions. ADRs 
were associated with 112 (3.9%) of the 2881 licensed medicines, and 6% 
(95) of the 1574 OL/UL medicines.  
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2.3.2 Definition of off-label and unlicensed use 
 
Among the studies included in this review, there were variations in the definition of OL and 
UL medicines’ use. Majority of the studies (26) defined OL and UL use based on the country’s 
national formulary and the information provided in the SPCs; 10  studies  adopted the Turner 
et al. (1998) definition of OL and UL medicines’ use, while two studies adopted the Neubert 
et al (2008) definition. Table 2.6 includes studies and definition the authors adopted. 
Table 2:6: Definitions of off-label and unlicensed medicines in the included studies 
Definition of OL/UL Number of 
studies 
Authors/Year 
National formulary 
and/or SPC 
26 (Bellis et al., 2013; Carvalho et al., 2012; Cuzzolin & 
Agostino, 2016; Dell’Aera et al., 2007;  Di Paolo et al., 2006; 
Dos Santos & Heineck, 2012; Gomes et al., 2015;  Hsien et al., 
2008; Jobanputra, Save & Bavdekar, 2015; Kieran et al., 2014; 
Laforgia et al., 2014; Lee et al., 2013; Morales-Carpi et al., 
2010; Mukattash et al., 2016; Neubert et al., 2004; Oguz et al., 
2012; Palcevski et al., 2012;  Porta et al., 2010; Saiyed, 
Lalwani & Rana, 2015; Schweigertova et al., 2016; Shah et al., 
2010; Ballard et al., 2013; Berg & Tak, 2011; Czarniak et al., 
2015; Taylor et al., 2015; Yasinta et al., 2015)  
 
Turner’s definition  10 (Berdkan et al., 2016; Craig, Henderson & Magee, 2001; 
Conroy et al., 2000; Conroy et al., 1999; Gavrilov et al., 
2000; Joret-Descout et al., 2015; Lindell-Osuagwu et al., 
2014; Lindell-Osuagwu et al., 2009; O’Donnell et al., 2002; 
Turner et al., 1999) 
Neubert’s definition 2 (Garcia-Lopez et al., 2017; Lass et al., 2011) 
 
 
 
 
 
 
 
 
 
54 
 
2.3.3 Studies that investigated prevalence of off-label and unlicensed medicines use 
 
Thirty-four studies investigated the prevalence of OL and UL medicines use in paediatrics 
(Table 2.1). Some of the studies reported prevalence of OL and UL medicine use separately 
while others reported it together. Among the studies conducted in NICU, Lass et al., 2011 
reported the highest combined OL/UL prevalence of 87%, Cuzzolin & Agostino, 2016 and 
Oguz et al., 2012 reported combined OL/UL prevalence of 73.5% and 62.3% respectively. 
Among the nine studies conducted in NICU, Conroy et al., 1999 reported highest OL 
prevalence of 54.7% and lowest UL prevalence of 9.9%. Up to 100% of patients in this setting 
received at least one OL or UL medicine (Conroy et al., 1999; Kieran et al., 2014; Lass et al., 
2011; O’Donnell et al., 2002). In the paediatric general ward, high prevalence OL and UL 
medicines use is also reported. In a prospective study of 342 patients, Dos Santos & Heineck 
(2012) reported that 95.3% of patients received UL or OL medicines. Prevalence of OL and 
UL medicine use in this setting is reported to be between 25% - 77% (Di Paolo et al., 2006; 
Gomes et al., 2015) and 3.2% - 24% (Joret-Descout et al., 2015; Di Paolo et al., 2006). OL and 
UL medicines use is therefore a common practice among all paediatric settings with higher 
incidence reported in intensive care units.  
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2.3.4 Studies that investigated safety issues associated with the use of off-label and 
unlicensed medicines 
 
Four studies (Bellis et al., 2013; Neubert et al., 2004; Turner et al., 1999; Saiyed, Lalwani & 
Rana, 2015) investigated adverse drug reactions (ADRs) associated with the use of OL and UL 
medicines’ use in paediatrics. The four studies were all of prospective design. 
In a prospective study of 1,046 admissions in which 48% of the patients received one or more 
OL or UL medicines, ADR occurred in 11% of the admissions. Approximately 4% of the ADRs 
were associated with licensed medicines and 6% was associated with OL/UL medicines 
(Turner et al., 1999). In a related study of 320 patients, 70% of prescribed medicines were OL. 
ADRs occurred in 10.8% of the patients, with the most common ADRs being macupapular 
rash, chills, ataxia and pyrexia (Saiyed, Lalwani & Rana, 2015). Bellis et al. (2013) reported 
12.4% ADR with OL and 14.9% ADR with UL medicines compared with 6.2% with licensed 
medicine. The study reported a prevalence of 23.7% for OL and 7.5% for UL medicines.  A 
summary of studies that investigated ADRs is provided in Table 2.7. 
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Table 2:7: Studies that investigated adverse drug reactions associated with use of off-label and unlicensed  
Study/Year 
Country 
Design Definition Duration Setting No. of 
prescriptions 
reviewed 
No. of 
patients 
Main findings 
Saiyed, 
Lalwani & 
Rana, 2015, 
India 
Prospective 
non-
interventional 
OL use of 
medicines was 
based on authors’ 
categorisation. 
6months paediatri
c ward 
1,645 medications 
administered 
320 aged 0 to 
12 years 
70% of medicines were OL. 51 ADRs occurred in 
10.85% out of 320 patients.  OL caused 367% 
ADRs; licensed medicines resulted in 33% of 
ADRs. ADR increased with increase in number of 
OL medicines (P = 0.002).  
Bellis et al.,  
2013, UK 
Nested case-
control study 
within a 
prospective 
cohort study 
OL and UL use of 
medicines was 
based on 
information 
obtained from the 
SPCs. 
12months Medical 
ward 
10,699 different 
medicines 
1388 patients 
aged between 
0 to 16 years 
and 11 
months. 
68.8% of medicines were licensed; 23.7% were 
OL, and 7.5% were UL. 6.2% of licensed 
medicines caused at least one definite or probable 
ADR; 12.4% of OL medicines and 14.9% of UL 
medicines caused at least one definite or probable 
ADR respectively. 
Neubert et 
al., 
2004, 
Germany 
Prospective 
pharmacoepide
miological 
Cohort-based 
survey  
OL and UL 
classified based 
on information 
obtained from 
Fachinfo compact 
disc 2001. 
8months Paediatri
c 
isolation 
ward 
740 drug 
prescriptions 
178 patients 
aged 0- 18 
years old 
27.7% medicines were used in OL and/or UL 
manner. 46 ADRs were observed in 31 patients 
(17.4%); ADRs were associated with 5.6% of the  
licensed prescriptions, and with 6.1% of the OL or 
UL prescriptions.  
Turner et 
al., 1999, 
UK 
Prospective 
surveillance 
study 
Turner et al. 1998 
definition  
13 weeks surgical, 
medical, 
neonatal 
surgical, 
cardiac 
intensive 
care and 
4,455 drug 
courses  
936patients 
aged from 
1day to 18 
years 
 
48% (507) out of 1046 admitted patients received 
one or more OL or UL medicine. ADRs occurred 
in 11% (116) of the 1046 admissions. ADRs were 
associated with 3.9% of licensed medicines, and 
6% of OL/UL medicines.  
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general 
paediatri
c 
intensive 
care units  
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2.4 Discussion 
 
This review adds to existing body of literature in confirming a high prevalence of OL and UL 
medicines use among paediatric patients in different paediatric settings. In 2007, the European 
Medicines Agency introduced a legislation, the Paediatric investigation Plan (PIP) that encourages 
inclusion of children in clinical trials (European Medicines Agency, 2007). This was to ensure 
sufficient paediatric formulations in the market, and to minimise OL and UL prescribing in 
paediatrics.  Lindell-Osuagwu et al. (2009) reported that the proportion of prescriptions for OL use 
in different paediatric settings was 58% prior to the PIP legislation. A repeat study 10 years after 
the first found that the proportion of prescriptions for OL use was 79% (Lindell-Osuagwu et al., 
2014). Although Lindell-Osuagwu et al reports show increase in OL prescribing following PIP 
legislation, Van Riet-Nales et al (2011) reported an improvement in development of newer types 
of paediatric dosage forms, such as mini-tablets or oro-dispersible films. The authors however 
concluded that there is still need for further research in paediatric medicines.  
Paediatric medicines research is influenced by recent legislation to develop age-appropriate 
formulations; however, there are many challenging factors that affect designing suitable 
formulations for the paediatric population (Buckley et al., 2017). These factors include the 
heterogeneity of paediatric population especially in swallowing abilities, taste preferences, and 
dosage requirements (Buckley et al., 2017).  To develop age-appropriate medicines therefore, 
collaboration between experts (formulators, clinicians, toxicologists and medicines’ disposition 
scientists) for production of suitable amount of excipients, dosing regimen, duration of treatment, 
route of administration, as well as the indication is needed (Schmitt, 2015). Another factor that 
affects design of age-appropriate medicines is excipients selection. This is because there is a lack 
of specific standards regarding the safety of the excipients commonly used in the different groups 
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of paediatric populations as some excipients are implicated in safety incidents when used in 
paediatric population while they used safely in adults (Fabiano et al., 2011). The consequence of 
these challenges is that, there is lack of paediatric age-appropriate formulations and OL and UL 
medicines’ use remains a problem in paediatric practice. Thus, most of medicines used for 
paediatric patients are used in an OL and/or UL manner with regard to age, indication, dosage and 
frequency (Ballard et al., 2013; Bellis et al., 2013; Conroy et al., 1999; Conroy et al., 2000; Di 
Paolo et al., 2006; Hsien et al., 2008; O’Donnell et al., 2002; Porta et al., 2010).  
A higher prevalence of OL and UL medicines’ use is reported in the neonatal intensive care unit 
than in other paediatric settings (Cuzzolin & Agostino, 2016; Lass et al., 2011; Lindell-Osuagwu 
et al. 2014; Oguz et al., 2012).  The paediatric population with highest exposure to OL and UL 
medicines is neonates, particularly preterm neonates with all preterm neonates reported to receive 
at least one OL or UL medicine (Lass et al., 2011).  That is because preterm neonates usually have 
very low body weight which affects absorption, distribution, metabolism and extraction of 
medicines. Underdeveloped organs, decrease in body water and co-morbidities during the 
developmental stages lead to further changes of the pharmacokinetics in this group of patients. 
There were variation in definitions and classifications of OL and UL between the authors. 
Although Neubert et al. (2008) published a consensus definition of OL and UL use of medicines, 
most of the studies defined OL and UL use based on national formulary and/or SPCs while others 
adopted the Turner et al. (1998) definition. Thus, there is currently no consensus on the definition 
of OL and UL medicines use in paediatric. This can makes the judgement on OL and UL use 
limited to authors’ classifications and categories, which made the comparison of published studies 
difficult. This review highlights the need for a consensus definition of OL and UL medicine use in 
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paediatrics and a uniform method of reporting OL and UL prevalence and safety to enable 
comparison.  
OL and UL medicines prevalence is reported differently between authors. Whilst some authors 
report combined OL/UL prevalence (Lass et al., 2011; Cuzzolin & Agostino, 2016; Oguz et al., 
2012), others report OL and UL separately (Conroy et al., 1999; Lee et al., 2013; O’Donnell et al., 
2002; Turner et al., 1999).  Thus, it is again difficult to compare the results between different 
studies.  
The different studies employed different designs (prospective and retrospective). The study’s 
design usually has a major effect in achieving the desired outcomes. Both prospective and 
retrospective designs involved review of drug charts and/or medical notes and databases.  
Variation in methods investigating the same subject can lead to variation in the results obtained. 
Although there is high prevalence of use of OL and UL medicines in children in different in-patient 
care settings, problems associated with their use are low (Taylor et al., 2015). Medicines related 
problems (MRPs) comprised of Adverse drug reactions (ADRs), adverse drug events (ADEs), and 
medication errors (MEs), however the four studies included in this review assessed one aspect of 
the MRPs associated with the use OL and UL medicines (ADRs). The prevalence of ADRs 
associated with the use of OL and UL medicines are higher when compared with licensed 
medicines (Neubert et al., 2004; Turner et al., 1999). The risk of ADRs to OL and UL medicines 
increases with increased number of OL and UL used (Saiyed, Lalwani & Rana, 2015). ADR was 
classified as definite, probable or possible (Turner et al., 1999). OL and UL medicines are reported 
to be associated with higher prevalence of definite or probable ADRs (Bellis et al., 2013). Despite 
the fact that OL and UL medicines’ use is common in paediatrics, it poses safety implications 
because of the major differences between children and adults in their pharmacokinetics and 
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pharmacodynamics. Thus, safety studies to explore all aspects of OL associated problems are 
important for this population. There is also the need for a holistic view at the problems that are 
associated with the use of OL and UL medicines in this patient population by assessing other 
aspects of MRPs.  
A major limitation of this review is that it only focused on studies of OL and UL use in in-patient 
paediatrics settings, thus the findings may not present the overall picture of the prevalence and 
problems associated with OL and UL use of medicines in the paediatric patients in other settings. 
Another limitation of this review is that a meta-analysis of included studies could not be performed. 
This was due to the variation in OL and/or UL definitions, author’s methodologies, participants 
age-groups, and settings. 
Findings of this systematic review confirms results of previous reviews, and revealed high 
prevalence of use OL and UL medicines in paediatric in-patients. While there is high prevalence 
of use of OL and UL, problems associated with their use were low, and comprised mainly of 
ADRs, such as, macupapular rash, chills, ataxia and pyrexia. Further studies are required to 
evaluate the safety and effectiveness of OL and UL medicines use in this setting by investigating 
all other aspects of MRPs. 
2.5 Chapter summary 
 
This chapter describes the systematic literature review that was undertaken to determine the 
prevalence of OL and UL medicines, and problems associated with the use of OL and UL 
medicines in paediatric patients.  
 Findings of the review show high prevalence of OL and UL medicines use among 
paediatric patients, especially those admitted to intensive care units.  
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 There was no consensus on the definition of OL and UL use of medicines among the 
authors of the included studies 
 There were no studies that investigated MRPs associated with use of OL and UL medicines 
in paediatric patients, however ADRs have been reported to be higher with the use of OL 
and UL medicines when compared with licensed medicines. 
 This review therefore highlights the need for further research to investigate all aspects of 
MRPs associated with the use of OL and UL medicines in paediatric patients.  
2.6 Research rationale, aim and objectives 
 
From the literature review, no study was found that investigated all aspects of MRPs associated 
with the use of OL and UL medicines in paediatric patients. Thus conducting a research to explore 
all aspects of MRPs associated with the use of OL and UL medicines in order to produce 
recommendations for improving paediatrics’ practice is justified. 
2.6.1 Research Questions 
 
1. What is the prevalence of MRPs associated with the use of OL and UL medicines in 
paediatric in-patients? 
2. What are the types of MRPs associated with the use of OL and UL medicines in paediatric 
in-patients? 
3. What is the severity of the identified MRPs?  
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2.6.2 Research Aim 
 
To investigate MRPs associated with the use of OL and UL medicines in paediatrics in-patients 
admitted to intensive care units (ICUs) of a paediatric hospital, London, United Kingdom. 
2.6.3 Research objectives 
 
 To determine the prevalence of OL and UL medicines use, particularly problems associated 
with the use of OL and/or UL medicines in patients admitted to ICU of the paediatric 
hospital.   
 To identify the type of MRPs experienced by patients admitted to ICU of the hospital.   
 To categorise these MRPs according to their severity. 
 To produce a list of recommendations to prevent MRPs associated with OL and UL 
medicines’ use in paediatrics.  
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Chapter 3: Methodology 
 
3.1 Introduction 
 
Research is the systematic and rigorous process of enquiry, which aims to describe phenomena 
and to develop and test explanatory concepts and theories (Hunter & Long, 1993). Research is a 
comprehensive area that is informed by several elements. Some of these include theory, 
epistemology, and ontology. In the following sections, these different elements that inform choice 
of research methods and designs will be discussed. 
3.1.1 Relationship between theory and research 
 
Theory can be defined as a generalisation about a phenomenon, an explanation of how or why 
something occurs. It can also be defined as a widely accepted principle or explanation of nature 
(Creswell, 2003). Theory as well as background literature provide the basis and justification for 
conducting research. Based on the influence of theory, research can be divided into two main 
categories which are deductive and inductive research. Theories generate hypotheses that can be 
proven or disproved by research. In conducting research, the researcher can draw on theoretical 
ideas or what is known about a particular area in order to deduce a hypothesis; this is termed 
deduction (Bryman, 2015). After a hypothesis is deduced, data are collected in relation to concepts 
that have been made up from the hypothesis.  Findings from data collected are then used to confirm 
or reject the hypothesis. Figure 3.1 shows the process of deduction and relationship between theory 
and research.  
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Figure 3:1: The process of deduction (Sources: Bryman, 2015, Social research strategies 
 
On the other hand, induction involves observation of phenomenon of interest. This is followed by 
collection of data and generalisations based on findings from data. Once a set of initial data has 
been collected, further data are then collected to establish conditions in which a theory will or will 
not hold (Bryman, 2015).  
3.1.2. Epistemology 
 
Epistemology is one of the branches of philosophy that is concerned with study of knowledge. It 
is concerned with what should be regarded as an acceptable source of knowledge. There are two 
2. Hypothesis 
1. Theory 
3. Data collection 
4. Findings 
5. Hypothesis confirmed or 
rejected 
6. Revision of theory 
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epistemological positions that have been adopted in the study of knowledge, these include 
positivism and interpretivism (Bowling, 2009; Bryman, 2015). 
Positivism assumes that true knowledge is obtainable through experiment and observation on the 
basis of experience of senses (Guba & Lincoln, 1994). The positivist approach to enquiry has 
directed research in the natural sciences (e.g. bio-medicine) (Bowling, 2009). Positivism is related 
to an empiricist and deterministic philosophy that assesses cause and effect relationships, and seeks 
to measure in quantitative terms, observe and make objective predictions of relationships in the 
variables (Cook, 2015).  Positivism is the world of science and testing hypotheses. In the positivist 
world, researchers are objective and strive to minimise sources of bias wherever they can. In other 
words, researchers exist apart from their data (Guba & Lincoln, 1994). Positivism aims to discover 
laws using quantitative methods to prove facts.  
Quantitative research is therefore an empirical and systematic research into the phenomena that 
are observable. It involves either measuring certain characteristics in the population, counting 
these characteristics and/ or transferring these characteristics to numbers (Shagoury, & Power, 
2012). Quantitative research methods include experiments which include randomised control trial 
(RTC), before-after, after-only, and time series; survey (cross-sectional and longitudinal surveys); 
computational and mathematical modelling and ex-post facto research (Bowling, 2009; Shagoury, 
& Power, 2012). Quantitative studies start with a predicament statement as well as include the 
hypothesis development, a literature evaluation and a quantitative statistics investigation 
(Creswell, 2003). Consequently, the approach will be objective; generate hypotheses and test them 
without any bias. 
Interpretivism is an epistemological position often assumed by social scientists.  It assumes that 
the study of social reality should not be subjected to the similar methods of research employed in 
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the natural sciences (Bryman, 2015). Interpretivists therefore hold the view that researchers need 
to be conscious of the fact that our language, ideas and concepts lead to our thoughts regarding the 
social world (Nelson, Groom & Potrac., 2014). For interpretivists, the research is interactive and 
jointly participative by the researcher and participants, thus the researchers’ opinions are the key 
element in concluding findings (Bryman, 2015). Methods commonly employed are qualitative. 
Qualitative research therefore investigates how people see or interpret events or how they make 
sense of their experience and the world around them. It describes and explains rather than count 
data (Goertz, & Mahoney, 2012). Methods of qualitative research include 
observation/ethnography, interviews, focus group, grounded theory study, and content analyses 
(Bowling, 2009). All qualitative strategies focus on three steps including namely: describing, 
explaining and interpreting composed data (Creswell, 2003). 
3.1.3. Ontology 
 
Ontology is the study of beings and it attempts to identify things that are in existence around us. 
Essentially, it is the study of beings and their relative similarities and differences. Ontology 
attempts to respond to questions that start with ‘what.’ The subject is concerned with whether 
things exist or do not exist. The main positions in ontology include objectivism and constructivism 
(Charlwood et al., 2014). Objectivism assumes that social phenomena and their meanings have an 
existence that is independent or separate from human actors (Goldkuhl, 2012). The objectivists 
rely on quantitative methods. Constructivism focuses on how humans form meaning relative to 
interaction of their ideas and experiences. Constructivism advocates learning to be an active 
process in which learners make discovery of facts, concepts and principles for themselves. Thus, 
intuitive thinking is a main feature in constructivism (Fosnot, 2005). Constructivists argue that 
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human beings construct their own social realities in relation to one another. The goal of 
constructivist research is to gain understanding, as opposed to prediction. Qualitative research 
leans towards constructivism (Bowling, 2009; Bryman, 2015). The table below (Table 3.1) shows 
differences between quantitative and qualitative research: 
Table 3:1: Comparisons between quantitative and qualitative studies 
Qualitative study Quantitative study 
Based on subjective data obtained through 
the scientific literature, focus groups and in-
depth interviews. 
Based on objective (numeric) data obtained 
through the scientific literature, structured 
observations and interviews. 
Inductive: Generates hypothesis/ theories. Deductive: Tests hypothesis/ theories and 
concepts. 
Subjective: Provides the viewpoint of the 
researcher. 
Objective: Provides observed effect regardless 
of the research viewpoint. 
Text based. Number based. 
Comprehensive information from smaller 
sample size.  
Partial information with larger sample size. 
Open ended questions and unstructured/ 
semi-structured response. 
Closed ended questions and structured 
response. 
No statistical data analysis. Statistical data analysis. 
 
While research methods have been broadly classified into two (quantitative and qualitative), 
there is increasing emphasis on the use of mixed methods in pharmacy practice research. 
According to Leech & Onwuegbuzie (2008), mixed methods research is the research that 
involves collecting, analysing, and interpreting both quantitative and qualitative data in a single 
study or in a series of studies that investigate the same phenomenon. According to Agency for 
Healthcare Research and Quality (AHRQ), using mixed methods strengthens and enhances 
validity of a study and offset weaknesses and limitations of certain research methods (AHRQ, 
2013). Mixed method approach also enables the researcher to collect comprehensive data from 
different perspectives, which helps to reduce the researcher’s personal bias.  
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This research followed a positivist approach because it sought to measure certain characteristics 
(medicines related problems (MRPs) associated with the use of off-label (OL) and unlicensed (UL) 
medicines) in a certain population (paediatric in-patients) by counting these characteristics. Thus, 
quantitative method was employed in this research.  
Quantitative methods provide the researcher the ability to capture and measure data. The 
relationship between dependent and independent variable is studied in a comprehensive manner. 
Hence, it is to the advantage of the researcher that the study is objective in terms of its findings 
and outcomes. The method is also used in the testing of hypotheses of experiments owing to its 
utility of statistical tools to establish relationship between data set. The key disadvantage of 
quantitative method is that the context of experiment or study is not taken into account when using 
statistical analysis. Quantitative method does not evaluate elements in natural settings or 
comprehends meaning of different aspects as it is in qualitative methods. Another disadvantage is 
that there may be an element of unintentional bias as statistical results may lead to correlation. 
However, correlation may not imply causality as can be deduced from outcomes (Goertz, & 
Mahoney, 2012).  
Quantitative research can employ experimental or observational designs. Experimental studies 
involve manipulation and randomisation of subjects while observational studies do not involve 
intervention or experiments and are conducted under a physical appearance of the researcher and 
document the phenomena of the interest without bias (Creswell, 2003; Smith, 2002). Observational 
studies can be cross-sectional (data is collected from population of interest at one point in time), 
or longitudinal (data is collected two or more times from the same population over a specified 
period) (Bowling, 2009). Observational studies can be conducted prospectively (where data 
70 
 
collection takes place over the forward passage of time) or retrospectively (data is collected from 
a phenomenon that occurred in the past).  
Prospective and retrospective cohort studies have different strengths and weaknesses. The 
major strength of a prospective cohort study is the accuracy of data collection with regard to 
exposures, confounders, and endpoints, but this is realised at the cost of an inevitable loss of 
efficiency, for this design is both expensive and time-consuming because of a usually long 
follow-up period. Vice versa, the retrospective design is a very time-efficient and elegant way 
of answering new questions with existing data, but one has no choice other than to work  with 
what has been measured in the past, often for another purpose (e.g. patient care) than the one 
under investigation. 
Retrospective cohort studies have the following distinct advantages when compared with 
prospective cohort studies (Sedgwick, 2014): 
 can be conducted on a larger scale 
 achieve greater variability 
 require less time to complete 
 fewer ethical objections 
 better for analysing multiple outcomes.  
 generally less expensive because outcome and exposure have already occurred, and the 
resources are directed at mainly collection of data  
 
On the other hand, retrospective studies have disadvantages when compared to prospective studies. 
These disadvantages include that some key statistics cannot be measured, and significant biases 
may affect the selection of controls (selection bias and miss-classification or information bias). 
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 With retrospective studies, the temporal relationship is frequently difficult to assess. Also, those 
who conduct retrospective studies cannot control exposure or outcome assessment but instead need 
to rely on others for accurate recordkeeping. That is particularly problematic because it can be very 
difficult to make accurate comparisons between the exposed and the non-exposed subjects. 
Retrospective studies may also need very large sample sizes for rare outcomes (Creswell, 2003). 
In retrospective studies bias is introduced in the sample selection; whereas in prospective studies 
it is introduced in outcome judgment (Gerhard, 2008). Table 3.2 summarises key elements of 
prospective and retrospective studies (Koop & Strang, 2001; Mann, 2003; Weinger, Slagle, Jain, 
& Ordonez, 2003): 
Table 3:2: Comparison of the key elements of retrospective and prospective studies 
Key element Prospective Retrospective 
Exposure Assessed at the time the study 
commences 
Assessed in the past. 
Direction Forward Backward  
Sample selection Samples are selected from the 
available participants 
Samples are selected from the 
available data  
Ethical requirements More ethical requirements Less ethical requirements 
Data collection Data is collected by the 
researcher 
Data is already available for 
the researcher 
Data analysis Analysis of the outcome and 
underlying factors 
Analysis of the outcome and 
underlying factors. 
Duration Longer study duration Shorter study duration  
Cost More expensive  Less expensive  
Outcome The outcome is pursued 
throughout the study 
The outcome has already 
occurred 
Intervention Intervention is possible Intervention is not possible 
While it is easier and less expensive to conduct a retrospective study, in this research both 
retrospective and prospective methods were employed to generate robust data and compare results 
from the different designs. Also because this is the first study to investigate MRPs associated with 
the use of OL and UL medicines, both methods were adopted to strengthen the findings.  
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3.2 Assessing quality in research 
 
3.2.1 Validity 
 
Validity refers to the extent to which the findings of a study are a true reflection of phenomena 
under study (Bryman, 2015). Validity refers to the degree in which test or measure device is truly 
measuring what we intended it to measure. It demonstrates the integrity of findings that concluded 
from the research. Types of Validity are (Bryman, 2015):  
 Internal validity: is concerned with the causal relationship between two or more variables 
in the study. 
 External validity or generalisability: is concerned with whether the findings can be 
generalised beyond the specific research context. The most important factors that 
determine the generalisability of study findings are the sampling strategies, procedures and 
sizes, and response rates (e.g. surveys), and representativeness and completeness of data 
(e.g. databases). If probability sampling strategy is employed; and there is 
comprehensiveness of databases and sampling frames, good response rates (surveys) and 
steps are taken to ensure data collected are valid, findings should be generalisable to the 
population from which the sample was drawn. 
 Construct validity: is the term given to a test that measures a construct accurately and there 
are different types of construct validity, mainly concurrent, content and predictive validity. 
In this research, a content validity was performed for the data collection form, identification of 
MRPs, causes of MRPs, intervention and outcome of MRPs, severity and preventability of MRPs. 
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3.2.2 Reliability 
 
 Reliability refers to the extent to which procedures, measures and data are reproducible. Methods 
of testing reliability include test-retest, alternate form and internal consistency (Bowling, 2009). 
In this research, method adopted to check reliability was test-retest of the data collection form. 
3.3 Sampling in research 
 
In research, sampling technique used depends on the type of research employed. In quantitative 
research, probability sampling techniques such as simple random sample, systematic sample, 
stratified sampling, cluster sampling are employed. Non-probability sampling techniques, such as, 
convenience sampling, purposive sampling and snowballing technique are employed in qualitative 
studies (Smith, 2002).  For the purpose of this study, random sampling was used as it demonstrates 
no bias, and all participants have the same chance of selection, and equal probability to be included. 
3.4 Study framework 
 
Research framework is defined according to Liehr and Smith (1999) as a structure that provides 
guidance for the researcher as study questions are fine-tuned, methods for measuring variables are 
selected and analyses are planned. Once data are collected and analysed, the framework is used as 
a mirror to check whether the findings agree with the framework or whether there are some 
discrepancies; where discrepancies exist, a question is asked as to whether or not the framework 
can be used to explain them (Smith, 2002). 
As indicated in Chapter 2, section 2.6, the aim of this research was to investigate MRPs in 
paediatric patients admitted to paediatric intensive care units (PICU) and neonatal intensive care 
unit (NICU) of a paediatric hospital. 
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The research was undertaken in two different phases: retrospective and prospective. The 
retrospective phase involved review of medical case notes of patients admitted into PICU between 
April and September 2014. This was carried out between March and August 2015. 
The prospective phase was divided into two studies and was conducted in the two units (PICU & 
NICU). The first study was undertaken in PICU for a period of six months from October 2015 to 
March 2016, and the second study was undertaken in NICU over a six months period from January 
2016 to June 2016. The studies covered different periods to ensure data collected included 
information from different seasons’ epidemiological illnesses. The figure below shows the timing 
and phases of the studies:   
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Figure 3:2: Medicines related problems study framework 
 
Systematic literature review of the use of off-label and unlicensed medicines in paediatric in-patients 
 
Protocol development, NHS 
Ethics and R&D approvals 
 
Aim: to investigate the prevalence of 
MRPs associated with the use of OL & 
UL medicines in paediatric in-patients 
  
 
Retrospective study- Medical records department (PICU) 
 Identify MRPs associated with OL & UL medicines using PCNE Version 6.2 
definitions and criteria 
 Verify MRPs by a second pharmacist 
 Expert validation of the Results 
 Expert panel for severity assessment 
 Preventability assessment with a second pharmacist (PI) 
 
  
 
 
 
 
 
Prospective study- PICU  
 Identify MRPs associated with OL & UL medicines using PCNE Version 6.2 
definitions and criteria 
 Verify MRPs by a second pharmacist 
 Expert validation of the Results 
 Expert panel for severity assessment 
 Preventability assessment with a second pharmacist (PI) 
 
  
 
 
 
 
 
Prospective study- NICU  
 Identify MRPs associated with OL & UL medicines using PCNE Version 6.2 
definitions and criteria 
 Verify MRPs by a second pharmacist 
 Expert validation of the Results 
 Expert panel for severity assessment 
 Preventability assessment with a second pharmacist (PI) 
 
  
 
 
 
 
 
Production of a list of recommendations 
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3.5 Study Setting 
 
The use of OL and UL medicines is common in paediatric healthcare settings. However, a 
systematic review assessing OL/UL prescription in paediatrics found higher rates in hospital 
versus community and primary care settings (Pandolfini & Bonati, 2005). In hospital settings, 
OL/UL prescription was found to be higher in paediatric and neonatal intensive care units than in 
general paediatric wards. Ninety percent of patients admitted to NICU are reportedly prescribed 
OL and/or UL medicines, while 67% of patients admitted to PICU are prescribed OL and/or UL 
medicine (Conroy, McIntyre & Choonara, 1999; Conroy et al., 2000). Therefore, the choice of the 
study setting (ICUs in secondary care setting) was based on the findings in literature, and was not 
based on the advantages and disadvantages of conducting research on primary and secondary care 
settings.  
3.6 Research Tools 
 
In this research, the Pharmaceutical Care Network Europe (PCNE V6.2) classification was used. 
The following section provides a brief description of PCNE. 
3.6.1 Pharmaceutical Care Network Europe  
 
The PCNE was established in 1994 by European researchers on pharmaceutical care. The first 
classification scheme for medicines related problems was produced in 1999 (Pharmaceutical Care 
Network Europe, 1999). The main aim of the classification system was to ensure an international 
standard system, which enable health care professionals to compare results from research, studies 
between different settings and different countries. This classification system has been updated 
several times, and different versions has been developed such as Version 5 and Version 6.01. 
According to the published studies, the PCNE classification version 5.00 has been used in the 
77 
 
hospital setting and in nursing homes (Lampert et al., 2008, Brulhart and Wermeille 2011) and the 
version 5.01 in community pharmacies during dispensing (Eichenberger et al., 2010), in 
medication review clinics (Chan et al., 2012) and among diabetics (van Roozendaal and Krass 
2009). 
The latest version was produced in 2010 defining MRPs as “an event or circumstance involving 
drug therapy that actually or potentially interferes with desired health outcomes” (PCNE, 2010). 
This latest classification scheme differs from the previous versions as it has separated the 
medicines’ problems from causes. It also has an open hierarchical structure for each category, 
which consists of type of problems, causes of the problems, interventions taken to solve the 
problems, and the outcome. The hierarchical structure also uses a coding system to facilitate data 
recording.  
While PCNE has been adopted by several researchers to evaluate MRPs, it is not without 
limitations. For example, Chan et al. (2012) in their study reported that several MRPs could not be 
classified into any existing PCNE categories. The authors also reported that the tool did not have 
a good indicator for poor medication adherence (that is, drug not taken/administered), 
consequently, they introduced a new category. Also Lampert, Kraehenbuehl & Hug (2008) in a 
study conducted in a hospital setting concluded that the PCNE system lacked some MRP’ 
categories such as incompatibilities, application errors or faulty transcriptions. In a related study 
to classify MRPs in community pharmacies, the authors introduced extra problems’ categories in 
the PCNE classification tool in order to capture all the identified MRPs (Eichenberger et al., 2010).  
Although the authors of studies described in the preceding paragraph identified problems that 
could not be classified into any PCNE category, the tool has been used in studying MRPs in 
paediatric in-patients because of its versatility (Rashed et al, 2012; Ibrahim et al., 2013).  The 
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PCNE was therefore adopted as the tool of choice for this research project. In addition, the coding 
system and hierarchical structure facilitates the data collection.  
The PCNE classification system was used concurrently with the Naranjo Scaling system of 
probability where there was more than one cause and where there was a strong existence of 
probability. 
3.6.2 Causality assessment  
 
Causality assessment is the evaluation of the likelihood that a particular treatment is the cause of 
an observed adverse event, and it assesses the relationship between a medicine treatment and the 
occurrence of an adverse event (Macedo, 2005). When an adverse event occurs in a patient, it may 
be difficult to determine whether the event was caused by a certain medicine in the presence of a 
complex therapy. Naranjo and colleagues have developed a probability scale, the Naranjo Adverse 
Drug Reaction Probability Scale (Naranjo Scale) (Appendix 2), to assess the probability that a 
drug administered in therapeutic doses caused an adverse event thereby classifying the event as an 
adverse drug reaction (ADR). This scale helps to reach a valid and reliable judgement of causes of 
adverse events via some questions and points, which are based on scoring system, and classified 
the causes of ADRs as definite, probable, possible and doubtful (Naranjo, 1981). 
Due to the fact that MRPs have no probability scale of causality, the Naranjo scale was used to 
identify the medicines that were associated with the identified MRPs. This scale was preferred 
because in practice, different forms of the same medicine might be used at the same time, or more 
than one medicine might be implicated in an adverse event or MRP. However there are many other 
causality systems in the literature, the most widely used scales are Naranjo Algorithm and World 
Health Organisation Collaborating Centre for International Drug Monitoring, the Uppsala 
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Monitoring Centre  system (WHO–UMC) (WHO, 1975). This system classified causes of ADRs 
as certain, likely, possible, unlikely, conditional and un-assessable. In this research project, 
Naranjo scale was preferred over the WHO system because the scale is easy to understand and the 
questions are straightforward thus, allowing meaningful conclusions to be drawn. After identifying 
the problems and their causes, the severity of these problems are of high importance to the health 
care professionals. As well as causality assessment, there is no severity scaling system for MRPs 
and so using adverse reactions and adverse events severity scoring system was the only choice. 
Thus, National Patients Safety Agency Level of harm was used to categorise the clinical 
significance of the identified medicines related problems. 
3.6.3  National Patient Safety Agency Level of Harm 
 
The NPSA level of harm was developed to assess patient safety incidents. The level of harm is 
categorised into five as follow (NPSA, 2011):  
 No harm:  
1. Impact prevented – any patient safety incident that had the potential to cause harm 
but was prevented, resulting in no harm to people receiving NHS-funded care.  
2. Impact not prevented – any patient safety incident that ran to completion but no 
harm occurred to people receiving NHS-funded care.  
 Low harm: Any patient safety incident that required extra observation or minor treatment 
and caused minimal harm, to one or more persons receiving NHS-funded care.  
 Moderate harm: Any patient safety incident that resulted in a moderate increase in 
treatment and which caused significant but not permanent harm, to one or more persons 
receiving NHS-funded care.  
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 Severe harm: Any patient safety incident that appears to have resulted in permanent harm 
to one or more persons receiving NHS-funded care.  
 Death: Any patient safety incident that directly resulted in the death of one or more persons 
receiving NHS-funded care.  
Although the NPSA system clearly defines all the different levels of harm, some confusion might 
still occur with regard to potential problems that did not reach the patient because some 
professionals might still evaluate the harm had it occurred. The assessment whether it is based on 
the actual or potential harm is challenging. Thus, clear communication and good explanation of 
how to use the system is crucial. The severity scoring in this research was done by a panel of 
experts consisting of consultant clinical pharmacist, a consultant paediatrician and a nurse.  
3.6.4 Preventability 
 
Preventability of the identified MRPs was assessed by the researcher and the clinical consultant 
pharmacist using Schumock and Thornton preventability scale (Schumock and Thornton, 1992). 
The Schumock and Thornton preventability scale is a validated scale and has been previously in 
paediatric MRPs studies (Rashed et al., 2012; Easton et al., 2004; Easton et al., 2003). Table 3.3 
below describes the Schumock and Thornton preventability scale.  
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Table 3:3: Schumock and Thornton preventability scale 
Definitely Preventable 
1. Was there a history of allergy or previous reactions to the drug? 
2. Was the drug involved inappropriate for the patient’s clinical condition? 
3. Was the dose, route or frequency of administration inappropriate for the patient’s 
age, weight or   disease state? 
4. Was a toxic serum drug concentration (or laboratory monitoring test) 
documented? 
5. Was there a known treatment for the adverse drug reaction? 
Probably Preventable 
6. Was required Therapeutic drug monitoring or other necessary laboratory tests not 
performed? 
7. Was a drug interaction involved in the ADR? 
8. Was poor compliance involved in the ADR? 
9. Were preventative measures not prescribed or administered to the patient? 
Not preventable If all above criteria not fulfilled 
Details of the use of the three tools used in this research are presented in chapters 4, 5 and 6.  
3.7 Ethical considerations 
 
Ethical approval for this research was sought and obtained from the University of Hertfordshire 
(Protocol Number: LMS/PG/00290) (appendix 3). Application was also made to the NHS REC 
Committee (NRES Committee North West - Greater Manchester South) (appendix 4) and an 
approval was obtained (15/NW/0263) (appendix 5). Application for access (appendix 6) was made 
to the Research and Development department of the hospital, a letter of access was obtained, 
(RJ115/N167). All patients’ relevant information was protected through different numbers of 
measures: Confidentiality agreement was signed by the researcher, patients’ information were 
anonymised, and electronic devices, where the data were stored, was a password protected. Data 
collected did not include any identifiers or patients’ identifiable information and all the collected 
parameters were anonymised. All the collected data will be destroyed after three years following 
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project completion. This research project was sponsored by the University of Hertfordshire 
(Appendix 7&8). 
Explicit patients’ consent was not required as that will limit the number of records to be reviewed 
as this study is a non-interventional study. The researcher was given an honorary contract and 
considered as a member of staff accountable to the consultant pharmacist, who was the local 
collaborator and principal investigator of the project. This honorary contract gives permission for 
viewing patients’ case-notes.  In addition, this study, aimed to establish the prevalence of 
medicines related problems associated with unlicensed and off-label medicines’ use in paediatrics, 
and if patient consent is required, this will affect the true number as not all patients may agree to 
a record review. In the event that the researcher identified an MRP that was clinically significant, 
the researcher would contact the pharmacist in charge of the unit, who would be responsible to 
deal and liaise with the clinical team to resolve the problem. The researcher also undertook an 
extensive training in line with the local policy to take a professional position in event that identified 
MRP might result in a serious harm to the patient. With regard to near misses and potential MRPs, 
the researcher was obligated to report to the head of the unit who was responsible for entering the 
data in the local incidents reporting system (DATIX).  
3.7.1 Implications of General Data Protection Regulations on research  
 
The new General Data Protection Regulations (GDPR) introduces protection of data subjects 
especially, the paediatric population. All subject data should be collected for specified and 
legitimate purposes and should be processed only for the stated purposes and not any incompatible 
purposes. Data size also should be minimised and limited to what is necessary. Consent should be 
obtained and freely given in an unambiguous, specific and clear affirmative action and needs to be 
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documented from a person who holds a parental responsibility of a child age under 13 years old, 
and an assent form must be signed by children over 13 years old. This might limit the sample size 
of paediatric patients in research on new medicinal products because of complexity of obtaining 
consent. However this ensure maximum protection for paediatric patients who participate in 
research studies and harmonisation of subject data which in turn will improve research quality and 
data will be treated fairly with minimum bias. Also, third parties will not be involved and there 
will be a high level of transparency of information of included participants. 
3.8 Chapter summary 
 
This chapter described the core elements that guide this research. The specific methods and the 
tools employed in this research are described. The steps taken to ensure this research complied 
with ethical requirements are also described. In the next chapter, description of the first study is 
provided. 
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Chapter 4: Retrospective study of off-label & unlicensed medicines’ related problems in 
paediatric intensive care unit 
  
4.1 Introduction 
In Chapter 1, section 1.10.3, it was found that a limited numbers of studies have investigated 
medicine related problems (MRPs) in the paediatric population. MRP was associated with 4.3% 
of paediatric hospital admissions in a study that sought to determine the frequency of paediatric 
hospital admissions due to MRPs (Easton, 2004). In a related study, 3.3% of emergency 
department admissions were associated with MRPs (Easton, 2003). Another study, which 
investigated MRPs in paediatric patients, found that the overall MRPs incidence in the United 
Kingdom was 39.4% among paediatric patients admitted to Paediatric Intensive Care Unit (PICU), 
Neonatal Intensive Care Unit (NICU) and general medical ward. The highest incidence of MRPs 
from the overall study cohort was reported from PICU (59.7%) (Rashed et al., 2012b). MRP is a 
broad term that includes adverse drug reactions (ADRs) and medication errors that can lead to 
treatment effectiveness’ problems (PCNE, 2010). While some studies have looked at ADRs 
associated with use of OL and UL medicines in paediatric in-patients (Turner et al., 1999; Rashed 
et al., 2012a), no study was found that investigated MRPs associated with the use of off-label (OL) 
and unlicensed (UL) medicines in paediatric patients.  The Pharmaceutical Care Network Europe 
(PCNE) classification system classifies MRPs into four domains, including treatment effectiveness 
(healthcare professional domain), adverse drug reactions (drug domain), treatment costs 
(economic domain), and others (patients and/or unclear problem domain) (PCNE, 2010). For the 
purpose of this project, MRPs due to OL and UL medicines use in paediatric inpatients was studied 
from healthcare professionals’ perspective.  
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4.2 Aim 
The aim of this retrospective study was to investigate MRPs associated with the use of OL and UL 
medicines in paediatric patients who were admitted to PICU of a paediatric hospital between April 
and September 2014. 
4.3 Objectives 
 To determine the prevalence of OL and UL medicines use in PICU of the hospital. 
 To determine the prevalence of MRPs in the unit. 
 To determine the prevalence of MRPs associated with the use of OL and UL medicines in 
this unit of the hospital. 
 To assess the severity of the identified MRPs. 
4.4 Methods 
 
4.4.1 Study setting 
 
The setting of this study is a 140-bed paediatric teaching hospital. The hospital has two intensive 
care centres, paediatric and neonatal intensive care units.   
4.4.2 Study population and sampling procedure 
 
In this retrospective study, data was collected from the medical records department of the 
hospital. Case notes of patients aged 0-18 years old, who were admitted to PICU between April 
and September 2014 were reviewed. Case notes for review were identified by members of the 
audit department of the hospital; the researcher then applied a computer random sampling to 
obtain the required sample size. 
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4.4.3 Inclusion and exclusion criteria 
Case notes of patients who were under 18 years old and were admitted to PICU and on medicines 
were included. Case notes of deceased patients were excluded as there was no access to their case 
notes. Also case notes of patients who were on nutritional products but not medicines were 
excluded.  
4.4.4 Sample size 
A study conducted by Conroy et al. reported that 67% of patients who were admitted to PICU 
received either off-label and/or unlicensed medicines (Conroy et al., 2000). The literature review 
of this thesis found no studies that investigated MRPs associated with the use of OL and UL 
medicines in paediatric population. Consequently, the sample size calculation was powered around 
the number of patients who were admitted to PICU, and prescribed OL and/or ULmedicines. The 
sample size for this retrospective study was calculated as follows (Ausvet, 2014):  
n = Zα/2
2 *p*(1-p) / MOE2 , where:  
Zα/2 is the critical value of the normal distribution based on the width of 95% confidence interval 
= 1.96 
MOE is the margin of error = 0.07 (or 7%) 
P is the sample proportion = 0.67 (67% of patients in PICU received either OL/UL medicines. 
Assuming that similar prevalence reported by Conroy et al. might be found in the study setting, 
the sample size for this retrospective study was calculated to be 176 patients’ case notes. The 
sample size was then inflated by 10% to make up for case notes that might have missing 
information, thus the sample size for this retrospective study was 194 case notes. 
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4.4.5 Power calculation for sample size 
A power calculation was performed for the sample size in order to ensure the quality of the 
research. The results were retrieved via statistical method by STATA, and it demonstrated a high 
level of accuracy (99.2%). 
4.4.6  Ethical considerations 
Ethical approval for this study was obtained from University of Hertfordshire, NHS Research 
Ethics Committee (REC) and Research and Development (R&D) department as described in 
Chapter 3 section 3.6. To ensure confidentiality of patient information, the research signed a 
confidentiality agreement. Data collected did not include any patients’ identifiable information; all 
parameters collected were presented anonymously. Data collected were stored in password-
protected devices. Explicit patients’ consent was not required in this study because this was a non-
interventional study.  
The following section describes a feasibility study conducted to validate data collection. 
4.4.7 Development of a data collection form to identify medicines related problems in 
paediatric in-patients 
A data collection form that incorporated all types of MRPs associated with the use of OL and UL 
medicines in paediatric in-patients was designed. This feasibility study was conducted at the beginning 
of the retrospective study (Phase 1) in order to assess the practicality of the data collection form and 
to ensure the accuracy of information collected.  The feasibility study was carried out by the 
researcher. Findings of the study facilitated the development of the tool to be used for data collection.  
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4.4.7.1 Process of assessing the practical use of the data collection form 
The parameters included in the form were: patients’ demographics including age, weight, height, 
gender and ethnicity. It also included: medicine name, date prescribed, route of administration, 
dose, frequency, duration, indication, and whether the medicine is licensed, unlicensed or off-label. 
MRPs were categorised according to the PCNE classification system version 6.2 (PCNE, 2010). 
Licensing status of medicines was assessed using Summary of Product Characteristics (SPC) of 
medicines obtained from the Electronic Medicines Compendium. 
4.4.7.2 Outcome of the feasibility study 
The form was initially used to collect data from medical records, drug charts and laboratory data 
of five patients. Some changes were made to the form (example, ethnicity was removed as it was 
not reported in most of the case notes). The second version of the form was used to collect data 
from 15 medical case-notes. Further changes were made to the layout of the form; the final version 
of the form was produced (appendix 9). The form was validated by a consultant clinical pharmacist 
with expertise in patient and medication safety, who was also the principal investigator in this 
study. 
4.4.8 Data collection 
Data collection included the retrieval of information from medical records, drug charts and 
laboratory data. Patients’ medical notes were obtained from the Medical Records Department of 
the hospital. Data retrieved included: patient age, weight, height, gender, length of stay and 
medications. Intensive chart review method was adopted as it has been used in a previous study in 
paediatric population (Ghaleb et al., 2010). Medicines dosage forms, route of administration, 
indication, dose, frequency and duration were retrieved. Medicines were classified as licensed, off-
89 
 
label and unlicensed according SPC as well as the Turner et al. (1998) classification of OL and UL 
use of medicines. Age was categorised into five different groups according to International 
Conference of Harmonization Guideline E11 as follows: preterm newborn infants, term newborn 
infants (0 – 27 days), infants and toddlers (28 days – 23 month), children (2 –11 years) and 
adolescents (12 to 17 years) (ICH, 2001). Diagnosis and co-morbidities were categorised 
according to the International Classification of Diseases version 10 (WHO-ICD, 2014). 
Definition and classification of MRPs was based on the PCNE classification version 6.2, which 
defines MRP as an event or circumstance involving drug therapy that actually or potentially 
interferes with desired health outcomes (PCNE, 2010). When an MRP was identified, Naranjo 
scale was used to identify the medicines that were associated with the identified MRPs. The details 
including the type of MRP, causes, interventions and outcome of the interventions were recorded. 
An example of how MRPs were identified is provided in the Table 4.1. 
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Table 4:1: Identification of medicines related problems 
Identification of medicines related problems 
Patient details Medical diagnosis & co-morbidities 
Study ID 188 Elective admission for atrial sept-ostomy, respiratory 
distress, high pulmonary pressure. 
Allergy was unknown at the beginning then the patient 
developed a skin reaction. 
 
Age  1week 
Weight 2.8kg 
Height Not recorded 
Gender F 
Length of 
stay  
3days 
Medications 
Name of medicine Dose Frequency  Route of administration 
Flucloxacillin 150mg Bd Iv 
Morphine 3mg/50ml 10/mcg/kg/hr Cont Iv 
Dopamine100micrograms 10micro/Kg/min Cont Iv 
Gentamicin 26mg Od Iv 
Benzylpenicillin 165mg Tds Iv 
Fentanyl 3mcg Stat Iv 
Ketamine 3mg Stat Iv 
Paracetamol 50mg Qds Ng tube 
Cefotaxime 150mg Stat Iv 
Clinical narrative 
The patient developed severe skin reaction after administration of flucloxacillin. The medicine was 
stopped and the patient was prescribed chlorphenarmine injections. Penicillin allergy was 
indicated in the patient’s case following the reaction to flucloxacillin. 
 
Data were stored electronically after review of the drug charts and medical notes in the audit office 
in the hospital. The data were coded anonymously to ensure patients confidentiality. To ensure 
validity of the identified MRPs, a consultant clinical pharmacist was asked to review the problems, 
causes, interventions and outcome during meetings with the researcher. 
To assess the severity of the identified MRPs, the National Patient Safety Agency categorisation 
for the level of harm was used. Table 4.2 shows the National Patient Safety Agency categorisation 
for the level of harm.  
 
91 
 
Table 4:2: National Patient Safety Agency categorisation for level of harm 
Level of Harm Definition 
No Harm A situation where no harm occurred: either a prevented patient safety 
incident or no harm patient safety incident.  
Low Any unexpected or unintended incident which required extra 
observation or minor treatment and caused minimal harm, to one or 
more persons.  
Moderate Any unexpected or unintended incident which resulted in further 
treatment, possible surgical intervention, cancelling of treatment, or 
transfer to another area and which caused short term harm, to one or 
more persons.  
Severe Any unexpected or unintended incident which caused permanent or long 
term harm, to one or more persons.  
Death Any unexpected or unintended incident which caused the death of one 
or more persons.  
 
A panel of three experts consisting of a consultant paediatrician, a consultant clinical pharmacist 
and a medicines’ safety and retrieval practitioner nurse assessed 10% percent of the identified 
MRPs. In this study, only 10% of identified MRPs were assessed for severity because of time 
constraints on the part of the experts invited. Secondly, no specific cut off for the number of 
cases for severity scoring was identified in literature. The consultant clinical pharmacist, who 
was also the principal investigator of this study, identified and recruited the other two experts 
using convenient sampling technique. Although the three experts had different backgrounds, it 
was important to explore opinions of experts from different professions to minimise bias. The 
experts rated the level of harm of each problem individually. Kappa test was used in order to 
assess the experts’ agreement on severity. The test is measured on a scale ranging up to a 
maximum agreement of one. Table 4.3 provides an interpretation of Kappa test ranges 
(https://wwwusers.york.ac.uk/~mb55/msc/clinimet/week4/kappash2.pdf ). 
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Table 4:3: Kappa test for level of agreement 
Value of Kappa Strength of agreement 
< 0.20 Poor 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Good 
0.81 – 1.00 Very Good 
 
Preventability of identified MRPs was assessed by the researcher and the clinical consultant 
pharmacist using Schumock and Thornton preventability scale. 
4.4.9 Data analysis 
Data collected were analysed using computer programmes including Excel, Statistical Package for 
the Social Sciences (SPSS) and STATA. Descriptive statistics including frequencies, medians, 
standard deviation, and interquartile range were performed.  Data were presented as numbers and 
percentages. Chi-squared test was used to detect significant differences for categorical variables 
while Kruskal–Wallis rank and Wilcoxon Rank-Sum (Mann–Whitney U) were used to determine 
significant differences between numerical variables. For all tests, p< 0.05 was selected as the level 
of statistical significance.  
Data analysis regarding MRPs was divided into nine parts: 
 
 Number of patients who developed MRPs due to different licensing status of medicines, 
the total number of medicines prescribed during the study period, and comparison of 
licensed, UL and OL medicines use and their associated problems using the Chi-square 
test.  
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 Prevalence of licensed, UL and OL medicines use in the different age groups and the 
associated problems. 
 Occurrence of MRPs between genders using Chi-square test.  
 MRPs categories in patients and the medicines associated with them.  
 The association between MRPs and the length of stay (LOS) in the hospital using Kruskal-
Wallis.  
 The relationship between the number of medicines and the number of MRPs using Pearson 
test. 
 MRPs causes, interventions and outcome using the PCNE classification system V 6.2. 
 Severity of the identified MRPs using Kappa test.  
 Preventability of MRPs using Schumock and Thornton Preventability Scale. 
 
4.5 Results 
 
4.5.1 Patients’ demographics 
A total number of 194 case-notes of paediatric patients who were admitted to PICU between April 
and September 2014 were reviewed over a 3-month period. In the study cohort, majority were 
infants (35%) and children (30%). Table 4.4 summarises different age groups in the study cohort. 
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Table 4:4: Different age groups of the study population 
Age group Age range Number of patients (n), Percentage (%) 
Preterm new born neonates Less than 38 weeks 15 (8) 
Term new born neonates 0- 27 days 35 (18) 
Infants 28 days- 2 years 69 (35) 
Children 2 years- 12 years 58 (30) 
Adolescents 12 – 18 years 17 (9) 
*Analysis involved descriptive statistics (frequencies and percentages) 
The most common diagnoses were congenital malformations abnormalities (n=113 patients), 
diseases of the respiratory system (n=22), and certain infectious and parasitic diseases (n=19). 
From the 113 patients who were diagnosed with congenital malformations abnormalities, 90% (n= 
102/113) were born as premature neonates.  The average length of stay was 3days (range 2-20 
days; M = 3, SD ± 2.9). Table 4.5 summarises the study participants’ diagnosis and number of 
patients who developed MRPs with each diagnosis. 
Table 4:5: Patients’ diagnosis and number of medicines related problems 
Diagnosis Number of 
patients 
Number of patients 
with MRPs 
Congenital malformations abnormalities 113 71  
Certain infectious and parasitic diseases 22 10  
Diseases of the respiratory system 19 6  
Disease of blood and blood-forming organs 16 7  
Certain conditions within perinatal period 15 4  
Disease of the digestive system 9 4  
Neoplasms 3 2  
*Analysis involved descriptive statistics (frequencies and percentages) 
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4.5.2 Medicines related problems in patients in relation to the different licensing status of 
medicines  
 
From the total number of patients, 53% (n= 102/194) developed at least one MRP during 
admission. Thirty percent (n= 57/193) of patients who received licensed medicines developed 
MRPs. Forty-five percent (n= 77/172) of patients who received UL medicines developed MRPs 
and 10% (n= 15/145) of patients who received OL medicines developed MRPs. The proportion of 
patients who experienced MRPs due to licensed, UL and OL medicines are summarised in Figure 
4.1. 
 
Figure 4:1: Medicines related problems in patients in relation to different medicines’ 
licensing status 
 
 
4.5.3 Medicines related problems occurrence in relation to different licensing status of 
medicines  
 
A total of 2,000 medicines were prescribed to the 194 patients, out of which 54.3% (n= 1085/2000) 
were licensed and 45.7% (n=915/2000) were OL and UL; 17.7% were OL (n= 354/2000), and 
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28% were UL (561/2000). Eight percent of the total number of medicines were associated with 
MRPs (n= 165/2000). 
Fourteen percent of UL medicines was associated with MRPs; 4% of OL medicines was associated 
with MRPs while 7% of licensed medicines was associated with MRPs. MRPs were therefore more 
common with the use of UL medicines, p<0.001. However, there was no significant difference 
between MRPs occurrence with licensed and OL medicines, p=0.11. The proportion of licensed, 
UL and OL medicines prescribed and the proportion implicated in MRPs are summarised in Figure 
4.2. 
  
Figure 4:2: Medicines related problems occurrence in relation to different medicines 
licensing status 
 
4.5.4 Medicines related problems in different age groups 
 
With respect to the occurrence of MRPs with use of licensed, OL and UL medicines in the different 
age groups, the results showed that use of OL medicines was significantly associated with 
75%
80%
85%
90%
95%
100%
Licensed
Medicines
Off-label
Medicines
Unlicensed
Medicines
93 96
86
7 4
14
M
R
P
s
Licensing ststus of medicines
MRPs occurrence in relation to different licensing status of medicines 
With MRPs
Without MRPs
97 
 
occurrence of MRPs in younger paediatric patients; 21% in preterm, 10% in term babies, but lower 
than 3% in older paediatric patients; p<0.001. Summary of results is shown in Table 4.6.  
 
Table 4:6: Occurrence of medicines related problems in relation to the use of licensed, off-
label and unlicensed medicines in the different age groups 
Medicine 
licensing 
status 
MRP 
occurrence 
Age categories     P-
value 
  Preterm new born 
N (%) 
Term 
new 
born 
N (%) 
Infant 
N (%) 
Children 
N (%) 
Adolescent 
N (%) 
 
Licenced No MRP 50 (100) 154 (92) 392 (93) 318 (95) 100 (92) 0.16 
 MRP 0 (0) 14 (8) 31 (7) 17 (5) 9 (8)  
        
Off-licence No MRP 15 (79) 81 (90) 137 (99) 78 (100) 28 (97) <0.001 
 MRP 4 (21) 9 (10) 1 (1) 0 (0) 1 (3)  
        
Unlicensed No MRP 8 (73) 99 (86) 200 (88) 136 (83) 39 (89) 0.51 
 MRP 3 (27) 16 (14) 28 (12) 27 (17) 5 (11)  
        
Analysis involved descriptive statistics (frequencies and percentages) 
4.5.5 Medicines related problems occurrence between genders in relation to different 
licensing status of medicines 
 
Eight percent of all medicines that were prescribed to male patients were associated with MRPs 
(n= 89/999medicines). Also 8% of the total medicines that were given to females’ patients were 
associated with MRPs (n= 76/836medicines).  
There was no significant difference in occurrence of MRPs with licensed, UL and OL medicines 
between the genders (Table 4.7). However, male patients tended to have more MRPs with use of 
UL medicines than female patients did, 52% versus 37%.  
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Table 4:7: Medicines related problems occurrence between genders in relation to different 
licensing status medicines 
Medication MRP Male 
N (%) 
Female 
N (%) 
P-value 
Licenced No MRP 74 (73) 62 (67) 0.37 
 MRP 27 (27) 30 (33)  
     
Off-label No MRP 68 (88) 62 (91) 0.57 
 MRP 9 (12) 6 (9)  
     
Unlicensed No MRP 42 (48) 53 (63) 0.04 
 MRP 46 (52) 31 (37)  
     
Analysis involved chi-square test 
4.5.6 Medicines related problems categories and associated medicines 
 
Where MRPs occurred, ADRs constituted 84% of the total number of MRPs (n=138/165); and 
treatment effectiveness problems accounted for 16% (27/165) of the identified MRPs. The sub-
domain of the problems is summarised in Table 4.8. 
Table 4:8: Medicine related problems categories 
Primary domain Code Sub-domain Number  
 P1.1 No effect of drug treatment 2 
Treatment effectiveness problems P1.2 Effect of drug treatment not optimal 24 
 P1.3 Wrong effect of drug treatment 1 
 P2.1 Non-allergic adverse drug event 60 
Adverse drug reactions P2.2 Allergic adverse event 23 
 P2.3 Toxic adverse event 1 
Analysis involved descriptive statistics (frequencies and percentages) 
Of the 194 patients in this study, 53% (n= 102) experienced at least one MRP. The proportion of 
patients who experienced different types of MRPs is shown in the figure below: 
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TE: treatment effectiveness; ADR: adverse drug reaction; MRPs: medicine-related problems 
Figure 4:3: Different medicines related problems categories in patients 
 
The most common prescribed medicines in the study population were morphine, paracetamol, 
clonidine, furosemide, spironolactone and potassium chloride. Using the Naranjo scale, morphine 
and furosemide were implicated in MRPs, 50% (n= 83/165) and 26% (n= 43/165) respectively. In 
appendix 10, a list of all the medicines with their licensing status is provided. Table 4.9 summarises 
the medicines that were frequently associated with probles; Table 4.10 includes the medicines that 
were associated with problems in different age groups. 
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Table 4:9: The most frequently prescribed medicines 
Medicine Licensing 
status 
Number of 
times 
prescribed 
Number of 
patients  
Number of times 
associated with 
MRPs 
Number of 
patients with 
MRPs 
Morphine UL 193 151 79 77 
Morphine L 11 11 4 4 
Paracetamol L 120 119 1 1 
Clonidine UL 146 135 0 0 
Furosemide L 110 102 43 43 
Potassium chloride L 74 71 1 1 
Analysis involved descriptive statistics (frequencies and percentages) 
Table 4:10: Medicines associated with problems in different age groups 
Age-group Medicines associated with MRPs Number of MRPs Category of MRP 
 Name  Licensing status    
Pre-term Paracetamol OL 4 TE 
 Morphine UL 3 ADR 
Term Morphine UL 16 ADR 
 Paracetamol OL 9 TE 
 Furosemide L 8 ADR 
 Flucloxacillin L 3 ADR 
 Gentamicin L 2 TE 
Infants Morphine UL 31 ADR 
 Furosemide L 24 ADR 
 Sytron L 1 ADR 
 Fentanyl OL 1 ADR 
 Co-amoxiclav L 1 TE 
Children Morphine UL 28 ADR 
 Furosemide L 7 ADR 
 Gentamicin L 3 TE 
 Azithromycin L 1 TE 
 Salbutomol L 1 ADR 
Adolescents Morphine UL 5 ADR 
 Furosemide L 4 ADR 
 Dihydrocodiene L 1 ADR 
 Tranexamic Acid OL 1 ADR 
 Oxycodiene L 1 ADR 
*ADR= Adverse Drug Reaction, L= Licensed, OL= Off-label, TE= Treatment Effectiveness problems, 
UL= Unlicensed. 
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4.5.7 Medicines related problems and the length of stay  
 
The association between the occurrence of MRPs and length of hospital stay (LOS) was examined. 
The average LOS was 3days (range 2-20 days; M = 3, SD ± 2.9). There was a significant 
association between MRPs and LOS. The longest LOS was found in those with 2+ MRPs, where 
the median LOS was 4 days. Fewer MRPs occur with LOS shorter than two days. The results are 
summarised in Table 4.11.  
Table 4:11: Relationship between medicines related problems and the length of stay 
Category Number patients LOS 
Median (IQR) 
P-value 
No MRPs 92 2 (2, 4)  
1 MRP 52 3 (2, 4) <0.001 
2+ MRPs 50 4 (4, 6)  
Analysis involved Kruskal-Wallis test. IQR- Inter quatile range 
4.5.8 Medicines related problems and number of medicines 
 
The average number of medicines per patient was 10.3 (SD= 4.7). There was positive correlation 
between the number of medicines and the number of MRPs. The number of MRPs increased with 
increase in the number of medicines (correlation coefficient 0.47, p<0.001). This is shown in Table 
4.12 below. 
Table 4:12: Relationship between medicines related problems and number of medicines 
Number of MRPs Number of patients Number of medicines per 
patient Mean (SD) 
0 92 8.4 (4.9) 
1 52 10.8 (2.8) 
2 40 12.4 (3.7) 
3 7 15.3 (4.4) 
4 3 20.0 (2.6) 
5 0 - 
Analysis involved Pearson test.  
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4.5.9 Medicines related problems’ causes, interventions and outcome 
 
One hundred and sixty-five medicines were associated with 165 MRPs, which were mainly 
treatment effectiveness problems and adverse drug reactions. Overall, 231 causes were identified 
for the 165 identified MRPs using the PCNE V6.2 classification system. The most frequent causes 
were medicine selection; dose selection; treatment duration; logistics of prescribing errors, and 
others. Table 4.13 describes the causes and categories. 
Table 4:13: Causes of medicines related problems 
Primary domain code Sub-domain Number 
of causes 
Drug selection C1.1 Inappropriate drug (Contra-indication) 19 
 C1.6 Too many drugs prescribed for indication 21 
 C3.1 medicine dose too low 40 
Dose selection C3.2 medicine dose too high 60 
 C3.5 No therapeutic monitoring 2 
 C3.7 Deterioration of disease requiring dose adjustment 2 
Treatment duration C4.2 treatment duration too long 53 
Logistics C6.2 prescribing errors 22 
Others C8.2 No obvious cause 10 
Analysis involved descriptive statistics (frequencies and percentages) 
The identified MRPs required 215 interventions; some of the MRPs required more than one 
intervention. As this was a retrospective study, interventions were counted from drug charts and 
patients’ case-notes at the medicines level. All interventions resulted in positive outcome and 
MRPs were resolved. Table 4.14 below summarises type and number of interventions. 
Table 4:14: Medicine related problems’ interventions 
Primary domain Code Sub-domain Number of 
interventions 
At medicine level I13.2 Dosage changed  102 
At medicine level I13.3 Formulation changed  19 
At medicine level I13.5 Drug stopped  49 
At medicine level I13.6 New medicine started 45 
Analysis involved descriptive statistics (frequencies and percentages) 
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4.5.10 Medicines related problems severity  
 
Using the NPSA level of harm, 5% of identified MRPs were rated by experts as causing no harm 
(n= 9/165); 71% resulted in low harm (n= 117/165), and 24% caused moderate harm (n= 39/165). 
An example of an MRP case study that was sent to the experts is shown in the Table 4.15. 
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Table 4:15: An example case study for medicines related problems severity 
Severity of MRPs/ Case no. 2 
Patient details Medical diagnosis & Co-morbidities 
Study ID 3 Elective admission for cardiac surgery, born as ex-
premature (32/40).  Age  6 year 
Weight 31 Kg 
Height 127 cm 
Gender Male 
Length of stay  2days 
Allergies NKDA 
laboratory tests: only Abnormal results are reported 
Parameter Abnormal Results Results after intervention 
Potassium 3.1mmol/L 3.5mmol/L 
Medication history 
Name of medicine Dose Frequency  Route of administration 
CEFUROXIME  750mg Stats Iv 
CHLORPHENIRAMINE 1mg Od Iv 
FUROSEMIDE 10mg Bd Iv 
IBUPROFEN 150mg Od Ngt 
MORPHINE 50mg/50ml 20mcg/kg/hr Con Inf 
PARACETAMOL 460mg Qds Po 
SPIRONOLACTONE 10mg Bd Iv 
POTASSIUM CHLORIDE 5mmol Stats Iv 
Clinical narrative 
The patient was on the correct dose of furosemide and the level of potassium dropped to 3.1, and 
required intravenous potassium chloride, which successfully increased level back to 3.5.  
Experts’ opinion 
Medicine related problem (MRP): “an event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes”. (Pharmaceutical Care Network 
Europe, 2010) 
  
Please rank the harm caused by the MRP identified based on NPSA scale of harm, insert  
 No harm (The incident caused no harm)   
 Low (Any patient safety incident that required extra observation or minor treatment, 
and caused minimal harm to the person(s) receiving NHS funded care)  
 Moderate (Any patient safety incident that resulted in a moderate increase in 
treatment, and which caused significant but not permanent harm to the person 
receiving NHS funded care) 
 Severe (Any patient safety incident that resulted in permanent harm to the person(s) 
receiving NHS funded care) 
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Each member of the panel rated all the 17 MRPs individually (Appendix 11). A summary of the 
number of responses in each category for each panel member is shown in Table 4.16. 
 
Table 4:16: Experts’ panel severity scoring of medicine related problems 
Expert No harm 
N (%) 
Low 
N (%) 
Moderate 
N (%) 
 Consultant pharmacist 1 (6%) 12 (71%) 4 (24%) 
Consultant 
paediatrician 
1 (6%) 12 (71%) 4 (24%) 
Nurse 1 (6%) 12 (71%) 4 (24%) 
Analysis involved descriptive statistics (frequencies and percentages) 
The MRPs were categorised in terms of the agreement between the three experts. A summary of 
the number and percentage of MRPs in each category is shown in the Table 4.17.  
 
Table 4:17: Level of agreement between assessors 
Level of agreement Number (%) 
All members in agreement 15 (88) 
Two in agreement, one disagreement   2 (12) 
All three members in disagreement 0 (0) 
 
The kappa statistic was calculated to be 0.82, with a 95% confidence interval from 0.59 to 1.00. 
This value implies very good agreement between the three experts. 
4.5.11 Medicines related problems preventability 
 
Using the Schumock and Thornton preventability scale, approximately 30.3% (50/165) of MRPs 
were deemed preventable. 
In Table 4.18, a case vignette that illustrates the most common prescribed medicines and associated 
problems, problem categories, severity and preventability is presented.
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Table 4:18: Examples case studies of the most common prescribed medicines and associated problems 
Case Medicine 
associated 
with MRP 
licensin
g status 
MRP 
Category  
MRP Severity  MRP 
Preventability  
A patient aged 5days (4kg) was admitted for Cardiac surgery, Co-arctation 
of the 
 Aorta, Ventilecular Septal Defect. The patient developed allergy after 
 administration of morphine, and settled after being given Chlorphenarmine 
 injections. 
Morphine L ADR Low harm 
from the three 
experts 
Non-preventable 
A patient aged 2weeks (3kg) electively admitted for coarctation of the aorta 
surgery The patients was on the correct dose of morphine but developed 
signs of seizures, 
respiratory depression and agitation. The patient recovered after being  
administered Naloxone intravenously.   
Morphine UL ADR Moderate harm 
from the three 
experts 
Non-preventable 
A patient aged 6weeks (4.5kg) was admitted for cardiac surgery, 
tricuspid valve atresia. The patient was on the correct dose of 
intravenous furosemide and the potassium level dropped to 3mmol/L, 
and required intravenous Potassium Chloride which successfully 
increased level back to 3.6mmol/L. 
Furosemide L ADR Low harm 
from the three 
experts 
Non-preventable 
A patient aged 6days (2kg), who was born at 36weeks gestational age, 
was electively admitted for cardiac management; Coarctation of Aorta 
and Left atrial isomerism. The patient was prescribed 16mg of 
gentamicin 8mg/kg.  A lower dose of Gentamicin was given (10mg), 
instead of 16mg due to wrong calculation. 
Gentamicin UL Treatment 
effectivenes
s 
Pharmacist: 
low harm 
Nurse: low 
harm 
Paediatrician: 
no harm 
Preventable 
A patient aged 1day (3.1kg), was admitted due to suspected sepsis. The 
patient developed severe skin reaction after administration of 
Flucloxacillin.  
Flucloxacili
n 
UL ADR 
 
Pharmacist: 
moderate harm 
Nurse: 
moderate harm 
Paediatrician: 
moderate harm 
 
Non-preventable 
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A patient aged 5days (3.5kg) was electively admitted for cardiac 
surgery. The patient received a high dose of paracetamol (75mg) 
 instead of the correct dose (26.5mg) due to wrong calculations. 
Paracetamol OL Treatment 
effectivenes
s problem 
Pharmacist: 
moderate harm 
Nurse: 
moderate harm 
Paediatrician: 
low harm 
 
preventable 
A patient aged 6weeks (4.5kg) was admitted for cardiac surgery, 
tricuspid valve atresia. The patient was on the correct dose of 
intravenous furosemide. The potassium level dropped and required 
intravenous potassium chloride tds. The dose of potassium chloride 
was insufficient due to the frequency, and then changed to a 
continuous infusion which successfully increased level back to 
3.6mmol/L. 
Potassium 
chloride 
L Treatment 
effectivenes
s problem 
Low harm 
from the three 
experts 
preventable 
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4.6 Discussion 
 
The main objectives of this study were to determine the prevalence of OL and UL medicines’ use 
in patients who were admitted to PICU and MRPs that were associated with their use. Findings of 
this study showed that the most common diagnosis in the study population were congenital 
malformations abnormalities, diseases of the respiratory system, certain infectious and parasitic 
diseases. The average length of stay in this population was 3 days. 
Of the 2,000 medicines that were prescribed to the study population, 54.3% were licensed (n= 
1085), 17.7% (n= 354) were OL and 28% (n= 561) were UL. A previous study had reported 
prevalence of 19% and 39% for UL and OL medicines respectively among neonates (Kieran et al., 
2014). A related study reported a prevalence of 11.1% for UL medicines and 30.2% for OL 
medicines in paediatric patients aged 0- 16 (Berdkan et al., 2016). Although the prevalence of UL 
and OL obtained in this study is not closely comparable with those reported by Kieran et al., 2014 
and Berdkan et al., 2016, it however confirms the use of OL and UL medicines is common in 
paediatric practice. 
In this study, 53% of the total number of patients developed at least one MRP. Findings of this 
study is similar to that of Rashed et al. (2012) that reported MRPs incidence of 59.7% in PICU in 
a prospective study to determine the epidemiology of MRPs. The similarity in findings may be 
due to the fact this study, like Rashed et al. was conducted in a similar setting, although the Rashed 
et al.’s study was conducted prospectively. 
Eight percent of the total number of medicines were associated with MRPs (n=165/2000); 14% 
of UL were associated with MRPs (n=79/561) and 4% of OL medicines were associated with 
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MRPs (n= 15/354), while 7% of licensed medicines were associated with MRPs (n=71/1085).  
From the total number of MRPs (165), 43% were associated with licensed medicines, while 57% 
were associated with OL and UL medicines (9% and 48% respectively). While no study was 
identified in the literature to compare these findings, studies of ADRs, a subset of MRPs have 
been carried out. These studies reported higher incidence of ADRs with the use of OL and/or UL 
medicines when compared to licensed medicines (Neubert et al., 2004; Saiyed, Lalwani & Rana, 
2015). Turner et al. (1999) reported ADRs were associated with 3.9% of 2881 licensed medicine 
prescription and 6% of 1574 UL medicine prescriptions in their study. Using the PCNE 
classification system, the main types of problems found in this study were ADRs and treatment 
effectiveness problems. The identified MRPs were predominantly ADRs (84%) and included 
non-allergic, allergic and toxic adverse drug reactions. They were type A reactions (dose-
dependent, predictable or augmentations of known pharmacologic effects of the medicine). This 
highlights the importance of accurate dose calculation and adjustment as well as clinical 
monitoring in the paediatric population especially due to changes in pharmacokinetics of 
medicines during development. Most of the ADRs were associated with the use of morphine and 
furosemide, and were extension of these medicines’ pharmacological effect which would 
normally occur regardless of the licensing status. On the other hand, treatment effectiveness 
problems (16%) were mostly classified as effect of medicine treatment not optimal, wrong effect 
of medicine treatment caused by the dose selection; medicine dose too low; medicine dose too 
high; treatment duration too long and prescribing errors. This is because of the challenges 
encountered with OL and UL prescribing in the treatment of paediatric population where there is 
lack of age-appropriate formulations, insufficient information for paediatric prescribing, and 
downscaling from adult doses which possess a risk of mistakes in dose calculations. Also, 
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prescribing for this group of patients is determined by other factors such as age, weight and body 
surface area (Wong et al., 2004). Although ADRs would occur regardless of the licensing status, 
treatment effectiveness problems are affected by the licensing status of the medicines. This is 
because prior to obtaining marketing authorisation, pharmaceutical companies are required to 
show evidence of efficacy and safety through clinical trials to regulatory agencies. Participants in 
these trials are often adults, thus prescribing information on dosing; adverse effects etc. are for 
adults, sometimes with a warning that safety in paediatric patients has not been established. 
When such medicines are used in UL and/or OL manner, there is the risk of error in dose 
calculation and manipulation to a dosage form that is suitable for the paediatric patients.  
Among the study population, there was no statistically significant difference in occurrence of 
MRPs between different age groups. Non-significant difference in overall MRPs between the age 
groups has been previously reported (Rashed et al., 2012). There was however a difference in 
occurrence of MRPs between age groups due to different licensing status of medicines, with the 
highest number of MRPs occurring in pre-term and term neonates with the use of OL medicines. 
Thus, OL use of medicines are associated with MRPs in younger paediatric patients when 
compared with older ones. Bellis et al. (2013) found that medicines licensed in children but given 
to children below the minimum age had the greatest odds of being implicated in ADRs supports 
finding of this study.  In the UK, the age group of 0-4 years was reported to be most vulnerable 
for medicines’ incidents (NPSA, 2011). This finding can be explained by the high prevalence of 
OL medicines use in this age group. Conroy et al. (1999) in their study of the prevalence of OL 
medicines in neonates admitted to NICU found that 90% of neonates received at least one UL or 
OL medicine. A related study of prevalence of OL medicines in neonates reported that 80% of 
infants received UL and/or OL medicine; this rose to 93% in extremely low birth weight infants 
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(Lindell-Osuagwu et al., 2009). This is because of the high level of OL prescribing in this age 
group due to the limited number of age-appropriate medicines, the complexity of prescribing and 
the paediatrics physical development. 
 
Findings of this study showed that there was no difference in the MRPs occurrence between the 
genders. Eight percent of all medicines prescribed were implicated in MRPs in male and female 
patients respectively. There was also no difference in occurrence of MRPs with licensed, UL and 
OL medicines between the genders. This agrees with a previous study that reported no difference 
in MRPs incidents between males and females participants (Rashed et al., 2012). This implies that 
occurrence of MRPs is not influenced by gender, that is, both male and female patients will 
experience MRPs to the same degree whether the medicine is licensed, OL or UL. 
 Besides assessing prevalence of use of OL and UL medicines, and the associated problems, this 
study also looked at the relationship between length of stay and polypharmacy. There was a 
significant association between MRPs and LOS as the number of MRPs increased with the increase 
in LOS. Findings of this study also showed a positive correlation between the number of MRPs 
and the number of medicines given to patients. These findings are supported by a related study 
which found that if the average number of prescriptions per patient was ≥5 prescriptions, the 
patient was more likely to experience an MRP (Rashed et al., 2012). This is because of the 
possibility of drug-drug interaction, drug- disease interaction as well as the age of the patient (the 
very young patients tend to have more MRPs because of the underdeveloped organs). 
Of the 165 MRPs identified in this study, only 24% were rated as moderate harm, 76% ranged 
between no-harm and low harm. While there were variations in the rating of the severity of MRPs 
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between the assessors, there was a good level of agreement (82%) from Kappa analysis. This 
finding is supported by a previous study that found that 72.2% of MRPs were minor (n= 345/478) 
and 27% were moderate (n= 129/478) (Rashed et al., 2012). This study also showed that 30.3% of 
the identified MRPs were preventable (n= 50/165). In their study, Rashed et al. (2012) found that 
80.3% of MRPs were preventable (n= 384/478); Easton et al. (2003) found that 51.3% of MRPs 
were preventable; Easton et al. (2004) also found that 46.9% of the MRPs were preventable. This 
can be explained by the difference in methodologies that were adopted as Rashed et al. and Easton 
et al. studies were conducted prospectively while this study was of a retrospective design. 
In this study, MRPs associated with UL medicines were higher when compared with OL 
medicines. To reduce incidence of MRPs with use of UL medicines, the paediatric population 
should be included in clinical trials in compliance with legislation, including the Paediatric 
Investigation Plan (PIP). Because UL and OL medicines’ use is a routine practice in management 
of paediatric illnesses, it is not feasible to obtain parents’ consents in the busy atmosphere in PICU. 
This highlights the need to establish a monitoring policy in PICU when UL medicines are 
prescribed. This policy should include education of parents so they could participate in monitoring 
any MRP that may result from UL medicines use. 
4.7 Strengths and limitations 
This is the first study to investigate MRPs associated with the use of OL and UL medicines in 
paediatric patients admitted to intensive care units. The intensive chart review method adopted has 
been reported as the most appropriate and gold standard in pharmaco-epidimiological studies 
(Ghaleb et al., 2010). Although this study was conducted in only one centre, the use of power 
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calculation in determination of sample size and randomisation enhanced the generalisability of 
findings. 
 The major limitation of this study is that deceased patients’ records were not reviewed. Thus, there 
might be bias in the clinical significance level as it was not certain if there is any MRP incident 
that led to death. Another limitation is that patients were moved between the two intensive care 
units, and that might affect any finding regarding a specific setting. Also poor documentation was 
found to be a major limitation of this study. There was no previous study to compare results with 
regard to MRPs associated with OL and UL medicines in paediatric patients. This study therefore 
draws the attention of paediatric health care professionals to the need to promote research into this 
area. Nonetheless, paediatric population is in need for more innovations in research and 
development. 
4.8 Implication of study findings in practice 
 
In this study, the identified MRPs were ADRs which were due to pharmacological effects of 
prescribed medicines, and treatment effectiveness problems which resulted from prescribing 
errors, medicine dose too low, medicine dose too high, or duration too long. While ADRs may 
not be readily preventable, treatment effectiveness problems are preventable. This implies that 
standard reference sources, such as SPCs should be incorporated into routine practice to 
minimise errors in dose calculations. There should also be a procedure that ensures dosing for 
paediatric patients is double checked as it always involves small decimal calculations to reduce 
the chances of mistakes. Also, continuous monitoring and dose adjustment are necessary for 
paediatric patients according to the clinical response. 
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It is important to have a tool to identify MRPs and practitioners should be trained to use the tool 
for early identification of MRPs. The identified MRPs should always be reported to the hospital 
incident reporting system. MRPs were found to be higher with off-label and unlicensed medicines 
when compared to licensed medicines, thus regular education programme to increase the 
awareness of MRPs associated with OL and UL medicines might help to reduce the number of 
MRPs in this population. This will in turn contribute to improving the paediatric healthcare quality 
by decreasing MRPs-related mortality, morbidity and financial burdens.  
4.9 Conclusion 
This study was undertaken to investigate MRPs associated with the use of off-label and unlicensed 
medicines in paediatric patients admitted to intensive care unit.  
 A total of 2,000 medicines were prescribed to 194 patients of which 54.3% were licensed, 
17.7% were off-label, and 28% were unlicensed. 
 53% of the total number of patients developed at least one MRP.  
 A total of 165MRPs were identified; 43% were associated with licensed medicines and 
57% were associated with off-label and unlicensed medicines (9% and 48% respectively).  
 The identified MRPs were predominantly ADRs (84%) and treatment effectiveness 
problems (16%). 
 Morphine and furosemide were found to be commonly associated with the identified 
MRPs. 
 There was no statistically significant difference in occurrence of MRPs between different 
age groups however; OL use of medicines was associated with more MRPs in younger 
paediatric patients when compared with older ones.  
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 Of 165 identified MRPs, 24% were rated as moderate harm, 76% ranged between no-harm 
and low harm; 30.3% of the identified MRPs were preventable.  
 
Findings of this retrospective study facilitated sample size determination for the prospective phase. 
The prospective phase was divided into two different studies in both PICU and NICU because an 
electronic prescribing was adopted in NICU by the time of the data collection. The next chapter 
describes a prospective study to determine prevalence of MRPs with the use of off-label and 
unlicensed medicines in patients admitted to PICU of the hospital. 
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Chapter 5: Prospective study of medicines’ related problems associated with off-label & 
unlicensed medicines in paediatric intensive care unit 
 
5.1 Introduction 
 
The use of unlicensed and/or off-label medicines in paediatric population has been associated 
with a number of adverse incidents (Bellis et al., 2013; Turner et al. 1999). This is because most 
of the medicines used in paediatrics have not studied in this population; their use is based on data 
obtained from the adult population. An Australian study has found that 4.3% of paediatric 
admissions and 3.3% of A&E visits were related to MRPs (Easton, 2003; Easton, 2004). A 
related study found that the overall incidence of medicines related problems (MRPs) was 59.7% 
in paediatric patients who were admitted to intensive care unit (Rashed et al., 2012).  
In Chapter 4, findings of the retrospective study to identify MRPs associated with the use of off-
label and unlicensed medicines in paediatric intensive care unit (PICU) were presented. In this 
chapter, data was collected prospectively. Findings of the literature review of this thesis showed 
that both prospective and retrospective study designs have been employed in the studies of 
prevalence of off-label and unlicensed medicines’ use in paediatric population. Although the use 
of different study design in investigation of the same subject may lead to variation in results, in 
this thesis, both retrospective and prospective design were employed to allow comparison of 
results as this is the first study to investigate MRPs associated with the use of off-label and 
unlicensed medicines in paediatric in-patients. Findings of the retrospective study were used for 
determination of sample size for the two prospective studies (PICU and Neonatal Intensive Care 
Unit, NICU). 
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5.2 Aim  
To prospectively investigate medicines related problems (MRPs) associated with the use of off-
label and unlicensed medicines in patients admitted to paediatric intensive care unit (PICU) of the 
paediatric hospital. 
5.3 Objectives  
 To determine prospectively the prevalence of OL and UL medicines use in PICU. 
 To determine the prevalence of MRPs in this unit. 
 To determine the prevalence of MRPs associated with OL and UL medicines use in this 
unit of the hospital. 
 To assess the severity of the identified MRPs. 
5.4 Method 
 
5.4.1 Study Setting  
This study was performed at the PICU, which serves patients from South London and South East 
England. The hospital’s intensive care unit is considered as one of the leading intensive care units 
in the UK; the 20-bed PICU is considered as one of the important cardiac units in the country 
(Tomlin, S., personal communication). 
5.4.2 Study population and sampling procedure 
Medical case notes of patients aged 0-18 years old admitted to PICU between October 2015 and 
March 2016 were reviewed. On the first day of data collection (12.10.15), all patients aged 0-18 
years admitted into the unit that day were recruited into the study. All new patients were 
subsequently recruited as they were admitted with the assistance of the unit’s administrative officer 
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who helped to identify new admissions. When up to 10 recruitments were made, the researcher 
would wait for some old patients to be discharge before further recruitment was made. 
5.4.3 Inclusion & exclusion criteria  
Patients who were less than 18 years old and admitted to PICU and on medicines were included in 
the study.  Patients who were admitted for less than 24 hours were excluded from the study. Also 
patients who were on nutritional products only were excluded. Patients who were isolated and 
there was no access to their medical case notes were also excluded.  
5.4.4 Sample size 
The sample size was calculated based on the findings from the retrospective study. The results 
showed that MRPs was observed in 53% of patients who were admitted to PICU. All patients 
received licensed, UL and/or OL medicines; however the number of patients who experienced 
MRPs due to OL and UL medicines was higher than the number of patients who experienced 
MRPs in association with licensed medicines. The results also showed that MRPs associated with 
the use of OL and UL medicines were higher when compared with the use of licensed medicines. 
The sample size for the prospective phase was calculated based on the difference in the percentage 
of patients with an MRP between licensed and OL and/or UL medicines. Level of significance was 
set at 5% and 95% power, it was calculated that 220 patients were required. This sample size was 
increased by 5% to allow for missing data. Thus, a total of 234 patients’ case notes were reviewed. 
This prospective phase was conducted in two settings, PICU and NICU.  Ratio of admission 
between these two settings is known to be 3:2 (Tomlin, S.). Consequently, 147 patients’ case notes 
were reviewed from PICU and 87 patients’ case notes from NICU.  
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A power calculation was performed for the sample size in order to ensure the quality of the 
research. The results were retrieved via statistical method by STATA, and it demonstrated a high 
level of accuracy (98.8%).  
5.4.5 Ethical considerations 
Ethical approval for this study was obtained from University of Hertfordshire, NHS REC, and 
Research and Development (R&D) department as described in section chapter 3 section 3.6. To 
ensure patient information were protected, the researcher was required to sign a confidentiality 
agreement. Patient information collected did not include any identifiers; data was anonymised and 
stored in password-protected devices. Explicit patients’ consent was not required as that will limit 
the number of records to be reviewed as this study was a non-interventional study. In the event 
that the researcher identified an MRP that was clinically significant, the researcher was required 
to contact the pharmacist-in-charge of the unit, who would take appropriate steps to resolve the 
problem.  
The following section describes a feasibility study conducted to validate data collection. 
5.4.6 Feasibility study: Development of a data collection form to identify medicines 
related problems in paediatric inpatients 
 
Development of data collection form for this phase was the same as the retrospective study. However, 
other parameters were included; these were changes of doses, dosage form, duration or frequency were 
also recorded daily. Introduction of new medicines, and/or stopping of any treatment was recorded as 
well as the associated problems. MRPs were categorised according to the Pharmaceutical Care Network 
Europe classification system version 6.2 (PCNE, 2010). Licensing status of medicines was assessed 
using Summary of Product Characteristics (SPC) of medicines that was obtained from the Electronic 
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Medicines Compendium. The form was initially used to collect data from ten patients’ medical case-
notes. Some changes were made to the form (example, introduction of comments about intervention). 
The second version was then used to collect data from 20 medical case-notes (appendix 12). The form 
was validated by a consultant clinical pharmacist with expertise in patient and medication safety, who 
was also the principal investigator in this study. 
5.4.7 Data collection 
Data collection included retrieval of information from patients’ case notes, drug charts and 
laboratory results. Intensive chart review method was adopted as it has been used in a previous 
study in paediatric population (Ghaleb et al., 2010). Information was obtained from drug charts 
and medical case-notes daily from the day of admission until discharge or a maximum of 28days. 
Patients who were discharged from PICU to other paediatric wards were classified as new patients 
in case of re-admission after more than 24hours. Most of the new admissions were included, 
however when the number of patients exceeded more than ten patients, the researcher would wait 
until discharge of some patients before including new admissions.  
Medicines were classified as licensed, off-label and unlicensed according to SPC with regard to 
age, dose, form and indication. Age was categorised according to the International Conference of 
Harmonization Guideline E11 (ICH, 2001). Diagnosis and co-morbidities were categorised 
according to the International Classification of Diseases version 10 (WHO-ICD, 2014). 
MRPs definition and classification were based on the PCNE classification system, version 6.2 
(Appendix 1). MRPs identification was as described in Chapter 4 (Table 4.1). When an MRP was 
identified, then the details including the type of MRP, causes, interventions and outcome of the 
interventions were recorded. Medicines associated with MRPs were identified using Naranjo 
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ADRs Probability Scale (appendix 2). The three experts who assessed severity of MRPs in the 
retrospective study were asked to assess the severity of random 10% of identified MRPs using the 
National Patients Safety Agency level of harm. The experts were recruited to explore opinions 
from different backgrounds; their participation in the retrospective study also enhanced their 
knowledge on MRPs severity scoring. The experts rated the level of harm of each problem 
individually. The level of agreement between the assessors was then measured using Kappa test. 
Preventability of MRPs was assessed using Schumock and Thornton Preventability Scale. Data 
was stored electronically and coded anonymously to ensure patients confidentiality. To ensure 
validity of the identified MRPs, a consultant clinical pharmacist was asked to review the problems, 
causes, interventions and outcome during meetings with the researcher. 
 
5.4.8 Data analysis 
Data collected were analysed using computer programmes including Excel, Statistical Package for 
the Social Sciences (SPSS) and STATA. Descriptive statistics including frequencies, medians, 
standard deviation, and interquartile range were performed.  Data are presented as numbers and 
percentages. Chi-squared test was used to determine statistical significance for categorical 
variables while Kruskal–Wallis rank and Wilcoxon Rank-Sum (Mann–Whitney U) was used to 
determine statistical significance between numerical variables. For all tests, level of significance 
was set at p< 0.05.  
Data analysis was divided into nine parts as in Chapter 4 and included the following: 
 Number of patients who developed MRPs due to different licensing status of medicines, 
the total number of medicines prescribed during the study period, and comparison of 
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licensed, UL and OL medicines use and their associated problems using the Chi-square 
test.  
 Prevalence of licensed, UL and OL medicines use in the different age groups and the 
associated problems. 
 Occurrence of MRPs between genders using Chi-square test.  
 MRPs categories in patients and the medicines associated with them.  
 The association between MRPs and the length of stay (LOS) in the hospital using Kruskal-
Wallis.  
 The relationship between the number of medicines and the number of MRPs using Pearson 
test. 
 MRPs causes, interventions and outcome using the PCNE classification system V 6.2. 
 Severity of the identified MRPs using Kappa test.  
 Preventability of MRPs using Schumock and Thornton scale. 
 
5.5 Results 
 
5.5.1 Patients’ demographics 
 
Data was collected from 147 patients of patients who were admitted to PICU over a 6-month 
period. In the study cohort, majority were infants (37%) and children (39%). Most of patients 
(78%) were born premature. Characteristics of the patient are summarised in Table 5.1.  
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Table 5:1: Patients’ demographics 
Patients characteristics  Category Number of patients, (%) 
Age group New born neonates 23(16) 
 Infant 55(37) 
 Children 57(39) 
 Adolescents 12(8) 
   
Gender Male 78(53) 
 Female 69(47) 
   
Gestation period at birth Mature 32(22) 
 Born Premature 115(78) 
*Analysis involved descriptive statistics (frequencies and percentages) 
Patients were categorised according to their diagnosis. Table 5.2 gives information on the three 
most common diagnoses.  
Table 5:2: The most common diagnosis in the study population 
Diagnosis Number of patients 
(%) 
Number of patients 
without MRP (%) 
Number of patients 
with MRP (%) 
Congenital malformations 
abnormalities 
94 (64) 
 
22 (23) 
  
72 (77) 
 
Diseases of the respiratory 
system 
17 (12) 
 
12 (29) 
 
10 (71) 
  
Certain infectious and 
parasitic diseases 
13 (9) 
  
9 (69) 
  
4 (31) 
  
*Analysis involved descriptive statistics (frequencies and percentages) 
About two-thirds (64%) of the patients were diagnosed with congenital malformations 
abnormalities; 77% of the total number of patients had an MRP. Just over 10% of patients were 
diagnosed with diseases of the respiratory system, and within this group, over two-thirds (71%) of 
the total number of patients had an MRP. Less than 10% of patients were diagnosed with certain 
infectious and parasitic diseases and less than a third (31%) had an MRP within this category. 
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5.5.2 Medicines related problems in patients in relation to the different licensing status of 
medicines  
 
Approximately 79% of patients (n= 116/147) received OL medicines and 95% of patients (n= 
139/147) received UL medicines. Results of this study showed that 66% of patients had an MRP 
(n= 97/147); 56% of patients who received UL medicines had an MRP (n= 78/139); 13% of 
patients who received OL medicines had an MRP (n= 15/116); 41% of patients who received 
licenced medicines had an MRP (n= 60/146).  Figure 5.1 provides a summary of the MRPs in 
patients in relation to the different licensing status of medicines. 
 
 
Figure 5:1: Medicines related problems in patients in relation to the different licensing 
status of medicines 
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5.5.3 Medicines related problems occurrence in relation to different licensing status of 
medicines  
 
A total of 1,578 medicines were prescribed to the 147 patients in this study. Eleven percent 
(n=178/1578) of the medicines were associated with MRPs. With regard to the different licensing 
status of medicines, the results showed that 5.4% (15/276) of OL medicines and 19.3% (91/471) 
of UL medicines were associated with MRPs, while 9% of licensed medicines associated with 
MRPs. A significant difference, p<0.001 was observed between the two groups (licensed 
medicines and OL/UL medicines). Figure 5.2 shows MRPs occurrence due to different licensing 
status of medicines. 
 
Figure 5:2: Medicines related problems occurrence in relation to different licensing status 
of medicines 
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5.5.4 Medicines related problems occurrence in different age groups 
Among the study population, the mean age was 46 months (SD 55 months; range 0.01-216). MRP 
occurrence in the different age groups was compared using chi-square test. There was a significant 
difference in MRPs occurrence between the different age groups, p <0.002, with new born patients 
being the most exposed to MRPs; 16% (n= 45). Summary is shown in Table 5.3. 
Table 5:3: Medicines related problems occurrence in different age groups 
Medicines Number of 
medicines in new 
born patients 
(% ) 
Number of 
medicines in 
infant 
(% ) 
Number of 
medicines in 
Children 
(%) 
Number of 
medicines in 
adolescent 
(% ) 
Without MRPs 231 (84) 536 (89)  522  (91) 111 (90) 
With MRPs 45 (16)  68 (11)  52 (9)  13 (10)  
*Analysis involved descriptive statistics (frequencies and percentages) 
A significant difference was also found in MRPs occurrence due to different licensing status of 
medicines between the age groups. Fifteen percent of OL medicines given to new-born patients 
were associated with MRPs compared to 5% or lower in all other groups, p<0.001. There was 
however no difference in occurrence of MRPs with licensed and UL medicines between different 
age groups. Table 5.4 describes MRPs occurrence in different age groups. 
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Table 5:4: Medicines related problems in different age groups with different licensing 
status of medicines 
Medicine 
licensing 
status 
MRP 
occurrence 
Age categories    P-
value 
  Neonates 
N (%) 
Infant 
N (%) 
Children 
N (%) 
Adolescent 
N (%) 
 
Licenced No MRP 99 (87) 288 (92) 309(93) 63(89) 0.16 
 MRP 15(13) 26(8) 23(7) 8(11)  
       
Off-licence No MRP 64 (85) 101(97) 78(100) 18(95) <0.001 
 MRP 11(15) 3(3) 0(0) 1(5)  
       
Unlicensed No MRP 68(78) 147(79) 135(82) 30(88) 0.51 
 MRP 19(22) 39(21) 29(18) 4(12)  
 
5.5.5 Medicines related problems between genders in relation to different licensing status 
of medicines 
A Chi-square test was carried out to compare the occurrence of MRPs between genders. The results 
showed no significant difference in occurrence of MRPs between male and female, p=0.81, (11% 
versus 11%).  The figure below shows the proportion of medicines that associated with MRPs in 
genders. 
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Figure 5:3: The proportion of medicines that were associated with medicines related 
problems between genders 
There was also no significant difference in occurrence of MRPs due to the different medicines 
licensing status between genders as shown in Table 5.5. 
Table 5:5: Medicines related problems occurrence between genders with different licensing 
status medicines 
Medicines licensing 
status 
MRP Male 
N (%) 
Female 
N (%) 
P-value 
Licenced  No MRP 427 (92) 332 (91)  0.57 
 MRP 38 (8) 34 (9)  
     
Off-label No MRP 151 (94) 
  
110 (95)  0.87 
 MRP 9 (6) 6 (5)  
     
Unlicensed No MRP 198 (80) 182 (82)  0.63 
 MRP 50 (20) 41 (18)  
Analysis involved chi-square test 
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5.5.6 Medicines related problems categories and associated medicines 
 
Of the 1,578 medicines prescribed to the study population, 11% were associated with 178 MRPs, 
of which 83% (n=147/178) were classified as ADRs and 17% (n= 30/178) were classified as 
treatment effectiveness problems. The sub-domain of the problems is summarised in Table 5.6. 
 
Table 5:6: categories of medicines related problems 
Primary domain Code Subcategory Number  
 P1.1 No effect of drug treatment 1 
treatment effectiveness problems P1.2 Effect of drug treatment not optimal 28 
 P1.3 Wrong effect of drug treatment 1 
 P2.1 Non-allergic adverse drug event 69 
adverse drug reactions P2.2 Allergic adverse event 77 
 P2.3 Toxic adverse event 1 
 
The Naranjo scale was used to identify medicines associated with MRPs. Among the study 
population, the most commonly prescribed medicines were morphine, paracetamol, clonidine, 
furosemide and spironolactone. Morphine was prescribed 172 times to 127 patients with MRPs 
occurring in 62% of the patients (n= 79). A complete list of medicines with their licensing status 
and associated problems is shown in Appendix 13. Table 5.7 summarises the medicines that were 
frequently associated with problems; Table 5.8 shows the medicines that were associated with 
problems in different age groups. 
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Table 5:7: Medicines frequently associated with problems 
Medicine Licensing 
Status 
Number of 
times medicine 
prescribed 
  
Number 
of 
patients  
Number of 
times 
medicine 
associated 
with MRPs 
Number of 
patients 
developed 
MRPs 
 
MORPHINE UL 164 127 80 77 
CLONIDINE UL 121 114 4 4 
PARACETAMOL L 105 104 3 3 
FUROSEMIDE L 92 86 48 48 
Analysis involved descriptive statistics (frequencies and percentages) 
Table 5:8: Medicines associated with problems in different age groups 
Age-group Medicines associated with MRPs Number of 
MRPs 
Category of 
MRP 
 Name  Licensing status    
     
New born (*) Morphine UL 17 ADR 
 Furosemide L 12 ADR 
 Paracetamol OL 10 TE 
 Gentamicin L 2 TE 
 Vancomycin UL 1 TE 
     
Infants Morphine UL 33 ADR 
 Furosemide L 21 ADR 
 Vancomycin L 4 ADR & TE 
 Clonidine UL 3 ADR 
 Flecainide OL 1 TE 
     
Children Morphine UL 28 ADR 
 Furosemide L 9 ADR 
 Gentamicin L 3 TE 
 Salbutamol L 2 ADR 
 Co-Amoxiclav L 2 TE 
     
Adolescents Furosemide L 6 ADR 
 Morphine UL 4 ADR 
 Tranexamic Acid OL 1 ADR 
 Gentamicin L 1 TE 
 Paracetamol L 1 TE 
     
(*) Term and pre-term babies were combined together as only a small number of pre-terms 
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5.5.7 Medicines related problems occurrence and length of stay 
 
The association between the occurrence of MRPs and the length of stay (LOS) in hospital was 
examined. The mean LOS was 4.0 days (SD= 3.1 days; range 2-20). The Kruskal-Wallis test 
showed a significant association between MRPs and LOS, p < 0.05. Patients with two or more 
MRPs had longer LOS. Figure 5.4 is a graphical illustration of MRPs occurrence and LOS of the 
study participants. 
 
Figure 5:4: Length of stay in study population 
 
5.5.8 Medicines related problems occurrence and number of medicines 
 
The results showed that the average number of medicines per patient was 10.7 (SD= 4.5, IQR= 8 
to 13). The results also showed that there was an association between number of medicines and 
number of MRPs. There was a positive correlation between the two measures, with a correlation 
coefficient of 0.51, which was statistically significant (p<0.001).  Table 5.9 shows the occurrence 
of MRPs with number of medicines. 
0
5
10
15
20
Le
ng
th
 o
f s
ta
y 
(d
ay
s)
No MRPs 1 MRP 2+ MRPs
132 
 
 
Table 5:9: Relationship between number of medicines related problems and number of 
medicines 
Number of MRPs Number of patients Number of medicines per patient, Mean (SD) 
0 50 8.4 (4.6) 
1 43 10.6 (3.2) 
2 35 11.6 (2.9) 
3 14 14.9 (4.7) 
4 3 15.7 (6.1) 
5 1 23.0 (-) 
>5 1 18.0 (-) 
Analysis involved Pearson test.  
5.5.9 Medicines related problems’ causes, interventions and outcome 
 
In this study, 11% of the total number of medicines was associated with 178MRPs (treatment 
effectiveness problems and ADRs). The total number of causes was 267 causes, including 
medicine selection; dose selection; treatment duration; logistics of prescribing errors, and others. 
Table 5.10 shows the causes and categories. 
Table 5:10: Medicines related problems causes 
Primary domain Code Subcategory Number 
Drug selection C1.1 Inappropriate drug (Contra-indication) 12 
 C1.6 Too many drugs prescribed for indication 13 
 C3.1 medicine dose too low 29 
Dose selection C3.2 medicine dose too high 37 
 C3.5 No therapeutic monitoring 5 
 C3.7 Deterioration of disease requiring dose adjustment 59 
Treatment duration C4.2 treatment duration too long 44 
Logistics C6.2 prescribing errors 39 
Others C8.2 No obvious cause 29 
Analysis involved descriptive statistics (frequencies and percentages) 
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 These MRPs required 201 interventions; some of the MRPs required more than one intervention. 
Approximately 31% (n= 62/201) of all interventions were carried out at the prescriber level and 
were done by the pharmacist in charge of the unit (that is, the interventions were recommended by 
the pharmacist and approved by the prescriber). 
Sixty-nine percent (n= 139/201) of the interventions were carried out at the medicine level (that 
is, dose changed, formulation changed, medicine stopped and new medicine started).  
At the medicines level, 36% (n= 50/139) of interventions were carried out by the pharmacist while 
64% (n= 89/139) were carried out by other healthcare professionals. All interventions resulted in 
a positive outcome and the identified MRPs were resolved. Table 5.11 below summarises the 
different types of interventions of the identified MRPs. 
 
Table 5:11: Medicines related problems interventions 
Primary domain Code Subcategory Number 
At prescriber level I1.3 Intervention proposed, approved by Prescriber  
 
62 
 I13.2 Dosage changed to 31 
At drug level I13.3 Formulation changed to 23 
 I13.5 Drug stopped  29 
 I13.6 New drug started 56 
Analysis involved descriptive statistics (frequencies and percentages) 
5.5.10 Medicines related problems severity  
 
The severity scoring of identified MRPs (178) showed that 6% (n= 11/178) were no harm, 72% 
(n= 128/178) were of low harm and 22% (n= 39/178) were of moderate harm.  An example of 
MRP case study that was sent to experts is shown in Table 5.12 below. 
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Table 5:12: An example case study for medicines related problems severity 
Severity of MRPs/ Case no. 16 
Patient details Medical diagnosis & Co-morbidities 
Study IDP 153 Admitted for removal of spinal correctional instrumentation, 
GORD, Epilepsy 
 
Age  15years 
Weight 38kg 
Gender M 
Length of stay  5days 
Allergies Morphine allergy 
Medication history 
Name of medicine Dose (mg) Frequency  Route of administration 
Teicopanin 380mg Stats Iv 
Enoxaparin 20U Od Sc 
Paracetamol 500mg Qds Iv/peg 
Cholocalcefirol 400iu Od Po 
Oxycodiene 2.5mg Qds PEG 
Diclofenac sodium 30mg Tds Po 
Gentamicin 95mg Stats Iv 
Vancomycin 570mg Tds Iv 
Movicol 2sachets Bd Po 
Nystatin 1ml Bd Po 
Omeprazol 20mg Od Po 
Domperidone 10ml Qds Po 
Clinical narrative 
The patient has GORD, and developed severe stomach pain and vomiting after taking diclofenac sodium orally.  
Medicine related problem (MRP): “A Drug-Related Problem is an event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes”. (Pharmaceutical Care Network Europe, 2010) 
Please answer the following question by either YES or No 
Does the case include any MRP based on the attached PCNE classification tool?    
Please rank the harm caused by the MRP identified based on NPSA scale of harm, insert  
 No harm (The incident caused no harm)   
 Low (Any patient safety incident that required extra observation or minor treatment, and caused minimal harm 
to the person(s) receiving NHS funded care)  
 Moderate (Any patient safety incident that resulted in a moderate increase in treatment, and which caused 
significant but not permanent harm to the person receiving NHS funded care) 
 Severe (Any patient safety incident that resulted in permanent harm to the person(s) receiving NHS funded 
care) 
 
None of the MRPs was rated as severe or death; thus only three levels were observed in the data. 
Table 5.13 shows summary of experts’ rating. 
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Table 5:13: Experts’ panel severity scoring of medicines related problems 
Scorer No harm 
Percentage % (n) 
 
Low 
Percentage % (n) 
 
Moderate 
Percentage % (n) 
 
Consultant pharmacist 6 (1)  72 (13)   22 (4) 
Consultant 
paediatrician 
6 (1) 72 (13)   22 (4) 
Nurse 6 (1) 72 (13)   22 (4) 
Analysis involved descriptive statistics (frequencies and percentages) 
 
 The identified MRPs were summarised in terms of whether all three experts agreed, 2 of the three 
experts agreed, or all the 3 experts disagreed. Using the Stata software, Kappa test was used to 
calculate the level of agreement between the three experts. The kappa test result was found to be 
0.83 (95% CI; 0.6-1.0). This value implies very good agreement between the three experts. 
Summary of agreements of experts is shown in Table 5.14. 
Table 5:14: Experts’ agreement 
Level of agreement Percentage % (n)  
All members in agreement  89 (16)  
Two in agreement, one disagreement 11 (2)   
All three members in disagreement 0 (0) 
 
 
5.5.11 Medicines related problems preventability 
 
Assessment of preventability using Schumock and Thornton Preventability Scale 34% of the 
identified MRPs were found to be preventable (n= 61/178). Table 5.15 shows a summary of case 
vignettes of the most common prescribed medicines and associated problems, problem categories, 
severity and preventability: 
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Table 5:15: Examples of case vignettes of most common prescribed medicines and associated problems 
 
Case Medicine 
associated 
with MRP 
licensin
g status 
MRP 
Category  
MRP Severity  MRP 
Preventability  
A patient aged 22days (3kg) was admitted for Cardiac surgery. The patient 
developed sign of seizures after IV morphine was administered.  
The patient recovered after the medicines was stopped. 
morphine UL ADR Pharmacist: 
low harm 
Nurse: low 
harm 
Paediatrician: 
no harm 
Non-preventable 
A patient aged 12years (33kg) electively admitted for coarctation of the aorta 
surgery. The patient developed severe allergic reaction which required 
administration of chlorpheniramine injection. 
 
morphine L ADR Low harm 
from the three 
experts 
Non-preventable 
A patient aged 4months was admitted for cardiac surgery. The patient 
was on the correct dose of intravenous furosemide and the potassium 
level dropped to less than 3mmol/L; administration of intravenous 
Potassium Chloride successfully increased level back to 3.6mmol/L. 
furosemide L ADR Low harm 
from the three 
experts 
Non-preventable 
A patient aged 1days who was born at 36weeks gestational age with a 
weight of less than 2kg was electively admitted for suspected sepsis. The 
patient was prescribed   20mg/kg every 8 hours, however the patient was 
received 20mg/kg every 4hours 
 
paracetam
ol 
UL Treatment 
effectivenes
s 
No harm from 
the three 
experts 
Preventable 
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5.6 Discussion 
 
The main objectives of this prospective study were to determine the prevalence of MRPs in the 
PICU, and the prevalence of MRPs associated with off-label and unlicensed medicines use. Like 
the retrospective study (Chapter 4), the most common diagnosis among the 147 patients included 
in the study were congenital malformations abnormalities, diseases of the respiratory system, and 
certain infectious and parasitic diseases. There was high rate of off-label and unlicensed 
medicines’ use among the study population as 79% of the patients received off-label medicines 
while 95% received unlicensed medicines. This finding is in agreement with a previous study of 
342 patients, which reported that 95.3% of the patients admitted to PICU received unlicensed 
and/or off-label medicine (Dos Santos & Heineck, 2012). Out of the 1578 medicines prescribed, 
approximately 47% were off-label and/or unlicensed. A previous study has reported similar 
finding; 46% of medicines were unlicensed or off-label (Palcevski et al., 2012). In comparison 
with the retrospective study, the proportion of off-label and/or unlicensed was 46%. Findings from 
literature and the retrospective and prospective studies showed consistency in the use of OL and 
UL medicines among paediatric in-patients. Approximately 50% of medicines used in treatment 
of paediatric in-patients are either off-label and/or unlicensed, therefore off-label and unlicensed 
use of medicines remains a major issue in paediatric practice. 
Among the 147 patients, 66% developed MRPs. In the retrospective study, 53% of the 194 patients 
developed MRPs. Findings of this study are therefore supported by a study to determine MRPs 
incidence in PICU which reported 59.7% incidence rate of MRPs (Rashed et al., 2012).   
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In this prospective study, 11% of the medicines were associated with MRPs; 5.4% (15/276) of OL 
medicines and 19.3% (91/471) of UL medicines were associated with MRPs, while 9% of licensed 
medicines associated with MRPs. At the time of literature review of this thesis, no study was found 
to compare these findings. However, the results of the retrospective study showed similar findings 
with 8% of the total number of medicines associated with MRPs; 10.3% of OL and UL medicines 
associated with MRPs, and 7% of licensed medicines associated with MRPs. Of the total number 
of the identified MRPs, this study found that 83% were ADRs (Type A reactions, which are 
extension of the medicine’s pharmacology), while 17% were treatment effectiveness problems 
(result from prescribing and other errors). This result suggests that proper dose calculations and 
monitoring is required to minimise treatment effectiveness problems.  In comparison with the 
retrospective study, ADRs were 84% and treatment effectiveness problems were 16%. Previous 
studies have reported higher prevalence of ADRs with use of OL and/or UL medicines when 
compared to licensed medicines (Neubert et al., 2004; Saiyed, Lalwani & Rana, 2015; Turner et 
al., 1999).  Although MRPs (mostly ADRs) occurred more with the use of off-label and/or 
unlicensed medicines than with licensed medicines, other factors including pharmacological 
effects of the medicines may have accounted for the occurrence. Medicine selection, dose 
selection, treatment duration, and logistics (prescribing errors) were found to be the causes of 
treatment effectiveness problems. This is because of the challenges of prescribing for this 
population where there are limited availability of formulations and insufficient information of the 
prescribed medicines.  
Among the study population, the age group most prone to MRPs were new-born patients (0- 
28days), p<0.001. As noted in a previous study (Cuzzolin & Agostino, 2016), this age group is the 
most exposed to off-label and unlicensed medicines. This may explain why incidence of MRPs 
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are higher in this age group due to the pharmacokinetic changes (absorption, distribution, 
elimination) during maturation. Also, the lack of information on prescribed medicines, and the 
factors that influence prescribing in this group (age, weight, body surface area and physical 
development) (Wong et al., 2004) may predispose this age group to development of MRPs.  It has 
also been reported that children who are aged between 0-4 years are the most vulnerable group for 
medicines’ incidents (NPSA, 2011).  
  Like the retrospective study, there was no significant difference in occurrence of MRPs between 
genders. Non-significant difference in occurrence of MRPs between male and female has 
previously been reported (Rashed et al., 2012). These findings imply that gender may not be a risk 
factor for development of MRPs with the use of off-label and unlicensed medicines, or other 
medicines in paediatric in-patients.  
In this prospective study, morphine, paracetamol, clonidine, furosemide and spironolactone were 
the most commonly used medicines among the study population; with MRPs occurring in 62% of 
patients who received morphine. This is similar to findings of the retrospective study. High 
occurrence of ADRs with use of morphine in paediatric patients has also been reported in a related 
study (Rashed et al., 2012). 
Like the retrospective study, results from this study showed that there was significant association 
between LOS and number of MRPs, p < 0.05. Patients with longer LOS had two or more MRPs. 
A previous study has found that LOS is a risk factor for ADRs (Weiss et al., 2002). Findings of 
this study also showed that the number of MRPs increased with the number of medicines. 
Polypharmacy has been previously identified as a one of the main risk factors for occurrence of 
MRPs, including ADRs (Rashed et al., 2012; Weiss et al., 2002; Zopf et al., 2008). 
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Assessment of severity and preventability of identified MRPs showed that 72% of MRPs were of 
low harm, 22% of MRPs were of moderate harm and 6% posed no harm. Thirty-four percent of 
the identified MRPs were preventable especially treatment effectiveness problems which were 
caused by dosing problems and prescribing errors. These findings may not be very close to those 
of Rashed et al. (2012), who reported 67.7% preventable MRPs. That is because this study was 
conducted in PICU while Rashed et al (2012) study of MRPs was conducted on different wards 
including medical ward where the highest percentage of MRPs was identified.  
MRPs associated with OL and UL medicines were found to be higher when compared with 
licensed medicines. A number of measures can be introduced to minimise the risk associated with 
these problems. These include inclusion of paediatric patients in clinical trials of new medicinal 
products, healthcare professionals should be encouraged to minimise medicines manipulations, 
and close monitoring for paediatric patients who are prescribed OL and/or UL medicines.  
5.7 Strength and limitations 
The methodology adopted in this study was intensive chart review, which has been recognised as 
the gold standard in pharmaco-epidimiological studies. Prospective observational intensive chart 
review method gave more chance to detect off-label and unlicensed medicines’ use than the 
retrospective study, as poor documentation was found as one of the limitations in retrospective 
chart review. Also unlicensed medicines in form of specials and extemporaneous medicines were 
easier to identify than in retrospective review as the researcher was able to detect which type of 
medicines were used. 
Although this study was conducted in only one centre, the use of power calculation in 
determination of sample size and randomisation enhanced the generalisability of findings. The 
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major limitation of this study is that not all patients were included; the researcher had to stop 
recruiting patients when the recruited patients were more than ten patients. Other limitation was 
that isolated patients were not included as there was no access to their room or their case notes. 
5.8 Implication of study findings in practice 
 
In this study, the identified MRPs were ADRs which were due to pharmacological effects of 
prescribed medicines and they are often not be preventable, and treatment effectiveness problems 
which resulted from prescribing errors, medicine dose too low, medicine dose too high, or 
duration too long. Treatment effectiveness problems are however preventable. Summary of 
product characteristics should be incorporated into routine practice as well as local guidelines to 
minimise errors in dose calculations. Double-checking of dose calculation by two or more 
healthcare professional should be introduced in routine practice. MRPs were found to be higher 
with OL and UL medicines when compared to licensed medicines, thus regular education 
programme to increase the awareness of MRPs associated with OL and UL medicines might help 
to reduce the number of MRPs in this population. Regular incident reporting of MRPs and near 
misses will help in minimising their occurrence. This will contribute to improving paediatric 
practice and decrease MRPs-related mortality, morbidity and financial burdens.  
5.9 Conclusion 
This study was carried out prospectively to investigate the prevalence of medicines related 
problems associated with the use of off-label and unlicensed medicines in patients admitted to 
paediatric intensive care unit of a paediatric hospital. 
  A total of 1,578 medicines were prescribed to the 147 patients in this study. 
 66% of the study participants were developed MRPs 
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 11% of the medicines were associated with MRPs.  
 5.4% of off-label medicines and 19.3% of unlicensed medicines were associated with 
MRPs, while 9% of licensed medicines associated with MRPs. 
 83% of the identified MRPs were ADRs and 17% were treatment effectiveness problems. 
 Morphine and furosemide were found to be commonly associated with the identified 
MRPs. 
 Longer length of stay and polypharmacy were found to contribute to occurrence of MRPs.  
 While less than half of identified MRPs were preventable, none was rated as being of severe 
harm to patients. 
At the time of this study, an electronic prescribing system was implemented in the neonatal 
intensive care unit (NICU); therefore a separate study was conducted to investigate MRPs 
associated with the use of OL and UL medicines and to ascertain whether the electronic prescribing 
has an impact MRPs occurrence or not. The next chapter describes the prospective study that 
conducted in NICU. 
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Chapter 6: Prospective study of off-label & unlicensed medicines’ related problems in 
neonatal intensive care unit  
 
6.1 Introduction 
 
In this chapter, findings of a prospective study undertaken in the Neonatal Intensive Care Unit 
(NICU) are presented. Over the past five years, there has been increasing emphasis on adoption of 
digital technology across the NHS to improve the quality of care, and increase patient safety and 
service efficiency (NHS England, 2012; NHS England, 2014). More recently, the Francis Inquiry 
Report into the failings of Mid Staffordshire NHS Foundation Trust highlighted the need for 
common information practices, and feeding of performance information into shared databases for 
monitoring purposes through introduction of electronic patient information systems (NHS, 2013). 
Consequently, the Secretary of State announced the Safer Hospitals, Safer Wards Technology 
Fund in May 2013. The objective of the fund was to assist NHS organisations to move from paper-
based to paper-light and effectively paperless, integrated digital care records (IDCRs). It also 
supports those organisations that seek to achieve demonstrable improvements in efficiency, quality 
and safety through introduction of electronic prescribing (e-prescribing) within acute settings and 
community settings (NHS, 2013). Implementation of e-prescribing has the following advantages 
(NHS, 2013): 
 improves the legibility and completeness of prescriptions and makes information about 
medicines available to the healthcare team at all times. 
 the need to move paper prescriptions around an organisation is removed,  
 patient safety issues associated with poor handwriting are addressed,  
 the quality of care is improved as queries are reduced and efficiencies delivered as paper 
is no longer chased  
144 
 
 local formulary implementation is supported by reminders at the point of prescribing 
reducing the need to constantly update prescribers about local policy 
 the use of decision support provides additional support for prescribers  
 guided prescribing can help to reduce inappropriate dosing,  
 facilitates correct drug selection and reduce the incidence of incorrect selection when an 
allergy or contraindications are present.  
At the time of this research, the NICU of the hospital had migrated to electronic medical record, 
called Medchart. Although findings of the studies in Chapters 4 and 5, and literature showed that 
the use of off-label/unlicensed (OL/UL) medicines is highest among neonates, and incidence of 
MRPs is also highest among neonates, it was decided to further conduct a study in NICU. This 
was to ascertain if implementation of Medchart havv any effect on the occurrence of medicines 
related problems (MRPs). 
6.2 Aim 
The aim of this prospective study was to investigate MRPs associated with the use of OL and UL 
medicines in neonates’ admitted to NICU at a paediatric hospital. 
6.3 Objectives 
 To determine the prevalence of OL and UL medicines use in NICU. 
 To determine the prevalence of MRPs in this unit. 
 To determine the prevalence of MRPs associated with the use of OL and UL medicines in 
this unit of the hospital. 
 To assess the severity of the identified MRPs. 
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6.4 Method 
 
6.4.1 Study setting 
 
This study was carried out at the NICU which serves patients from South London and South East 
England. The NICU is considered as one of the leading intensive care units in the UK (Tomlin, S., 
personal communication).   
6.4.2 Study population and sampling procedure 
In this prospective study, data was collected from electronic medical records between December 
2015 and May 2016; drug charts and laboratory results were reviewed. Fluids recorded in paper-
charts were also reviewed. A computer random sampling was applied in selection of participants’ 
case-notes. 
6.4.3 Inclusion & exclusion criteria 
Patients who were admitted to NICU in the 6 months period of data collection and were on 
medicines were included in the study.  Patients who were admitted for less than 24 hours and 
patients who were on nutritional products only were excluded from the study.  
6.4.4 Sample size 
Determination of sample size for this study is as described in Chapter 5. Sample size was calculated 
to be 87 patients.  
6.4.5 Ethical considerations 
Ethical approval for this study was obtained from University of Hertfordshire, NHS REC, and 
Research and Development (R&D) department as described in Chapter 3 Section 3.6. To ensure 
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patient information was protected, the researcher was required to sign a confidentiality agreement. 
Patient information collected did not include any identifiers; data was anonymised and stored in 
password-protected devices. Explicit patients’ consent was not required as that will limit the 
number of records to be reviewed as this study is a non-interventional study. In the event that the 
researcher identified an MRP that was clinically significant, the researcher was required to contact 
the pharmacist in charge of the unit, who would take appropriate steps to resolve the problem.  
6.4.6 Data collection   
At the time of this study, the NICU had implemented electronic prescribing. The system allows 
both prescribing and reconciliation to be done electronically. All patient data including the NHS 
number, hospital number, date of birth, gestational age, diagnosis, allergies, medication history, 
and current medications was captured. Medicines names, doses by age or body weight, and other 
relevant information are incorporated in the software. The system raises alerts for 
contraindications, incorrect doses, and wrong calculations of medicines. All requested 
investigations and/or examination, test’ results and further referrals of each patient are accessible 
when a user logs into electronic medical chart. Patients’ allergy status is indicated in red at the top 
of each page of the medical chart. Any changes in patient’s medical condition(s) and treatment(s) 
are updated electronically. When pharmacists make changes to the existing treatment plan, they 
are required to sign for these changes as well as the daily reconciliation of medicines. While 
majority of prescribing in NICU was done electronically, however intravenous fluids as well as 
medicines given via intravenous fluids were prescribed using paper chart. Information was 
obtained from medical electronic patients’ notes and fluid charts every day from the day of 
admission until discharge or a maximum of 28days. Patients who were discharged from NICU to 
other paediatric wards were classified as new patients in case of re-admission into NICU after 
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more than 24hours. Data collection form used in this study was the same as the one used in the 
prospective study in PICU (Appendix 12). Data collected included patient demographics: age, 
weight, height, weight on birth, and gender.  Patients’ medical history, diagnosis, co-morbidities, 
and allergy status were recorded. Doses, dosage form, frequency, duration, and indications for 
each prescribed medicine were also recorded. Medicines were classified as licensed, OL and UL 
according to SPC with regards to age, dose, form and indication. Age was categorised according 
to the International Conference of Harmonization Guideline E11 (ICH, 2001). Diagnosis and co-
morbidities were categorised according to the International Classification of Diseases version 10 
(WHO-ICD, 2014). 
MRPs definition and classification were adopted from the PCNE classification version 6.2 
(Appendix 1). MRPs identification was as described in Chapter 4 (Table 4.1). When an MRP was 
identified, then the details including the type of MRP, causes, interventions and outcome of the 
interventions, were recorded. Medicines that were associated with problems were identified using 
the Naranjo ADRs Probability Scale (appendix 2). A panel of experts was asked to assess severity 
of MRPs using the National Patients Safety Agency level of harm (NPSA, 2009). The experts who 
also participated in previous two studies were recruited via convenient sampling technique with 
the principal investigator.  
Preventability of MRPs was also assessed using Schumock and Thornton Preventability Scale. 
Data was stored electronically and coded anonymously to ensure patients confidentiality. To 
ensure validity of the identified MRPs, a consultant clinical pharmacist was asked to review the 
problems, causes, interventions and outcome during meetings with the researcher. 
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6.4.7 Data analysis 
Data collected were analysed using computer programmes including Excel, Statistical Package for 
the Social Sciences (SPSS) and STATA. Descriptive statistics including frequencies, medians, 
standard deviation, and interquartile range, were performed.  Data are presented as numbers and 
percentages. Chi-squared test was used to detect significant differences for categorical variables 
while Kruskal–Wallis rank and Wilcoxon Rank-Sum (Mann–Whitney U) used to determine 
significant differences between numerical variables. For all tests p< 0.05 was selected as the level 
of statistical significance.  
Data analysis was divided into eight parts including the following: 
 Number of patients who developed MRPs due to different licensing status of medicines, 
the total number of medicines prescribed during the study period, and comparison of 
licensed, UL and OL medicines use and their associated problems using the Chi-square 
test.  
 Occurrence of MRPs between genders using Chi-square test.  
 MRPs categories in patients and the medicines associated with them.  
 The association between MRPs and the length of stay (LOS) in the hospital using Kruskal-
Wallis.  
 The relationship between the number of medicines and the number of MRPs using Pearson 
test. 
 MRPs causes, interventions and outcome using the PCNE classification system V 6.2. 
 Severity of the identified MRPs using Kappa test.  
 Preventability of MRPs was using Schumock and Thornton scale Preventability. 
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6.5 Results 
 
6.5.1 Patients’ demographics 
 
Approximately 76% (n= 66/87) of the 87 patients were born as pre-mature neonates; 52% (n= 
45/87) were male. Seventy five percent (n= 65/87) of the patients were referred to the hospital 
from other hospitals by South Thames Retrieval Services (STRS); 24% (n= 21/87) were admitted 
from the maternity department; one patients was admitted from the A&E department. 
The most common diagnosis was respiratory system diseases. Ninety percent (n= 78/87) of the 
patients developed MRPs. All patients received at least one OL and/or UL medicine. Table 6.1 
gives an overview of MRPs occurrence in patients. 
 
Table 6:1: Medicines related problems occurrence in study population 
Variable Category Number of patients (%) 
   
MRP  No MRP 9 (10%) 
 MRP 78 (90%) 
   
Type of MRP  ADR only 78 (100%) 
 TE  problems only 0 (0%) 
 ADR and TE 0 (0%) 
*Analysis involved descriptive statistics (frequencies and percentages) 
 
6.5.2 Medicines related problems in patients in relation to different licensing status of 
medicines 
 
Seventy-four percent of patients who received licensed medicines experienced MRPs; 45% of 
patients who received OL medicines experienced MRPs; and 33% of patients who received UL 
medicines experienced MRPs. Neonates who were born as premature babies were found to have a 
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higher rate of problems (n= 57patients) when compared to patients who were born as mature babies 
(n=21patients). Figure 6.1 provides information on MRPs occurrence in patients who received 
medicines’ with different licensing status. 
 
Figure 6:1: MRPs in patients in relation to different licensing status of medicines 
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6.5.3 Medicines related problems occurrence in relation to different licensing status of 
medicines 
 
A total number of 1,978 medicines were prescribed to the study population, of which 
approximately 58% (n= 1,139) were licensed medicines, 14% (n= 278) were OL medicines and 
28% (n= 561) were UL medicines. Nine percent (n= 186/1978) of the total number of medicines 
were associated with MRPs. 
Comparison of MRPs occurrence between medicines’ licensing status showed that 9% 
(n=103/1,139) of licensed medicines were associated with MRPs; 15% (n=43/278) of OL were 
associated with MRPs, and 7% (n= 40/561) of UL medicines were associated with MRPs. MRPs 
were higher with OL medicines than licensed or UL medicines, p<0.001. Figure 6.2 provides detail 
of different medicines licensing status and their association with MRPs. 
 
Figure 6:2: Medicines related problems occurrence in relation to different licensing status 
of medicines 
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6.5.4 Medicine related problems between genders with different licensing status of 
medicines 
 
Among the study population, the Chi-square test showed that there was no significant difference 
in occurrence of MRPs between the genders, p= 0.24 (42 males versus 36 females). 
There was also no significant difference between genders in occurrence of MRPs due to licensed, 
OL and UL medicines. Table 6.2 below summarises MRPs occurrence due to different licensing 
status of medicines between genders. 
 
Table 6:2: Medicines related problems between genders with different licensing status of 
medicines 
Medication MRP Male 
Number (%) 
Female 
Number (%) 
P-value 
All medication No MRP 915 (90)  877 (91) 0.33 
 MRP 102 (10) 84 (9)  
     
Licenced No MRP 521 (90) 332 (92) 0.33 
 MRP 57 (10) 46 (8)  
     
Off-label No MRP 118 (86) 117 (84) 0.66 
 MRP 20 (14) 23 (16)  
     
Unlicensed No MRP 276 (92) 254 (94) 0.24 
 MRP 25 (8) 15 (6)  
Analysis involved chi-square test 
 
6.5.5 Medicines related problems categories and associated medicines 
 
In the previous two studies (Chapters 4 & 5) both adverse drug reactions and treatment 
effectiveness problems were identified; however, in this study identified MRPs were mainly 
ADRs. Table 6.3 below the subcategories of MRPs in the study populations. 
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Table 6:3: Medicines related problems categories in study population 
Primary domain Code Subcategory Number  
adverse drug reactions P2.1 Non-allergic adverse drug event 39 
 P2.2 Allergic adverse event 38 
 P2.3 Toxic adverse event 1 
Analysis involved descriptive statistics (frequencies and percentages) 
Morphine, paracetamol, furosemide and benzylpenicillin were the most common medicines 
associated with MRPs. Table 6.4 below gives examples of the identified problems with their 
associated medicines; a full list of all medicines prescribed to study participants, their licensing 
status and associated problems is provided in appendix 14. 
 
Table 6:4: Medicines frequently associated with problems 
Medicine Licensing 
status 
Number of 
times 
medicine 
prescribed 
Number of 
patients  
Number of 
MRPs 
associated 
with 
Number of 
patients 
developed 
MRPs 
BENZYLPENICILLI
N 
L 92 87 45 45 
MORPHINE UL 92 74 36 35 
FUROSEMIDE OL 52 51 27 27 
CEFUROXIME L 47 45 13 13 
CO-AMOXICLAV L 18 17 16 15 
Analysis involved descriptive statistics (frequencies and percentages) 
6.5.6 Number of medicine related problems and length of stay 
 
The association between the occurrence of MRPs and the length of stay in hospital was examined 
using the Kruskal-Wallis test. The results showed that there was no significant association between 
MRPs and LOS, P=0.13. Summary of the relationship between LOS and the number of MRPs is 
shown in Figure 6.3: 
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Figure 6:3: Relationship between length of stay and number of medicine related problems 
 
 
6.5.7 Medicine related problems occurrence and number of medicines 
 
The results of this study showed a significant association between number of medications and 
number of MRPs (p=0.006, coefficient of 0.29). Table 6.5 below shows the relationship between 
number of medicines and number of MRPs. 
Table 6:5: Relationship between number of medicines and number of medicines related 
problems 
Number of MRPs Number of patients Number of medicines per 
patient 
Mean (SD) 
0 9 20.8 (2.3) 
1 26 22.8 (3.0) 
2 24 21.2 (5.5) 
3 12 23.6 (4.9) 
4 10 25.0 (3.6) 
5 5 25.2 (3.3) 
Analysis involved Pearson test.  
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6.5.8 Causes, interventions and outcomes 
 
One hundred and eighty-six medicines were associated with 186 MRPs. There were 186 causes 
classified as others according to the PCNE V6.2 manifested medicines effects. One hundred and 
ninety-six interventions were required for the identified MRPs. The pharmacists in charge of the 
unit were responsible for 20% (n= 25/123) of interventions carried out at the prescriber level (that 
is, the interventions were recommended by the pharmacist and approved by the prescriber) and 
10% (n= 7/73) of interventions carried out at medicines’ level. All interventions resulted in a 
positive outcome and MRPs were resolved. Table 6.6 below shows the different MRPs 
interventions. 
Table 6:6: Medicines related problems interventions 
Primary domain Code Subcategory Number 
At prescriber level I1.3 Intervention proposed, approved by Prescriber  
 
123 
 I13.2 Dosage changed to 1 
At medicine level I13.3 Formulation changed to 9 
 I13.5 Medicine stopped  11 
 I13.6 New medicine started 52 
Analysis involved descriptive statistics (frequencies and percentages) 
6.5.9 Medicines related problems severity 
 
From experts’ rating, approximately 6% (n= 11/186) of the identified MRPs were no harm, 92% 
(n= 171/186) were low harm, and 2% (n= 4/186) were moderate harm. An example of an MRP 
case study that was sent to experts is shown in Table 6.7 below. 
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Table 6:7: An example of case study for medicines related problems severity 
Severity of MRPs/ Case no. 13 
Patient details Medical diagnosis & Co-morbidities 
Study IDP 114 Elective admission for Coarctation of the aorta surgery. 
Increased work of breathing since birth, suspected sepsis. Age  2weeks 
Weight 2.9kg 
Gender M 
Length of stay  3days 
Allergies NKDA 
Medication history 
Name of medicine Dose (mg) Frequency  Route of administration 
Morphine 3mg/50ml 10mcg/Kg/hr Cont Iv 
Fentanyl 6mcg Stats Iv 
Ketamine 3mg Stats Iv 
Cefuroxime 80mg Stats Iv 
Clonidine 9mcg Tds Ngt 
Paracetamol 45mg Tds Ngt 
Furosemide 3mg Tds Iv 
Spironolactone 3mg Tds Ngt 
Naloxone 30mcg Stats Iv 
Coamoxiclav 90mg Tds Iv 
Coamoxiclav 0.75ml Tds Po/ngt 
Lactulose 2.5ml Bd Po 
Clinical narrative 
The patient was on the correct dose of morphine, the patient developed signs of seizures, respiratory 
depression and agitation. The patient recovered after being administered naloxone intravenously.   
Medicine related problem (MRP): “an event or circumstance involving drug therapy that actually or 
potentially interferes with desired health outcomes”. (Pharmaceutical Care Network Europe, 2010) 
Please answer the following question by either YES or No 
Does the case include any MRP based on the attached PCNE classification tool?    
Please rank the harm caused by the MRP identified based on NPSA scale of harm, insert  
 No harm (The incident caused no harm)   
 Low (Any patient safety incident that required extra observation or minor treatment, and 
caused minimal harm to the person(s) receiving NHS funded care)  
 Moderate (Any patient safety incident that resulted in a moderate increase in treatment, and 
which caused significant but not permanent harm to the person receiving NHS funded care) 
 
 Severe (Any patient safety incident that resulted in permanent harm to the person(s) 
receiving NHS funded care) 
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None of the MRPs was rated as severe or death; thus only three levels were observed in the data. 
All experts determined that 60% of MRPs were low harm, 25% of MRPs were moderate harm and 
15% at no harm. Table 6.8 summarises experts’ rating.  
Table 6:8: Experts’ panel severity scoring of MRPs 
Scorer No harm 
Percentage (n) 
Low 
Percentage (n) 
Moderate 
Percentage (n) 
    
Consultant pharmacist 15 (3) 60 (12) 25 (5) 
Consultant 
paediatrician 
15 (3) 60 (12) 25 (5) 
Nurse 15 (3) 60 (12) 25 (5) 
Analysis involved descriptive statistics (frequencies and percentages) 
The agreement between panel’s members is provided in Table 6.9 below. The results showed that 
there was agreement between the three experts in 90% of the identified MRPs. The kappa statistic 
was found to be 0.88, (CI 95%, 0.69- 1.0) which implies very good agreement between the three 
experts.  
Table 6:9: The agreement between panel’s members 
Level of agreement Number (%) 
  
All members in agreement  18 (90%) 
Two in agreement, one disagreement 2 (10%) 
All three members in disagreement 0 (0%) 
 
6.5.10 Medicines related problems preventability 
 
Assessment of preventability using Schumock and Thornton preventability scale showed identified 
MRPs were all non-preventable. Table 6.10 below shows case vignette of identified MRPs and 
their associated medicines in the study population.  
 
 
158 
 
Table 6:10: Case vignettes of most common prescribed medicines and associated problems 
Case Medicines 
associated 
with 
MRPs 
Licensing 
status 
MRP 
category 
MRP 
severity 
A patient aged 1day (2kg) was admitted  
with seizure of epilepsy . The patient developed signs of 
respiratory depression after administration of a correct 
dose of morphine. The patient recovered after being 
administered Naloxone intravenously. 
 
morphine UL ADR: toxic Moderate 
harm from 
the three 
experts 
A patient aged 2hours admitted for a suspected 
sepsis. The patient developed severe allergic 
reactions after administration of benzylpenicillin. 
The patient recovered after the medicine was 
stopped and after administration of 
chlorphenarmine injection. 
benzylepe
nicillin 
Licensed ADR: 
allergic 
Pharmacist: 
moderate 
harm 
Nurse: 
moderate 
harm 
Paediatricia
n: low harm 
 
A patient aged 1day was diagnosed with cardiac 
problem and commenced on intravenous 
furosemide.The potassium level dropped and 
required to administer potassium chloride infusion 
to correct it. 
furosemid
e 
OL ADR: non-
allergic 
No-harm 
from the 
three experts 
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6.6 Discussion  
 
The results of the prospective study in Chapter 5 showed that OL and UL medicines were 
associated with more MRPs than licensed medicines. Findings of this study (NICU) showed that 
90% (n= 78/87) of the total number of patients had at least one MRP and 9% (n= 186/ 1,978) of 
all medicines were associated with MRPs.  
Findings of this study showed that MRPs associated with the use of OL medicines were higher 
than with licensed medicines; 9% (n=103/1,139) of licensed medicines were associated with 
MRPs; 15% (n=43/278) of OL were associated with MRPs, and 7% (n= 40/561) of UL medicines 
were associated with MRPs. These findings are consistent with the findings of PICU prospective 
study, which showed that MRPs associated with the use of OL medicines were higher in newborn 
patients than with the other age groups. This can be explained by the high use of OL medicines in 
this age group (Cuzzolin & Agostino, 2016).  
In this study, all the identified medicines problems were classified as ADRs; there were no 
treatment effectiveness problems.  This difference may be due to the electronic prescribing system 
(Medchart) that was introduced in this setting prior to the start of the study which has a number of 
advantages (such as, reduction in inappropriate dosing, facilitation of correct drug, provision of 
additional support for prescribers) over the traditional paper prescribing.  
The electronic system alerts prescribers to wrong information inputted. For example, if a patient’s 
details (such as, age, weight), the name of the medicine, and a possible wrong dose is inputted, the 
system alerts the prescriber to the wrong dose. The prescriber must then try to re-enter the 
information and that will continue until the prescriber inputs the correct dose or ignores the alert 
by pressing the ignore button. In the traditional paper prescribing however, the prescriber would 
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use a calculator and then write down the dose, where in each of these steps an error might occur. 
The use of electronic prescribing therefore helps to minimise MRPs caused by medication errors, 
especially prescribing errors. However, the electronic system has no influence on the occurrence 
of ADRs; this is because adverse drugs reactions are related to pharmacological effect of medicines 
and are sometimes non-preventable.  
Among the study population both genders had MRPs, but males had more MRPs (93%) than 
females (86%). However, there was no statistical difference between the genders. This result is in 
line with the retrospective and prospective studies conducted in PICU (Chapter 4 and 5 
respectively), and supported in the literature by a study of MRPs that reported there was no 
difference in MRPs incidence between males and females patients (Rashed et al., 2012). 
With regard to the length of stay in the hospital, there was no association between the number of 
MRPs and the length of stay of patients. This finding was opposed to the findings from previous 
two studies where MRPs increased with increase in LOS. This can be explained by the fact that 
the identified MRPs were allergic and non-allergic ADRs, which are directly related to the 
commenced medicines and would have happened regardless of the length of the hospital stay 
because they are part of the pharmacological effect of these medicines. 
The severity of the identified MRPs were of low harm (92%), 6% were of no harm and 2% were 
of moderate harm to patients. This is similar to the findings of the previous two studies and is 
supported by a study that found that 72.2% of MRPs were minor (n= 345/478) and 27% were 
moderate (n= 129/478) (Rashed et al., 2012). 
 Unlike the previous two studies and finding from literature (Easton et al., 2003; Easton et al., 
2004) where some of the identified MRPs were preventable, none of the identified MRPs in this 
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study was preventable. These findings are supported by an MRP study conducted by Rashed et al 
(2012) where it was found that NICU has the lowest percentage of the preventable MRPs (8.2%). 
Also in this study, the nature of MRPs as well as the system currently in use can be an explanation 
for that. That is because of the pharmacological activity of the prescribed medicines, as well as the 
unexpected response of these new-born patients to the medicines.  
6.7 Strength and limitations 
 
One of the major strengths of this study is that the electronic prescribing helped to minimise the 
challenge of poor documentation and writing mistakes. This increased the level of accuracy of data 
collected. The electronic prescribing system allows patient information to be accessed remotely, 
thus the researcher was able to access patients’ charts remotely from the pharmacy department 
and/or nurse stations to check further information without necessarily having to be present in the 
ward. This helped to facilitate the study and decreased data collection time experienced in the 
previous two studies. 
Moreover with the Medchart, the researcher was able to check for daily pharmacist re-conciliation 
of medicines. This helped in probing for more clarification of the patients’ current situation, while 
in paper prescribing it was difficult to know if reconciliation had been carried out without the 
pharmacist signature, thus the researcher would assume reconciliation was not done. This system 
therefore facilitate the recording of intervention level as any updates have to be signed for. Also, 
the training the researcher received on the use of the software and the technology involved 
enhanced accurate data collection. 
The major limitations of this study was that infusions were still written manually in fluids charts 
and the researcher had to mingle between software and paper copies for data collection of 
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medicines being prescribed. Another limitation of this study was the inability to access any drug 
chart when it was in use by other members of staff. 
6.8 Implications of study in practice 
 
In this study, the identified MRPs were mainly ADRs, which, were due to pharmacological 
effects of the administered medicines, and they were non-preventable. Electronic prescribing 
should therefore be implemented in other wards to minimise treatment effectiveness problems 
that are due to medication errors. Monitoring and reporting of ADRs should be routine practice 
in healthcare settings; healthcare professionals should be encouraged to review the reported 
incidents as a learning process. There should also be evaluation after an intervention is 
implemented to prevent MRPs to assess the effectiveness of such intervention. MRPs were found 
to be higher with off-label and unlicensed medicines when compared to licensed medicines, thus 
regular education programme to increase the awareness of MRPs associated with OL and UL 
medicines might help to reduce the number of MRPs in the paediatric population. This will 
contribute to improving the practice and patients’ quality of life. 
 
6.9 Conclusion 
This study was carried out prospectively to investigate the prevalence of medicines related 
problems associated with the use of off-label and unlicensed medicines in patients admitted to 
neonatal intensive care unit of a paediatric hospital. 
 A total of of 1,978 medicines were prescribed to 87patients. 
 90% of patients developed at least one MRP. 
 9% of the total number of medicines were associated with MRPs. 
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 15% of OL medicines and 7% of UL medicines were associated with MRPs, while 9% of 
licensed medicines were associated with MRPs. 
 All the identified medicines related problems were classified as adverse drug reactions 
 Electronic prescribing had positive impact and significantly reduce treatment effectiveness 
problems caused by prescribing errors 
 Morphine, benzylpenicillin and furosemide were found to be commonly associated with 
the identified MRPs. 
 None of the identified MRPs was preventable; none was rated as being of severe harm to 
patients. 
 
Overall discussion of the research is presented in the next chapter. 
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Chapter 7: Overall discussion 
 
7.1 Introduction 
 
Prior to widespread use of any medicine, pharmaceutical companies are required to provide 
information on the safety, efficacy and quality of the medicine to national medicines regulatory 
agencies. When a medicine is approved, a marketing authorisation or license is issued with a 
Summaries of Product Characteristics (SPC) (Silva, Ansotegui & Morais-Almeida, 2014). This 
usually follows from extensive clinical trials to evaluate the safety and efficacy of such medicines. 
These trials are mostly conducted with selected adult populations with the paediatric population 
grossly under-represented (Kimland et al., 2012; Magalhães et al., 2015). Thus, the majority of 
medicines prescribed for paediatrics have not been tested in this population and the safety and 
efficacy of paediatrics’ medicines are reportedly supported by low quality of evidence (Silva, 
Ansotegui & Morais-Almeida, 2014). Therefore many medicines used in treating paediatrics in 
both primary and hospital care settings are used in the off-label (OL) and/or unlicensed (UL) 
manner (Magalhães et al., 2015; Turner, Nunn, Fielding & Choonara, 1999). UL medicines use is 
defined as the use of medicines without a product license or marketing authorisation. OL medicine 
use is the use of licensed medicines outside of the terms of their product license or marketing 
authorisation with regard to the dose, indication, age and route of administration as well as 
contraindicated drug use (Tomlin & Morris., 2009; Turner, Nunn & Choonara, 1998).  UL and OL 
use of medicines is a common practice in paediatric population (Batchelor & Marriott, 2015; 
Kimland, 2012; Magalhães et al., 2015; RCPCH, 2013; Richey et al., 2013; Turner, Nunn, Fielding 
& Choonara, 1999). The risks associated with OL and UL medicines use consist of inaccurate 
utilisation of formulae and calculations, opting for improper ingredients, utilising erroneous 
quantities, and production of unstable products (Fontan, Mille, & Brion, 2004).  
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Prescription of UL and/or OL has been associated with higher incidence of adverse drug reactions 
(ADRs), a subtype of medicine related problems (MRPs) (Fontan, Mille, & Brion, 2004; Rees et 
al., 2017; Turner et al., 1999; WHO, 2007).  A limited number of studies have investigated MRPs 
in paediatric patients (Rashed et al., 2012; Ibrahim et al., 2013; Easton et al., 2003; Easton et al., 
2004). Problems associated with the use of OL and UL medicines in paediatric patients have been 
investigated with regard to ADRs. MRPs include ADRs, treatment effectiveness problems, 
patients’ satisfaction and cost (PCNE, 2010). To investigate MRPs associated with OL and UL 
medicines in paediatric patients, a literature review was carried out to determine the prevalence of 
use of OL and UL medicines in paediatric population as well as problems associated with their 
use. Findings of the literature review showed there were no studies that investigated the different 
types of MRPs that may result from the use of OL and UL medicines. 
The aim of this research was therefore investigate MRPs associated with the use of OL and UL 
medicines in paediatric inpatients. 
To achieve this aim, a systematic literature review was carried out in Chapter 2. Findings of the 
review informed the research questions, aim and objectives of this research. In Chapter 4, 
retrospective review of case notes of patients admitted to PICU was conducted in medical records 
department. In Chapters 5 and 6, prospective study was carried out in PICU and NICU 
respectively.  
 
7.2 Key findings 
 
A total of 38 studies were included in the literature review of this thesis. Among the included 
studies, there was no unified definition of OL and UL use of medicines. Majority of the studies 
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defined OL and UL use based on the information from the SPCs. OL and UL medicines’ use was 
found to be higher in intensive care units than in general paediatric wards with neonates being the 
most exposed (Cuzzolin & Agostino, 2016; Lass et al., 2011; Lindell-Osuagwu et al. 2014; Oguz 
et al., 2012).  Up to 100% of patients in NICU receive at least one off-label or unlicensed medicine 
(Conroy et al., 1999; Kieran et al., 2014; Lass et al., 2011; O’Donnell et al., 2002). Age, indication, 
dosage and frequency were the main reasons for OL use of medicines in paediatrics (Ballard et al., 
2013; Bellis et al., 2013; Conroy et al., 1999; Conroy et al., 2000; Di Paolo et al., 2006; Hsien et 
al., 2008; O’Donnell et al., 2002; Porta et al., 2010).  The use of OL and UL medicines was 
associated with higher incidence of ADRs than licensed medicines (Turner et al., 1999). Although 
OL and UL use of medicines are prevalent among children, investigation of all possible problems 
associated with their use has not been carried out. 
In Chapter 4, of 2000 medicines prescribed to 194 patients, 54.3% were licensed, 17.7% were OL 
and 28% were UL. Eight percent of the total number of medicines resulted in MRPs; MRPs were 
higher with OL and/or UL medicines than licensed medicines (57% vs 43%). The main types of 
problems found in this study were ADRs and treatment effectiveness (84% vs 16%). Most of the 
ADRs were caused by morphine and furosemide, as these two medicines were commonly used in 
PICU and more than 90% of patients were prescribed morphine or furosemide. Treatment 
effectiveness problems were mostly classified as effect of drug treatment not optimal, and wrong 
effect of drug treatment caused by the dose selection; medicine dose too low; medicine dose too 
high; treatment duration too long and prescribing errors. The literature review of this thesis did not 
identified studies that investigated MRPs in relation to OL and/or UL medicines use in paediatrics. 
However, studies of ADRs in paediatric patients have reported higher incidence of ADRs with the 
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use of OL and/or UL medicines when compared to licensed medicines (Neubert et al., 2004; 
Saiyed, Lalwani & Rana, 2015; Turner et al., 1999).    
In Chapter 5, 1578 medicines were prescribed to the study population of which approximately 
47% were OL and/or UL. Previous studies have reported similar prevalence. Palcevski et al. (2012) 
reported that 46% of medicines prescribed to paediatric patients admitted to general and surgical 
wards were OL or UL. Kieran et al. (2014) reported 39% of medicines used in treating neonates 
are prescribed in OL manner. Of the OL medicines prescribed to study population, 5.4% were 
associated with MRPs; 19.3% of UL medicines resulted in MRPs while 9% of licensed medicines 
were associated with MRPs. Identified MRPs were ADRs and treatment effectiveness; these were 
commonly associated with morphine, paracetamol, clonidine, furosemide and spironolactone.  
In Chapter 6, 1,978 medicines were prescribed to the 87 neonates, of which 58% were licensed, 
14% were OL, and 28% were UL. Nine percent of the total number of medicines was associated 
with MRPs and 90% of patients developed at least one MRP. MRPs associated with the use of OL 
medicines were found to be higher when compared to licensed medicines (p<0.001); 9% of 
licensed medicines were associated with MRPs; 15% of OL medicines were associated with 
MRPs; and 7% of UL medicines were associated with MRPs. The identified MRPs were classified 
as non-preventable ADRs; there were no treatment effectiveness problems.  
Findings of the three studies are consistent with literature (Berdkan et al., 2016; Conroy et al., 
1999; Kieran et al., 2014; Kimland & Odlind, 2012; Magalhães et al., 2015; Pandolfini & Bonati, 
2005) in establishing the fact that the use of OL and UL medicines is a common in paediatric 
practice. This shows that there is still lack of age-appropriate medicines and/or formulations in 
spite of legislations such as, Paediatric Investigation Plan (PIP) for European countries (European 
Parliament & EU Council, 2006) and Paediatric Study Plan (PSP) for the Americas. These 
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legislations encourage inclusion of children in investigation of new medicines and manufacture of 
age-appropriate formulations. There is therefore a need for evaluation of the effectiveness of these 
legislations, such as, assessment of availability of new medicines and/or formulations for the 
paediatric use following publication of these legislations. Furthermore, there is a need to explore 
alternatives to UL compounding and OL prescribing. This will help to clarify whether OL and/or 
UL use of medicines is a prescribers’ habit or a result of the limited availability of paediatric-
appropriate medicines or formulations. 
Findings of the three studies are also consistent with literature (Bellis et al., 2013; Neubert et al., 
2004; Saiyed, Lalwani & Rana, 2015; Turner et al., 1999) in confirming that the incidence of 
MRPs is higher with OL and/or UL medicines when compared to licensed medicines. In two of 
the studies (retrospective PICU, Chapter 4 and prospective PICU, Chapter 5) the main types of 
MRPs identified were ADRs and treatment effectiveness problems. However, it is difficult to relate 
these problems to the licensing status of medicines because the identified MRPs were seen with 
the most frequently used medicines (morphine, furosemide) among the study population. These 
problems would normally occur regardless of the licensing status, because they are part of the 
pharmacological effects of these medicines.     
Implementation of electronic prescribing (e-prescribing) in one of the settings in this research 
(NICU, Chapter 6) showed that e-prescribing significantly decreased the number of MRPs, 
especially treatment effectiveness problems that often result from medication errors. Thus 
implementing e-prescribing in other hospital wards would have great impact on health care 
quality, by reducing mortality and morbidity-related medicine incidents.  This will ultimately 
reduce the financial burden for the NHS. The Personalised Health and Care 2020: Using Data 
and Technology to Transform Outcomes for Patients and Citizens (NHS England, 2014), and the 
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Safer Hospitals, Safer Wards Technology Fund (NHS England, 2013) are therefore laudable 
government initiatives that will ensure health prosperity and quality.   
7.3 Research contribution to knowledge 
 
This research is the first to investigate MRPs associated with use of OL and UL medicines in 
paediatric in-patients as well as determine their categories. Identified MRPs were ADRs and 
treatment effectiveness problems. MRPs were higher with the use of OL and UL medicines than 
with licensed medicines. Although previous studies have reported incidence of ADRs (non-
preventable MRPs resulting from pharmacological activity of administered medicines) with use of 
OL and UL medicines in paediatrics, the use of PCNE classification system identified another 
domain of MRP: treatment effectiveness problems. Treatment effectiveness problems are 
preventable as they are often caused by the dose selection; medicine dose too low; medicine dose 
too high; treatment duration too long and prescribing errors. Implementation of electronic 
prescribing can prevent treatment effectiveness-related MRPs. 
7.4 Implications for practice 
 
This research has successfully filled the gap in knowledge about MRPs associated with the use of 
OL and UL medicines in paediatric patients. MRPs associated with the use of OL and UL 
medicines were up to 60% in paediatric patients admitted to intensive care units, further 
investigation is however required to ascertain whether MRP occurrence is actually due to the 
licensing status of the medicines or not. 
 Medicines optimisation is a crucial element to ensure a safe practice for paediatric population 
because OL and UL medicines’ use is common in this population. In light of the fact that OL 
and/or UL medicines’ use is associated with higher incidence of MRPs when compared with 
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licensed medicines, effort should be geared towards optimising use of OL and UL medicines. This 
would include: 
 double-checking of paediatric prescriptions by two or more healthcare professionals as well 
as reconciliation play important role in minimising treatment effectiveness problems, 
including prescribing errors. This is due to manipulation and adjustment of adult 
formulation and/or doses to meet paediatric needs.  
 using standard reference sources such as, the SPCs as it stipulates the uses of medicines; 
this can help to avoid errors and safety incidents.  
 using a unified tool such as, the PCNE classification tool  for MRPs’ identification in all 
hospital wards. This will ensure uniformity in data collection and analysis and increase the 
knowledge about the contributory factors to MRPs thereby eliminating them.  
Pharmacovigilance of MRPs associated with OL and UL medicines should be promoted in 
paediatric practice. Healthcare professionals as well as parents or carers should be encouraged to 
report all safety incidents associated with OL/UL medicines to a central reporting system such as, 
the National Reporting and Learning System (NRLS). Also introducing a category of the licensing 
status of medicines in incidents reporting system is very important and healthcare professionals 
should be encouraged, when reporting a safety incident, to report whether the medicine was 
licensed, off-label or unlicensed. That would help to identify the medicines’ license status that is 
most implicated with safety incidents. This would serve educational purposes, ensure safety of 
medicines and also improve practice. 
 Although pharmaceutical companies were encouraged to include paediatric patients in clinical 
trials for new medicinal products and to make sure that paediatric population is well represented 
(PIP & PSP), some companies might be exempted after a waiver application. This should be 
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minimised to promote the development of new medicines for paediatric population. Also 
introducing a category of the licensing status of medicines in incidents reporting system is very 
important and healthcare professionals should be encouraged, when reporting a safety incident, to 
report whether the medicine was licensed, off-label or unlicensed. That is might help to increase 
the awareness of the healthcare professionals not only with certain medicines that contributed with 
incidents, but also with the licensing status that are mostly implicated with safety incidents. Also 
a new policy to distinguish between licensed and off-label /unlicensed medicines should be 
introduced, such as a colour coded system which tells the professionals that this medicines is an 
off-label or unlicensed medicines. This will ensure that practitioners will pay more attention to the 
medicines that were prescribed as off-label and/or unlicensed medicines. Although pharmaceutical 
companies were encouraged to include paediatric patients in clinical trials for new medicinal 
products and to make sure that paediatric population is well represented (PIP & PSP), some 
companies might be exempted after a waiver application. This should be minimised to promote 
the development of new medicines for paediatric population. 
7.5 Research Recommendations 
 
The following recommendations if implemented would improve paediatric practice with respect 
to OL and UL medicines: 
 The research community should develop an international consensus definition for OL and 
UL medicines and disseminate same in peer-reviewed journal. This will allow comparison 
of findings of OL and UL medicines research in paediatrics from different countries and 
settings. 
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 The National Patient Safety Agency (NPSA) should increase the awareness of MRPs 
identification, causes, interventions and outcomes through educational programmes such 
as, posters, brochures, and leaflets.  
 The role of the pharmacist in identifying and intervening to resolve MRPs is pivotal. Thus, 
NHS Trust boards should provide funding that would ensure a pharmacist is available on 
a 24-hour basis in the ward to review all OL and UL prescription, detect and resolve MRPs. 
 Currently, hospital incident reporting is mostly performed by the nurses. The pharmacist, 
who is the medicines expert, should be encouraged to take the lead in identifying and 
documenting MRPs. 
 While the hospital has its local prescribing guideline, this guideline does not have medicine 
manufacturers’ information. Prescribers often rely on local guidelines without reference to 
Summary of Product Characteristics (SPCs). It is therefore crucial that healthcare 
professionals should be encouraged to access the information in the SPCs of medicines to 
identify off-label and/or unlicensed use of medicines.  
  Severity scoring systems available now are designed for ADRs and MEs, which are 
subsets of MRPs. The research community should develop a scoring system for MRPs to 
minimise the confusion that might occur when using other systems. 
 Findings of this research showed that there were less treatment effectiveness problems with 
the use of electronic prescribing. Thus, implementation of electronic prescribing in all 
hospital wards will help reduce MRPs and improve the quality of healthcare. 
 It is recommended that a national survey be conducted to evaluate the availability of 
paediatric medicines. Such survey can be repeated after 10 years to evaluate the 
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effectiveness of the paediatric regulations (e.g., PIP) in increasing the availability of 
authorised and age-appropriate medicines. 
 
7.6 Future Research 
 
 Hospital-wide studies involving all paediatric wards should be conducted to investigate 
MRPs associated with the use of OL and UL medicines. 
 Further research should involve both quantitative and qualitative studies to explore 
healthcare professionals’ perceptions and attitudes about OL and UL medicines’ use. This 
should include practitioners in practice settings (secondary, primary, and community)  
 Further study should be conducted to investigate hospital and A&E admissions resulting 
from MRPs associated with OL and UL use of medicines. 
7.7 Research Strength and limitations 
 
7.7.1 Research Strength 
 
 The use of retrospective and prospective approaches provided a holistic picture of MRPs 
with use of OL and UL medicines in children. 
 Randomisation of participants enhanced the generalisability of study results. 
 The methodology adopted in the first two studies (Chapters 4 and 5), that is, intensive chart 
review has been recognised as the most appropriate and gold standard in pharmaco-
epidimiological studies (Rashed et al., 2012).  
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7.7.2 Research Limitations 
 
 Major limitation is that the systematic literature review was restricted to original research 
papers presented in English language only and other studies published in other languages 
were excluded.  
 There was no access to medical case-notes of patients in isolated rooms as well as deceased 
patients. Therefore there is no judgment about MRPs associated with the use of off-label 
and unlicensed medicines in those patients. 
 This research did not investigate the treatment cost and patients’ perspectives. 
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7.8 Conclusion 
 
The limited availability of age-appropriate medicines for children and the consequential 
high rates of OL and UL use of medicines in this patient population are a worldwide 
concern (Nunn et al., 2014). OL and UL medicines use may hamper the effectiveness of 
pharmacotherapy and/or increase the risk of adverse events and problems. Findings of this 
research showed higher prevalence of the use of OL and UL medicines in the studied 
settings (PICU and NICU) and thus confirm previous studies (Conroy et al., 1999; Conroy 
et al., 2000). This research also showed that the use of OL and UL medicines in paediatric 
in-patients was associated with more MRPs than licensed medicines and between 9- 14% 
of OL and UL medicines were implicated in MRPs. Approximately 53% of patients 
admitted to PICU and 90% of patients admitted to NICU had MRPs. Although there is no 
study to compare these finding, higher incidence of MRPs have been reported in PICU 
when compared with general paediatric medical ward (Rashed et al., 2012). Findings of 
this research showed that the use of electronic prescribing led to reduction in occurrence 
of treatment effectiveness-related MRPs. Migration to electronic prescribing in all 
hospitals wards will help in MRPs reduction.  
This research has filled a gap in knowledge in that it is the first to investigate MRPs 
associated with the use of OL and UL medicines in paediatric in-patients. There is a need 
for pharmaceutical companies to comply with the PIP regulation in order to reduce the use 
of OL and/or UL medicines in this population. Further research in paediatric practice is 
highly needed, and industry and policy makers are encouraged to work collaboratively with 
the healthcare research in order to assure advanced implementations of high quality of 
healthcare systems. 
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Research Output  
Abstracts submissions: 
o Elhijazi, W., Tomlin, S., Umaru, N., Liu, F., Ghaleb, M., Foulsham, 
R.,Kostrzewski, A. Development of a Tool to Identify Medicines Related Problems 
in Paediatric In-patients. LMS Research Conference 2015. School of Life and 
Medical Science, University of Hertfordshire, UK. 
o Elhijazi, W., Ghaleb, M., Foulsham, R.,Kostrzewski, A.  Medicines Related 
Problems Associated with the Use of Unlicensed& Off-label Medicines in 
Paediatric In-patients: A Systematic Literature Review.  LMS Research Conference 
2014. School of Life and Medical Science, University of Hertfordshire, UK. 
 
 Conference posters’ presentations:  
 
o Elhijazi, W., Tomlin, S., Liu, F., Ghaleb, M., Umaru, N. Medicines’ Problems 
Associated with the Use of Unlicensed & off-label Medicines in Paediatric 
Population. The Clinical Pharmacy Congress Conference 2016, London, UK. 
 
o Elhijazi, W., Tomlin, S., Liu, F., Ghaleb, M., Umaru, N. Medicines’ Problems 
Associated with the Use of Unlicensed & off-label Medicines in Paediatric 
Population. PPP Research Conference 2016. School of Life and Medical Science, 
University of Hertfordshire, UK. 
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o Elhijazi, W., Tomlin, S., Umaru, N., Liu, F., Ghaleb, M., Foulsham, 
R.,Kostrzewski, A. Development of a Tool to Identify Medicines Related Problems 
in Paediatric In-patients. LMS Research Conference 2015. School of Life and 
Medical Science, University of Hertfordshire, UK. 
 
o Elhijazi, W., Ghaleb, M., Foulsham, R.,Kostrzewski, A.  Medicines Related 
Problems Associated with the Use of Unlicensed& Off-label Medicines in 
Paediatric In-patients: A Systematic Literature Review.  LMS Research Conference 
2014. School of Life and Medical Science, University of Hertfordshire, UK. 
 
 Seminars: 
o Pharmacy Practice Presentation and Research Showcase Evening; University of 
Hertfordshire. May 2014: Medicines Related Problems Associated with the Use of 
Off-label & Unlicensed Medicines in Paediatric In-patients. 
o Pharmacy Practice Presentation and Research Showcase Evening; University of 
Hertfordshire. July 2015: Medicines Related Problems Associated with the Use of 
Off-label & Unlicensed Medicines in Paediatric In-patients. 
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Appendix 2: Naranjo ADR probability scale-items and score 
 
 
 
 
 
Scoring for Naranjo algorithm:  
> 9 definite ADR 
5–8 = probable ADR  
1–4 = possible ADR 
 0 = doubtful ADR 
 
 
 
 
 
 
Question Ye
s 
No Don’t know 
Are there previous conclusion reports on this reaction? +1 0 0 
Did the adverse event appear after the suspect drug was administered? +2 -1 0 
Did the AR improve when the drug was discontinued or a specific 
antagonist was administered? 
+1 0 0 
Did the AR reappear when drug was re-administered? +2 -1 0 
Are there alternate causes [other than the drug] that could solely have 
caused the reaction? 
-1 +2 0 
Did the reaction reappear when a placebo was given? -1 +1 0 
Was the drug detected in the blood [or other fluids] in a concentration 
known to be toxic? 
+1 0 0 
Was the reaction more severe when the dose was increased or less severe 
when the dose was decreased? 
+1 0 0 
Did the patient have a similar reaction to the same or similar drugs in any 
previous exposure? 
+1 0 0 
Was the adverse event confirmed by objective evidence? +1 0 0 
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Appendix 9: Data collection Form for PICU retrospective study 
ID:  
Age GENDER WEIGHT HIEGHT Length of Stay Allergy Diagnosis 
       
  
MEDICATIONS: 
NAME Strength DATE DOSE ROUTE FREQU- 
ENCY 
MRP MRP 
Category 
Licensing 
status 
Comments 
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 
Comments: 
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Appendix 10: Retrospective study’s medicines and their associated MRPs 
 
Medicine Licencing 
status 
Number of times 
medicine 
prescribed 
Number 
of 
patient 
Number of 
times 
medicine 
associate with 
MRPs 
Number of 
patients 
developed 
MRPs 
  
MORPHINE UL 193 151 79 77 
CLONIDINE UL 146 135 0 0 
PARACETAMOL L 120 119 1 1 
FUROSEMIDE L 110 102 43 43 
SPIRONOLACTON
E 
UL 97 93 0 0 
CEFUROXIME L 87 85 0 0 
ROCURONIUM OL 76 71 0 0 
POTASSIUM 
CHLORIDE 
L 74 71 1 1 
LACTULOSE L 72 72 0 0 
MILRINONE UL 72 72 0 0 
FENTANYL OL 68 59 1 1 
KETAMINE L 51 49 0 0 
CO-AMOXICLAV L 49 44 2 2 
PARACETAMOL OL 43 32 13 13 
PROPOFOL L 42 40 0 0 
GENTAMICIN L 41 40 7 7 
IBRUPOFEN L 31 30 0 0 
ADENOSINE L 29 7 0 0 
DOPAMINE L 22 22 0 0 
BENZYLPENICILLI
N 
L 21 21 0 0 
CAPTOPRIL UL 19 18 0 0 
CHLORPHENIRAM
INE 
OL 18 18 0 0 
LORAZEPAM OL 18 17 0 0 
OMEPRAZOLE UL 17 17 0 0 
ACICLOVIR L 16 16 0 0 
VITAMIN K L 15 15 0 0 
CEFTRIAXONE L 15 15 0 0 
MIDAZOLAM OL 14 14 0 0 
FLUCLOXACILLIN L 14 14 3 3 
ASPRIN L 14 14 1 1 
PREDNISOLONE L 13 13 0 0 
GLYCERIN L 12 12 0 0 
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CEFOTAXIME L 12 12 0 0 
PANTOPRAZOLE L 12 12 0 0 
HEPARIN OL 11 11 0 0 
AMIODARONE OL 11 9 0 0 
MORPHINE L 11 11 4 4 
DALTEPARIN OL 9 8 0 0 
PHENYTOIN L 9 7 1 1 
PROPRANOLOL L 8 8 0 0 
TEICOPLANIN L 8 8 0 0 
DOMPERIDONE OL 8 8 0 0 
ONDANSETRON L 8 8 0 0 
CLINDAMYCIN L 8 7 0 0 
SALBUTAMOL L 8 7 1 1 
DEXAMETHASONE L 7 7 0 0 
SILDENAFIL OL 7 7 0 0 
ADRENALINE L 7 7 0 0 
KAY-CEE-L L 7 7 0 0 
DIGOXIN OL 7 6 0 0 
SYTRON L 7 7 1 1 
MOVICOL L 5 5 0 0 
MEROPENEM OL 5 5 0 0 
RANITIDINE L 5 5 0 0 
VANCOMYCIN L 5 5 1 1 
CLARITHROMYCI
N 
OL 5 5 0 0 
ABIDEC L 5 5 0 0 
AMOXICILLIN L 5 5 0 0 
NORADRENALINE OL 5 5 0 0 
METRONIDAZOLE L 5 4 0 0 
TAZOCIN L 4 4 0 0 
FLECAINIDE UL 4 4 0 0 
MUPIROCIN L 4 4 0 0 
PHENOBARBITON
E 
L 4 2 0 0 
ORAMORPH OL 4 4 0 0 
DNASE L 4 4 0 0 
NALOXONE L 4 4 0 0 
MONTELUKAST L 4 4 0 0 
NYSTATIN OL 4 4 0 0 
DINOPROSITONE UL 4 4 0 0 
BUDESONIDE OL 4 4 0 0 
DALIVIT L 4 4 0 0 
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PERIPHERAL 
DOPAMINE 
L 3 3 0 0 
DICLOFENAC L 3 3 1 1 
CYCLIZINE OL 3 3 0 0 
FOLIC ACID L 3 3 0 0 
CARNITINE UL 3 3 0 0 
PROSTIN L 3 3 0 0 
DIHYDROCODIEN
E 
L 3 3 2 2 
CARVEDILOL OL 3 3 0 0 
AZITHROMYCIN L 3 3 1 1 
TRIMETHOPRIM OL 3 3 0 0 
MAGNESIUM 
SULPHATE 
UL 2 2 0 0 
SERETIDE 125 L 2 2 0 0 
GLYCOPYRROLAT
E 
OL 2 2 0 0 
LISINOPRIL OL 2 2 0 0 
AMLODIPINE OL 2 2 0 0 
CEFRUROXIME L 2 2 0 0 
ALFACALCIDOL L 2 2 0 0 
SENNA OL 2 2 0 0 
CLOBAZAM L 2 2 0 0 
LEVOTHYROXINE L 2 2 0 0 
MAGNESIUM 
GLYCOPHOSPHAT
E 
UL 2 2 0 0 
FLUCONAZOLE L 2 1 0 0 
ACETAZOLAMIDE L 2 2 0 0 
TRANEXAMIC 
ACID 
OL 2 2 1 1 
SODIUM 
VALPORATE 
L 1 1 0 0 
UROKINASE L 1 1 0 0 
BECLOMETHASON
E 
L 1 1 0 0 
ATROPINE L 1 1 0 0 
ACTRAPID 
INSULIN 
L 1 1 0 0 
FENTANYL L 1 1 0 0 
NOVORAPID L 1 1 0 0 
DALTEPARIN L 1 1 0 0 
PENICILLIN V L 1 1 0 0 
GAVISCON OL 1 1 0 0 
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SODIUM 
CHLORIDE 
L 1 1 0 0 
LOPERAMIDE OL 1 1 0 0 
OXYCODIENE L 1 1 1 1 
VORICONAZOLE L 1 1 0 0 
CALCIUM L 1 1 0 0 
VIGABATRIN OL 1 1 0 0 
CIPROFLOXACIN L 1 1 0 0 
PANCURONIUYM L 1 1 0 0 
SANDO-K L 1 1 0 0 
ENOXAPARIN L 1 1 0 0 
SODIUM 
PHOSPHATE 
OL 1 1 0 0 
SODIUM 
CHLORIDE 
UL 1 1 0 0 
AMINOPHYLLINE OL 1 1 0 0 
RIFAMPICIN L 1 1 0 0 
HEPARIN L 1 1 0 0 
POTASSIUM 
CANRENOATE 
L 1 1 0 0 
CAFFEINE 
CITRATE 
OL 1 1 0 0 
COLECALCIFERO
L 
OL 1 1 0 0 
LEVETIRACETAM OL 1 1 0 0 
AMIKACIN L 1 1 0 0 
STIRIPENTOL L 1 1 0 0 
ENOXIMONE OL 1 1 0 0 
OMEPRAZOLE OL 1 1 0 0 
NITROPRUSSIDE L 1 1 0 0 
NEOSTIGMINE UL 1 1 0 0 
METHYLEPREDNI
SOLONE 
L 1 1 0 0 
SODIUM 
FEREDETATE 
OL 1 1 0 0 
ATENOLOL OL 1 1 0 0 
VITAMIN D L 1 1 0 0 
CETRIZINE L 1 1 0 0 
POTASSIUM 
CITRATE 
L 1 1 0 0 
SLOW K L 1 1 0 0 
DOCUSATE 
SODIUM 
OL 1 1 0 0 
LANTUS L 1 1 0 0 
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LANSOPRAZOLE OL 1 1 0 0 
BACLOFEN L 1 1 0 0 
SUXAMETHONIUM L 1 1 0 0 
IPRATROPIUM L 1 1 0 0 
PEPTAC L 1 1 0 0 
FLECANIDE OL 1 1 0 0 
PENTASA L 1 1 0 0 
ESMOLOL OL 1 1 0 0 
CHLORAL 
HYDRATE 
OL 1 1 0 0 
TEMAZEPAM OL 1 1 0 0 
DOPUTAMINE L 1 1 0 0 
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Appendix 11: Retrospective study panel’s Severity Scoring summary: 
 
 
Case= MRP 
Panel= 3 assessors (Consultant, Pharmacist, Nurse) 
Scoring system= 5levels (No harm, Low, moderate, Severe, Death) 
Case number Member 1 
Pharmacist 
Member 2 
Consultant 
Member 3 
Nurse 
Case 1 
 
Low Low Low 
Case 2 
 
Low Low Low 
Case 3 
 
Moderate Moderate Moderate 
Case 4 
 
Moderate Moderate Moderate 
Case 5 
 
Low Low Low 
Case 6 
 
Low Low Low 
Case 7 
 
Low Low Low 
Case 8 
 
Low Low Low 
Case 9 
 
Low Low Low 
Case 10 
 
No harm No harm Low 
Case 11 
 
Low Low Low 
Case 12 
 
Low Low Low 
Case 13 
 
Moderate Moderate Moderate 
Case 14 
 
Low Low No harm 
Case 15 
 
Low Low Low 
Case 16 
 
Low Low Low 
Case 17 
 
Moderate Moderate Moderate 
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Appendix 12: Data collection Form for prospective study 
 ID:  
Date:  
Age GENDER WEIGHT 
(kg) 
HIEGHT 
(cm) 
Length of Stay 
(days) 
Allergy Comorbidities Admitted from 
        
  
Reason for Admission Diagnosis  
 
 
 
 
 
MEDICATIONS: 
NAME DATE DOSE ROUTE FREQUENC
Y 
Duration Licensing 
status 
MRP MRP 
Code 
No  
Of 
Causes 
C  
Code 
Inter 
vention 
I 
code 
outcome O code 
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Day 2: 
Medicine Initial dose New dose Why changed/ 
stopped 
Comments 
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Appendix 13: PICU prospective study medicines and associated problems 
 
Medicine Licensing 
status 
Number of 
times 
medicine 
prescribed 
  
Number 
of patients  
Number of 
times 
medicine 
associated 
with MRPs 
Number 
of 
patients 
develop
ed 
MRPs 
 
MORPHINE UL 164 127 80 77 
CLONIDINE UL 121 114 4 4 
PARACETAMOL L 105 104 3 3 
FUROSEMIDE L 92 86 48 48 
SPIRONOLACTONE UL 80 78 0 0 
CEFUROXIME L 73 71 0 0 
MILRINONE UL 64 64 0 0 
ROCURONIUM OL 60 57 0 0 
POTASSIUM CHLORIDE L 54 51 1 1 
LACTULOSE L 53 53 0 0 
FENTANYL OL 47 43 1 1 
KETAMINE L 39 37 0 0 
CO-AMOXICLAV L 38 35 1 1 
PROPOFOL L 33 31 0 0 
PARACETAMOL OL 31 22 10 10 
IBRUPOFEN L 30 29 0 0 
GENTAMICIN L 18 18 5 5 
LORAZEPAM OL 18 17 0 0 
DOPAMINE L 17 17 0 0 
CHLORPHENIRAMINE OL 14 14 0 0 
MIDAZOLAM OL 14 14 0 0 
ADENOSINE L 13 5 0 0 
CAPTOPRIL UL 13 12 0 0 
OMEPRAZOLE UL 13 13 0 0 
ACICLOVIR L 13 13 0 0 
PREDNISOLONE L 12 12 0 0 
CEFTRIAXONE L 12 12 0 0 
ASPRIN L 12 12 1 1 
PANTOPRAZOLE L 10 10 0 0 
SALBUTAMOL L 9 8 2 2 
AMIODARONE OL 9 7 0 0 
ONDANSETRON L 8 8 0 0 
FLUCLOXACILLIN L 8 8 1 1 
BENZYLPENICILLIN L 8 8 0 0 
MORPHINE L 8 8 2 2 
DALTEPARIN OL 8 6 1 1 
GLYCERIN L 8 8 0 0 
302 
 
PHENYTOIN L 8 6 1 1 
KAY-CEE-L L 7 7 0 0 
DOMPERIDONE OL 7 7 0 0 
SYTRON L 7 7 1 1 
TEICOPLANIN L 7 7 0 0 
HEPARIN OL 7 7 0 0 
PROPRANOLOL L 6 6 0 0 
DIGOXIN OL 6 4 1 1 
CEFOTAXIME L 6 6 0 0 
CLINDAMYCIN L 6 5 0 0 
CLARITHROMYCIN OL 5 5 0 0 
SILDENAFIL OL 5 5 0 0 
DEXAMETHASONE L 5 5 0 0 
ABIDEC L 5 5 0 0 
ADRENALINE L 5 5 0 0 
RANITIDINE L 4 4 0 0 
VITAMIN K L 4 4 0 0 
PHENOBARBITONE L 4 2 0 0 
TAZOCIN L 4 4 0 0 
DALIVIT L 4 4 0 0 
DNASE L 4 4 0 0 
VANCOMYCIN L 4 3 2 2 
MEROPENEM OL 4 4 0 0 
MONTELUKAST L 4 4 0 0 
AZITHROMYCIN L 3 3 1 1 
ORAMORPH OL 3 3 0 0 
NYSTATIN OL 3 3 0 0 
MOVICOL L 3 3 0 0 
NORADRENALINE OL 3 3 0 0 
CYCLIZINE OL 3 3 0 0 
METRONIDAZOLE L 3 2 0 0 
VANCOMYCIN UL 3 2 3 2 
MAGNESIUM SULPHATE UL 2 2 0 0 
FOLIC ACID L 2 2 0 0 
AMLODIPINE OL 2 2 0 0 
CLOBAZAM L 2 2 0 0 
NALOXONE L 2 2 0 0 
MAGNESIUM 
GLYCOPHOSPHATE 
UL 2 2 0 0 
SERETIDE L 2 2 0 0 
TRIMETHOPRIM OL 2 2 0 0 
BUDESONIDE OL 2 2 0 0 
AMOXICILLIN L 2 2 0 0 
FLUCONAZOLE L 2 1 0 0 
DIHYDROCODIENE L 2 2 1 1 
ALFACALCIDOL L 2 2 0 0 
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PROSTIN L 2 2 0 0 
GLYCOPYRROLATE OL 2 2 0 0 
GENTAMICIN UL 2 2 2 2 
DINOPROSITONE UL 2 2 0 0 
LISINOPRIL OL 2 2 0 0 
ACETAZOLAMIDE L 2 2 0 0 
TRANEXAMIC ACID OL 2 2 1 1 
CO-AMOXICLAV UL 2 2 2 2 
MUPIROCIN L 2 2 0 0 
LEVOTHYROXINE L 2 2 0 0 
ACTRAPID INSULIN L 1 1 0 0 
OMEPRAZOLE OL 1 1 0 0 
IPRATROPIUM L 1 1 0 0 
FLECAINIDE OL 1 1 1 1 
CARVEDILOL OL 1 1 0 0 
LANTUS L 1 1 0 0 
AMINOPHYLLINE OL 1 1 0 0 
BECLOMETHASONE L 1 1 0 0 
BACLOFEN L 1 1 0 0 
ESMOLOL OL 1 1 0 0 
PENTASA L 1 1 0 0 
LOPERAMIDE OL 1 1 0 0 
DEXTROS L 1 1 1 1 
FENTANYL L 1 1 0 0 
LANSOPRAZOLE OL 1 1 0 0 
VORICONAZOLE L 1 1 0 0 
FLECANIDE OL 1 1 0 0 
SLOW K L 1 1 0 0 
DALTEPARIN L 1 1 1 1 
CALCIUM L 1 1 0 0 
NOVORAPID L 1 1 0 0 
CETRIZINE L 1 1 0 0 
DOCUSATE SODIUM OL 1 1 0 0 
POTASSIUM CITRATE L 1 1 0 0 
NEOSTIGMINE UL 1 1 0 0 
ATENOLOL OL 1 1 0 0 
CARNITINE UL 1 1 0 0 
SODIUM VALPORATE L 1 1 0 0 
SODIUM FEREDETATE OL 1 1 0 0 
ENOXIMONE OL 1 1 0 0 
VITAMIN D L 1 1 0 0 
PEPTAC L 1 1 0 0 
PERIPHERAL 
DOPAMINE 
L 1 1 0 0 
FLECAINIDE UL 1 1 0 0 
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METHYLEPREDNISOLO
NE 
L 1 1 0 0 
CIPROFLOXACIN L 1 1 0 0 
SODIUM CHLORIDE L 1 1 0 0 
NITROPRUSSIDE L 1 1 0 0 
SENNA OL 1 1 0 0 
LEVETIRACETAM OL 1 1 0 0 
PENICILLIN V L 1 1 0 0 
STIRIPENTOL L 1 1 0 0 
SODIUM PHOSPHATE OL 1 1 0 0 
POTASSIUM 
CANRENOATE 
L 1 1 0 0 
PANCURONIUYM L 1 1 0 0 
RIFAMPICIN L 1 1 0 0 
GAVISCON OL 1 1 0 0 
VIGABATRIN OL 1 1 0 0 
SANDO-K L 1 1 0 0 
AMIKACIN L 1 1 0 0 
UROKINASE L 1 1 0 0 
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Appendix 14: NICU prospective study medicines and associated problems 
 
Medicine Number of 
times medicine 
prescribed 
Number of 
patients  
Number of MRPs 
associated with 
Number of 
patients 
developed MRPs 
FENTANYL 108 87 1 1 
BENZYLPENICILLIN 92 87 45 45 
MORPHINE 92 74 36 35 
DEXAMETHASONE 91 87 0 0 
CEFOTAXIME 89 87 0 0 
SODIUM CHLORIDE 88 87 0 0 
CUROSURF 87 87 0 0 
ATROPINE SULPHATE 87 87 0 0 
GLYCERYL 
TRINITRATE 
87 87 0 0 
FOLIC ACID 87 87 0 0 
CAFFEINE CITRATE 87 87 0 0 
SUXAMETHONIUM 
CHLORIDE 
87 87 0 0 
PHYTOMENADIONE 87 87 0 0 
PARACETAMOL 82 74 9 9 
CLONIDINE 71 66 4 4 
FUROSEMIDE 52 51 27 27 
SPIRONOLACTONE 49 47 0 0 
CEFUROXIME 47 45 13 13 
POTASSIUM 
CHLORIDE 
40 38 0 0 
MILRINONE 39 39 0 0 
ROCURONIUM 32 30 0 0 
LACTULOSE 25 25 0 0 
KETAMINE 20 18 0 0 
PROPOFOL 20 19 0 0 
CO-AMOXICLAV 18 17 16 15 
IBRUPOFEN 17 16 0 0 
GENTAMICIN 11 11 4 4 
LORAZEPAM 10 9 0 0 
CHLORPHENIRAMINE 10 10 0 0 
DOPAMINE 9 9 0 0 
ADENOSINE 9 2 9 2 
ASPRIN 9 9 1 1 
OMEPRAZOLE 9 9 0 0 
PANTOPRAZOLE 8 8 0 0 
MIDAZOLAM 8 8 0 0 
CEFTRIAXONE 7 7 0 0 
CAPTOPRIL 7 7 0 0 
FLUCLOXACILLIN 7 7 1 1 
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PREDNISOLONE 7 7 0 0 
SYTRON 7 7 1 1 
ACICLOVIR 6 6 0 0 
SALBUTAMOL 6 5 0 0 
AMIODARONE 6 4 0 0 
ONDANSETRON 6 6 0 0 
GLYCERIN 5 5 0 0 
PHENYTOIN 5 4 1 1 
HEPARIN 5 5 0 0 
CLINDAMYCIN 4 4 0 0 
DOMPERIDONE 4 4 0 0 
DALTEPARIN 4 3 0 0 
SILDENAFIL 4 4 0 0 
ADRENALINE 4 4 4 4 
KAY-CEE-L 4 4 0 0 
VITAMIN K 4 4 0 0 
ABIDEC 3 3 0 0 
METRONIDAZOLE 3 2 0 0 
TEICOPLANIN 3 3 0 0 
NORADRENALINE 3 3 0 0 
DIGOXIN 3 2 1 1 
MORPHINE 3 3 1 1 
CYCLIZINE 3 3 0 0 
MOVICOL 3 3 0 0 
ALFACALCIDOL 2 2 2 2 
DNASE 2 2 0 0 
AMOXICILLIN 2 2 2 2 
MAGNESIUM 
SULPHATE 
2 2 0 0 
PHENOBARBITONE 2 1 0 0 
LISINOPRIL 2 2 0 0 
TRANEXAMIC ACID 2 2 1 1 
RANITIDINE 2 2 0 0 
CLOBAZAM 2 2 0 0 
LEVOTHYROXINE 2 2 0 0 
PROPRANOLOL 2 2 0 0 
FLUCONAZOLE 2 1 0 0 
DALIVIT 2 2 0 0 
MEROPENEM 2 2 0 0 
CO-AMOXICLAV 2 2 2 2 
DINOPROSITONE 2 2 0 0 
MONTELUKAST 2 2 0 0 
ORAMORPH 2 2 0 0 
CLARITHROMYCIN 2 2 0 0 
TRIMETHOPRIM 2 2 0 0 
DOCUSATE SODIUM 1 1 0 0 
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PENICILLIN V 1 1 0 0 
ACETAZOLAMIDE 1 1 0 0 
IPRATROPIUM 1 1 0 0 
SANDO-K 1 1 0 0 
VANCOMYCIN 1 1 1 1 
TAZOCIN 1 1 0 0 
BUDESONIDE 1 1 0 0 
VANCOMYCIN 1 1 0 0 
MUPIROCIN 1 1 0 0 
LANSOPRAZOLE 1 1 0 0 
LANTUS 1 1 0 0 
NYSTATIN 1 1 0 0 
SODIUM VALPORATE 1 1 0 0 
POTASSIUM CITRATE 1 1 0 0 
ACTRAPID INSULIN 1 1 0 0 
AMIKACIN 1 1 1 1 
NOVORAPID 1 1 0 0 
SERETIDE 1 1 0 0 
RIFAMPICIN 1 1 0 0 
CIPROFLOXACIN 1 1 1 1 
PERIPHERAL 
DOPAMINE 
1 1 0 0 
GLYCOPYRROLATE 1 1 0 0 
AZITHROMYCIN 1 1 0 0 
ENOXIMONE 1 1 0 0 
BACLOFEN 1 1 0 0 
GAVISCON 1 1 0 0 
CALCIUM 1 1 0 0 
NALOXONE 1 1 0 0 
CARNITINE 1 1 0 0 
STIRIPENTOL 1 1 0 0 
ESMOLOL 1 1 0 0 
FENTANYL 1 1 0 0 
CARVEDILOL 1 1 0 0 
SODIUM PHOSPHATE 1 1 0 0 
MAGNESIUM 
GLYCOPHOSPHATE 
1 1 0 0 
DALTEPARIN 1 1 1 1 
METHYLEPREDNISOL
ONE 
1 1 0 0 
LOPERAMIDE 1 1 0 0 
FLECAINIDE 1 1 0 0 
BECLOMETHASONE 1 1 0 0 
PEPTAC 1 1 0 0 
NEOSTIGMINE 1 1 0 0 
PROSTIN 1 1 0 0 
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DIHYDROCODIENE 1 1 1 1 
POTASSIUM 
CANRENOATE 
1 1 0 0 
LEVETIRACETAM 1 1 0 0 
OMEPRAZOLE 1 1 0 0 
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Appendix 15: Summary of the three studies’ findings 
 
 
 
Setting Design Total 
patients 
Patients 
with 
MRPs 
Total 
medicine
s 
Medicines 
with 
MRPs 
Total 
MRPs 
Total  
L 
L with 
MRPs 
Total OL 
& UL  
OL & 
UL with 
MRPs 
MRPs 
categories 
MRPs 
severity 
preventability 
              
PICU 
 
Retrospect
ive study 
194 53% 
(102) 
 
2000 8% 
(165) 
 
165 1085 7% 
(71) 
 
915 10.3% 
(94) 
84% 
ADRs 
& 16% 
TEs 
5% no 
harm  
71% low 
harm 
24% 
moderate 
harm 
30.3% 
 
              
PICU 
 
Prospectiv
e study 
147 79% 
(116) 
 
1578 11% 
(178) 
 
178 831 9% 
(72) 
 
747 14.2% 
(106) 
83% 
ADRs & 
17% TEs 
6% no 
harm 
72% low 
harm 
22% 
moderate 
harm 
34% 
              
NICU 
 
Prospectiv
e study 
87 90% 
(78) 
 
1978 9% 
(186) 
 
186 1139 9% 
(103) 
 
839 10% 
(83) 
100% 
ADRs 
6%  no 
harm 
92% low 
harm 
2% 
moderate 
harm 
None 
              
